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Pulmonary fibrosis (IPF) is a debilitating progressive disease mostly affecting the elderly, 
and due to dysregulated wound healing repair. It is characterised by increased matrix 
production and altered ECM composition, leading to increased tissue rigidity, and eventually, 
death. 
In mammalian lungs, mechanical stretch is generated by the diaphragm and chest 
muscles and transferred first to lung septa and then at cellular level. In lung fibrosis the 
increase in ECM causes mechanical stretch impairment due to the increase in tissue stiffness, 
which is thought to be mostly dependant on increased fibrillar collagen. 
Using an ad hoc in vitro system, the effects of collagen as culture substrate, age and 
mechanical stretch on several ECM genes were investigated in both primary and immortalised 
lung cells. My results indicated profibrotic roles for collagen as a substrate and age, while 
mechanical stretch appeared to have a protective role against fibrosis. 
Pharmacological use of microRNAs to fine tune mRNA expression is a novel field of 
research. MicroRNA based therapies either aim to increase expression of a microRNA to 
repress a target mRNA (mirmimics), or decrease microRNA expression to upregulate a target 
mRNA (antagomir). Analysis of microRNA expression in the Bleomycin mouse model of lung 
fibrosis identified more than 20 microRNAs that were significantly modified in their expression 
during fibrosis induction and progression. 
Using the Bleomycin model, I identified 4 microRNAs (miR-21a-5p, miR-34a- 5p, miR-
29a-3p and miR-378-5p) as potential pro-fibrotic microRNAs due to progressively increased 
expression correlated with progression of fibrotic features. 
Results from primary mouse fibroblast cultures showed that overexpression of miR-29a-
3p results in a reduction of Col1a1 expression, suggesting an antifibrotic role for this 
microRNA. miR-21a-5p expression decreased Smad7 expression in both primary mouse lung 
fibroblasts and in the Bleomycin model of lung fibrosis. Treatment with a miR-21a mirmimic 
resulted in increased lung fibrosis in the Bleomycin mouse model, while treatment with a miR-
21a antagomir resulted in reduced lung fibrosis. My results identify miR-21a repression as a 
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1.1. Tissue Fibrosis overview 
 
Tissue fibrosis is a multifactorial disease characterized by an excessive production and 
deposition of extracellular matrix (ECM). The accumulation of ECM disrupts tissue 
architecture and eventually leads to organ failure. Tissue fibrosis accounts for more than 45% 
of all cases of death in developed countries (Jun & Lau, 2018). The excessive production of 
ECM underlays dysregulation in the wound healing repair system, a feature common to all 
fibrotic disease. Tissue fibrosis can affect virtually every tissue and can rise from a broad range 
of pathological conditions such as heart failure, Scleroderma, cancer or without a certain 
aetiology (as for Idiopathic Pulmonary Fibrosis or IPF). Interestingly, liver fibrosis can originate 
also from Hepatitis B and C (HVB HVC) virus, leading eventually to cirrhosis, while kidney 
fibrosis can develop as a consequence of metabolic dysregulation such as in diabetes or 
hypertension (Jun & Lau, 2018).  
 
Wound healing is a finely regulated mechanism which, when impaired leads to 
development of fibrosis. Tissue repair consists of three distinct and overlapping mechanisms: 
immune recruitment after damage, activation of immune cells and myofibroblasts, and 
myofibroblast renewal of ECM (Jun & Lau, 2018). The wound healing repair system allows to 
repopulate a damaged tissue and it is a key mechanism for individual survival. 
 
After damage, platelets form a fibrin clot to protect tissue parenchyma and they release 
chemokines and cytokines to recruitment immune cells. Tissue injury is also sensed through 
damage-associated-molecular-patterns (DAMPs) by innate immune granulocytes. DAMP-
activity is not confined to native immunity cells, as DAMPs are constantly released during all 
phases of wound healing repair and also activate non-immune cells (mesenchymal, epithelial, 
and endothelial cells). Once activated, innate immunity cells protect a damaged tissue from 
any possible infections and remove cells debris. Innate immune cells produce and release of 
cytokines and chemokines to mount a specific immune response, known as adaptive immunity 
(Jun & Lau, 2018). Therefore, innate immune response is unspecific and rapid.  
Innate immunity response starts with neutrophils, which are the first cells to be 
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recruited as the most abundant granulocyte population in the bloodstream. Subsequently, 
macrophages arrive on the site of damage to produce a more robust inflammatory response. 
Innate immunity through cytokines and chemokines then recruits cells from adaptive 
immunity, which mount a more specific immune response. However, the release of cytokines 
has a plethora of cellular effectors that can either boost or repress inflammatory response. In 
this context, macrophages have a key role in the development of inflammation, which 
dramatically impacts fibrotic development. This is because during wound healing repair, 
macrophages can change their cytokine expression profile, which affects mesenchymal ECM 
turnover. 
Macrophages are leucocyte cells deriving from either the mother yolk sac or the bone 
marrow. The first type forms the organ resident macrophage (alveolar macrophages, Kupffer 
cells as example) and the second the monocyte population in the circulation (fig. 1.1) (Distler 
et al., 2019). 
 
 
Figure 1.1 Macrophage activation and differentiation in tissue repair and fibrosis. Tissue resident 
macrophages and circulating bone marrow derived macrophage progenitors can differentiate into 
M1 and M2 with specific cytokine production profile. (from Distler et al, 2019). 
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For long macrophages have been distinct in two types, based on the difference in 
cytokine expression (known as M1 and M2 polarization), which triggers a diverse adaptive 
immune response.  
M1 polarization sees the expression of IFN-ϒ, LPS, TNF-, while IL-4, IL-13, IL-1, IL-12 and 
TGF-ß are expressed during the M2 polarization. Evidence from studies on fibrosis 
demonstrated that macrophages can change the polarization state in response to tissue 
environment (Mack, 2018). Macrophages switch from M1 to M2 to calm the inflammation 
and to stimulate ECM production through TGF-ß (see below). However, when the M2 
response is persistent, it stimulates an excessive production of ECM, which can evolve into a 
fibrotic phenotype. ECM turnover is strongly influenced by a family of enzymes known as 
Metalloproteinases (MMPs), which if dysregulated, may induce a fibrotic development. 
Macrophages control and regulate MMP expression and activation, and they also regulate 
their inhibitors (TIMPs) expression and their activity (Mack, 2018). Therefore, macrophages 
switch from M1 and M2 and vice versa based on the cytokine environment, influencing the 
type of immune response and ECM turnover, both mechanisms crucial in tissue fibrosis. 
Collectively, a large number of publications show that monocytes/macrophages play 
important but multifaceted roles in regulation of inflammation, regeneration, and fibrosis, 
depending on their polarization within tissues and the type and stage of diseases (Mack, 
2018). Possibly fine tuning the macrophage polarization state can be a future pharmacological 
strategy for cellular therapies against tissue fibrosis. (Jun & Lau, 2018). 
  
As mentioned, macrophages (and other antigen presenting cells) activate adaptive 
immunity through MHC complex interaction with T-cells receptor (TCR). This allows the 
correct mounting of the specific immune response to damage. Releasing specific subsets of 
cytokines and chemokines, T-cells produce inflammation to eradicate the source of damage 
(infective, tissue damage neoplastic, etc.), which subsequently activates mesenchymal cells 
involved in the tissue repair. Mesenchymal cells produce and release both ECM and enzymes 
able to metabolise ECM (MMPs). Mesenchymal cells are usually in a quiescent state, but after 
activation through cytokines (TGF-ß) first expand and then start producing large amounts of 
ECM. Dysregulation in this crosstalk between immune and mesenchymal cells can boost a 




In healthy wound healing, inflammation should stop once the cause of damage is 
eradicated, while mesenchymal cells remodel the ECM and repair the damage. By contrast, in 
tissue fibrosis the inflammatory response is persistent, and the repair machinery is constantly 
activated. The persistent inflammation and mesenchymal activation are chronic hallmarks of 
tissue fibrosis (Wynn, 2004). White and Mantovani in a short review defined inflammation in 
fibrosis as “too much of a good thing”, highlighting inflammation duality (White & Mantovani, 
2014). However, results from several fibrotic experimental models do not correlate the 
severity of inflammation with the amount of fibrosis, indicating that fibrogenesis and 
inflammation hold diverse roles in fibrosis outcome (Wynn, 2004).  
 
Cytokines can activate signalling pathway networks with dramatic changes on the 
surrounding environment. This is because cytokines possess autocrine and paracrine tropism 
on all cells present in a parenchyma. Therefore, in case of damage, cytokine release can 
rapidly change tissue structure through the recruitment and activation of specialised cells. The 
subsets of cytokines generally associated with a fibrotic response are the ones produced by 
Th2 cells, although TNF- and IL-1ß are also produced by Th1 cells have been found in patients 
affected by IPF and SSc (Distler et al., 2019). In addition, Th-17 cells may regulate TNF- and 
IL-1ß release by Th1 cells, and stimulate ECM production in fibrosis (Mack, 2018). It is probable 
that the Th1 and Th-17 cells control the first acute adaptive response to tissue damage, while 
Th2 cells control the progression into inflammation and tissue remodelling. This possibility is 
supported by evidence identifying a more important role of Th2 response in fibrosis 
progression, rather than initiation (Wynn, 2004). 
Typical cytokines released by Th2 cells are IL-4, IL-5, IL-10, IL-11, IL-13, and TGF-ß which 
activate the mesenchymal tissue remodelling. IL-4 can dampen the inflammation and increase 
ECM release; while IL-13 although profibrotic can attenuate fibrosis through IL-13 receptor 
decay (Mack, 2018). Interestingly, IL-4 expressing macrophages have been identified as a class 
of fibrosis related macrophages, while inhibition of IL-11 reduced fibrosis in the Bleomycin 
mouse model of lung fibrosis. IL-4 and IL-13 have pleiotropic effects and similar targets, which 






TGF-ß is the most important cytokine in the context of tissue fibrosis. This pleotropic 
cytokine is upregulated in all forms of tissue fibrosis and several studies have associated TGF-
ß activation with the molecular and cellular dysregulation underlying fibrotic disease. For this 
reason, treatment with TGF-ß or analogues are well-establish methods used in experimental 
biology to reproduce fibrotic phenotypes. TGF-ß can activate fibroblasts and other 
mesenchymal and non-mesenchymal cells to become pro-fibrotic myofibroblasts (Wynn, 
2011). However, TGF-ß is also involved in other cellular processes such as metastasis and 
angiogenesis. Myofibroblasts are mesenchymal cells fundamental in wound healing repair. 
This cell population originates from different progenitors such as fibroblasts, pericytes, 
fibrocytes, and epithelial and endothelial cells. Dysregulation of normal myofibroblast activity 
triggers fibrotic “un-healing” which culminates in the excess in ECM. In tissue fibrosis, 
myofibroblasts accumulate, crosslink, and overproduce collagen fibres and other ECM 
components. The excessive increase in ECM augments tissue stiffness, impairing the diffusion 
of nutrients and oxygen, which further propagate the dysregulated wound healing repair (D. 
J. Tschumperlin et al., 2018). In vitro studies investigating the actions of TGF-ß indicate that 
even at a concentration of 0.5 ng/mL, TGF-ß can rapidly stimulate collagen synthesis 
(Fragiadaki et al., 2011). In connective tissues, TGF-ß is present as either a free homodimer or 
attached to fibrillin through latent TGF-ß binding protein (LTBP) (Theocharis et al., 2019). This 
allows fast release of the cytokine to induce tissue restoration in case of damage.  
The TGF-ß superfamily includes TGF-ß1-ß3, activins, Bone morphogenic proteins (BMPs) 
and myostatin, which, after binding to their receptors, all transduce their intracellular signal 
through a phosphorylation cascade. TGF-ß receptors are heterodimers consisting of a 
serine/threonine kinase type I, also known as ALK 1-7, and a structural subunit (Hartmann & 
Yang, 2020). Free TGF-ß activates receptor dimerization, allowing autophosphorylation of the 
serine/threonine residues in the ALK domains (Chaudhury & Howe, 2009). The then leads to 
kinase activity resulting in the phosphorylation of activatory SMADs (SMAD1, SMAD2, SMAD3, 
SMAD5 and SMAD9). Generally, SMAD1 and 5 are also activated by BMP7, while SMAD2 and 
3 are only activated by TGF-ß. SMAD2 and 3 are activated through a mechanism involving an 
anchor protein, known as SARA (Smad Anchor for Receptor Activation). Binding to phospho-
SMAD 2 and 3, SARA brings this complex in close proximity to the TGF-ß receptor, increasing 
the affinity to SMAD4. SMAD4 is a regulatory member of the SMAD family and it is necessary 
for nuclear translocation and DNA binding, which enhances ECM gene transcription (fig 1.2) 
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(X. Yan, Liu, & Chen, 2009). The SMAD2/3/4 complex acts as transcription factor binding to 
SBE (Smad binding elements) stimulating transcription of a variety of genes (Col1a1, Col1a3, 
CCN2, Snail, Slug, Fibulin-1, PDGRFRα, TGF-ß1 receptor, IL-1ß etc.). This pathway also triggers 
a positive feedback loop on TGF-ß1 receptor expression, which further increase the 
expression of key genes involved in organ fibrosis. This mechanism rapidly augments ECM 
production by mesenchymal cells (Troncone et al., 2018). However, to limit the power of this 
pathway, inhibitory Smads (SMAD6 and -7) are upregulated by TGF-ß as well. SMAD6 and -7 
serve as a negative feedback loop to limit the activity of the TGF-ß signalling cascade 
(Troncone et al., 2018).  
Through this canonical pathway, fibrillar collagens, CCCN2/CTGF, laminins, fibronectins 
and other structural protein are upregulated in their expression (Wynn, 2011). This activation 
results in increased ECM synthesis and secretion by fibroblasts and partially by epithelial cells 
(Chaudhury & Howe, 2009). In healthy repair conditions, ECM production creates a barrier to 
pathogens and helps to sustain the epithelial regeneration. In contrast, in fibrosis, this 
activation, for reasons that are as yet unknown, triggers an excessive production of ECM and 
tissue disruption (X. Yan et al., 2009). 
 
 
Figure 1.2 Schematic cartoon of TGF-ß canonical pathway (see SMAD pathway). On the right side 
of the cartoon pathways at the basis of EMT activation from TGF-ß (see text). 
Non-canonical TGF-ß pathways, although starting from the same TGF-ß receptor, differ 
from the canonical pathway in the downstream effectors (PI3K/Akt, Rho, Rock, and Grb2). The 
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activation of this signalling pathway results in epithelial to mesenchymal transition (EMT), a 
fibrosis-related mechanism.  
EMT is a biological mechanism that is the opposite of mesenchymal to epithelial 
transition (MET, which is rarer). EMT was first discovered in gastrulation and neural crest 
formation, processes controlled by SNAIL, a DNA repressor protein family (Kalluri & Weinberg, 
2009). An EMT-dependent increase in mesenchymal cells appears to participate in tissue 
fibrosis, as it increases the mesenchymal cell pool in a damaged tissue. Evidence from in vitro 
studies identified TGF-ß as master regulator of EMT (Chaudhury & Howe, 2009). In epithelia 
associated with a fibrotic cytokine environment, TGF-ß triggers Snail and Slug activation 
through a SMAD dependent mechanism (Thiery et al., 2009), leading to an increase in 
myofibroblasts.. This mechanism can trigger a fibrotic development. However the importance 
of EMT has only been conclusively shown in kidney fibrosis in vivo, while there is still a lack of 
information regarding the role of EMT in liver and lung fibrosis (Kalluri & Weinberg, 2009). 
The 2007 EMT meeting has decided to classify EMT in three categories related to: 
embryogenesis (type 1), wound healing/tissue regeneration and fibrosis (type 2) and 
cancer/metastasis (type 3) (Kalluri & Weinberg, 2009). However, this classification was made 
to distinguish between the same molecular mechanisms in three different biological 
processes that differ dramatically.  
At the cellular level EMT is governed by a finely tuned transcriptional regulation, which 
determines cytoskeletal remodelling and dramatic changes in the expression of cell adhesion 
molecules and surface markers. The resulting cells present mesenchymal markers and 
respond to mesenchymal stimuli. The type 2 EMT (fibrotic) is the process that allows an 
epithelial cell to become a mesenchymal cell after an inflammatory stimulation or in response 
to TGF-ß. However, once the damage has been repaired, the mesenchymal cells should 
undergo apoptosis or MET to revert to normal tissue homeostasis. In fibrosis, however, the 
constant level of inflammation potentiates EMT, giving rise to abnormal mesenchymal cell 
numbers (Kalluri & Weinberg, 2009). EMT is not an instant mechanism, but a progressive 
series of changes associated with phenotypical alteration in terms of adhesion, cytoskeleton, 
and protein secretion. Non-canonical  TGF-ß activation promotes epithelial polarization 
through Smurf (Smad associated E3-ubiquitin ligase)-dependent Rho GTPase degradation, 
which triggers tight junction disruption (Massagué, 2012). Gradually the epithelial cells gain 
mesenchymal markers such as N-cadherin, instead of E-cadherin (Thiery et al., 2009). Next, 
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surface integrins gradually change, switching from E- to N-cadherin. For example, integrin the 
expression of β4 is decreases, leading to decreased contacts with basal membrane. Then, in 
later stages of this process, cells will start to increase expression of α-smooth actin and fibrillar 
collagens  The non-canonical TGF-ß pathway also contributes to this transformation through 
Phoshoinositol-3 kinase (PI3K) and p38 (MAP kinase) activation (Massagué, 2012). However, 
it is not clear if cytoskeletal modification results from the non-canonical pathway activation 
or as a secondary effect of TGF-ß canonical activation. Moreover, PI3K and p38 signalling 
pathways also occur in type 3 EMT (metastatic EMT) and SMAD signalling is over-expressed in 
tumour initiating cell stemness and is considered pro-metastatic (Massagué, 2008). However, 
in metastasis ECM remodelling leads to cancer stem cell escape, while in tissue fibrosis ECM 
remodelling triggers parenchymal disruption, two phenotypical distinct processes. 
The contribution of EMT to fibrosis can be quite dramatic, it has been estimated that 
EMT accounts for the 30% of the mesenchymal cell population in kidney fibrosis. Increasing 
evidence currently also demonstrates the role of endothelial to mesenchymal transition 
(EndoMT) in tissue fibrosis (Hashimoto et al., 2010) (Kalluri & Neilson, 2003).  
 
Mesenchymal fibroblasts are considered to be the most important cell type in tissue 
fibrosis. Fibroblasts are slow contractile cells, with unique proliferative capabilities 
(Abercrombie, 1979). As mentioned, fibroblasts are mesenchymal cells, distributed sparsely 
in the connective tissue, where they create (in development) and model (in adult life) ECM. In 
adult life fibroblasts remodel ECM by increasing fibre cross-linking, which makes fibres resist 
digestion by degrading enzymes. Fibroblasts regulate enzymatic crosslinking via lysyl-oxidase 
(LOX) and tissue transglutaminase (TG2), which crosslink diverse collagen fibres and can also 
cross-link collagens to fibronectin (see paragraph on fibrillogenesis). This mechanism 
dramatically increases in pathological condition and with ageing (Theocharis et al., 2019). 
Fibroblasts maintain ECM stability moving across connective tissue and organ interstitium 
through chemotaxis (Kendall & Feghali-Bostwick, 2014). Without environmental stimulation, 
adult fibroblasts do not produce large quantities of ECM (Laurent, 1986). In contrast, after 
tissue damage fibroblasts activate into myofibroblasts, which rapidly respond to damage, 
remodelling ECM. As described above, myofibroblasts can originate from mesenchymal cell 
lineage such as fibroblasts, fibrocyte, smooth muscle cells, and from epithelial and endothelial 
cells through EMT and Endo-MT respectively (Kendall & Feghali-Bostwick, 2014). Although 
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myofibroblasts have a key role in wound healing repair, excess myofibroblast activity 
underpins all known forms of tissue fibrosis. Exacerbation and persistent TGF-ß signalling 
activation can lead to fibrotic development. TGF-ß expression can rapidly increase through a 
positive feedback mechanism. Although SMAD6 and SMAD7 suppress the canonical TGF-ß 
pathway, this inhibition does not seem to be able to prevent development of fibrosis (X. Yan 
et al., 2009). The positive feedback loop in the TGF-ß signalling  potentiates ECM release by 
myofibroblasts, leading to fibrosis (Kendall & Feghali-Bostwick, 2014). The effects induced by 
TGF-ß in this cell population are not limited to ECM expression. Interestingly, TGF-ß rapidly 
increases CTGF/CCN2 and IL-6 expression, two proteins that boost collagen expression in 
myofibroblasts (Kendall & Feghali-Bostwick, 2014). As mentioned above, TGF-ß is often bound 
to a protein complex that reduces cytokine availability and to fibrillin (Theocharis et al., 2019). 
Matrix remodelling through activation of MMPs, mostly derived from macrophages, can 
degrade fibrillin fibres, leading to release of the TGF-ß, and increased pro-fibrotic signalling.  
Understanding the role of TGF-ß in fibrotic fibroblasts or myofibroblasts, is a challenge, 
as myofibroblasts can originate from different sources (as mentioned above). Excluding EMT, 
myofibroblasts involved in fibrosis originate from different mesenchymal sources, however, 
understanding the single sub-type contribution is challenging. Moreover, there is not a 
univocal cluster of cell markers that clearly identify myofibroblasts. Myofibroblast activation 
changes cell morphology due to cytoskeletal rearrangement, highlighted by -smooth actin 
expression (Rybinski et al., 2014). This mechanism allows myofibroblasts to move across the 
septa and the damaged epithelium to repair the damage. The repair dysregulation taking 
place in fibrosis is thought to be due to a prolonged activation in response to chronic damage, 
which exacerbates myofibroblasts activation (Rybinski et al., 2014). 
 
Studies from animal models have shown that fibrosis might be reversible in early stages 
and once the aetiology is eliminated. However this is not the case for idiopathic lung fibrosis 
(Jun & Lau, 2018). Although organ fibrosis presents a similar mechanism of action, it has 
distinct phenotypes in each organ, reflecting differences in tissue structure and organization 
as well as ECM composition. For this reason liver and kidney fibrosis appear more treatable 
than heart and lung fibrosis (Jun & Lau, 2018).  
 
Liver contains highly specialized cells involved in metabolisms and hepatocytes have 
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considerable regenerative capability. Cellular therapies using macrophages have 
demonstrated the possibility to decrease collagen deposition in animal models of liver fibrosis 
(Mack, 2018). Therapies for kidney fibrosis are demonstrating the possibility to recapitulate 
disease phenotype as well. Tim Johnson developed a selective inhibitor of transglutaminase 2 
TG2, which appears to revert disease hallmarks. This TG2 inhibitor has now passed pre-clinical 
trial, as it was extensively demonstrated the possibility to revert increase in collagen 
deposition in a model of chronic kidney fibrosis in rabbits (Atkinson, Pullen, Da Silva-Lodge, 
Williams, & Johnson, 2015). By contrast, cardiac fibrosis can be irreversible in some severe 
conditions. In cardiac fibrosis, hypertension and cardiac infraction can dramatically change 
disease outcome, despite cardiomyocytes have little regenerative capability and therefore 
they cannot deposit enormous quantity of collagen (Jun & Lau, 2018). On the other hand, 
pericyte and smooth muscle cells becoming myofibroblasts can dramatically increase fibrotic 
formation. At the state of art there are no effective therapies to revers cardiac fibrosis.  
 
In summary, after tissue damage, megakaryocytes release chemokines and cytokines. 
Cytokines activate cells of the innate immune system and alveolar epithelial type-II cells, 
which release inflammatory mediators for host-protection, while chemokines recruit immune 
cells. Neutrophils and macrophages are usually the first cells that mediate innate immunity. 
Neutrophils possess a high secretory activity of lytic enzymes and inflammatory mediators, 
which recruit lymphocytes and activate macrophages to switch from M1 to M2. This 
mechanism starts a more robust inflammatory response, activating leucocytes Th2-response 
with secretion of IL-1ß, TNF-α, IL-4, IL-11, IL-13 and TGF-ß. Those cytokines activate 
myofibroblasts, which remodel ECM to repair the damaged tissue. Then, if wound healing 
repair apparatus is altered, this results in a persistent response to damage which gradually 





Figure 1.3 Schematic mechanism of fibrosis. After an epithelial injury, inflammatory mediators 
recruit innate immune cells and T cells mount an inflammatory response. T-cells secrete 
proinflammatory cytokines and TGF-ß. Cytokine environment activates fibrocyte, resident 
fibroblast, epithelia cells (through EMT) to remodel ECM. In healthy condition ECM is produced to 
trigger epithelia regeneration, once this result is achieved ECM is degraded, myofibroblasts 
undergoes apoptosis and tissue integrity is restored. In IPF (as well in other fibrotic development) 





1.2. Interstitial lung disease, IPF and Bleomycin usage as model for lung 
fibrosis 
 
Interstitial lung disease (ILD) and pulmonary fibrosis comprise a wide range of lung 
diseases (Kalchiem-Dekel, Galvin, Burke, Atamas, & Todd, 2018). Figure 1.4 shows a schematic 




Figure 1.4 Set-theoretic classification of ILD phenotypes. Pulmonary fibrotic outcome is one of most 
likely pathological progression of ILD, IPF holding the worst prognosis (from Kalchiem-Dekel et al., 
2018) 
ILDs start with acute inflammation and little fibrotic development, therefore treatment 
with anti-inflammatory drugs are quite effective in early stages of disease (Kalchiem-Dekel et 
al., 2018). By contrast, in IPF or severe forms of pulmonary fibrosis, pulmonologists advice 
against the use of immunosuppressive and anti-inflammatory treatments (Fujimoto, 
Kobayashi, & Azuma, 2015).  
ILDs are usually classified in interstitial pneumonia (UIP), organizing pneumonia (OP) 
and non-specific interstitial pneumonia (NSIP). UIP and NSIP show sparse dense fibrotic areas 
with necrotic fibroblasts immerse in ECM (fibroblasts foci), whereas OP shows spindle-shaped 
fibroblasts and oval-shape ECM (Kalchiem-Dekel et al., 2018). Without considering diseases 
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aetiology, in most of cases, ILDs show progressive evolution into fibrosis from an inflammatory 
state. However, IPF and PF phenotypes are associated more with UIP than NSIP (Murray et al., 
2012). Both diseases present differences in aetiology, histopathological pattern, and in 
biomarker associated with the disease. However, lack of a precise histopathological 
classification of clinically recognized pulmonary fibrosis resulting from conflicting reports has 
been for long a problem in diagnosis (Kalchiem-Dekel et al., 2018). ILD induced by systemic 
sclerosis (SSc-ILD) can be confused with IPF and vice versa, as both present fibrotic 
development, similar biomarkers (IL-13, IL-1R, CCN2/CTGF as example),and similar 
histopathological and CT scan patterns (Lagares et al., 2017). This limitation in diagnosis has 
critical consequences in disease treatment, as an anti-inflammatory treatment can worsen 
IPF. (Murray et al., 2012). Although SSc-ILD (autoimmune ILD in fig. 1.4) appears 
phenotypically very similar to IPF, in the last decade high resolution tomography has evolved 
to discern between the two phenotypes (Lagares et al., 2017). Tomography scans from both 
SSc-ILD and IPF consist in sparse attenuation of X-ray (also called GGO, ground-glass opacities) 
across lung subpleural cross-sections. However, GGO has a different appearance in SSc-ILD 
versus IPF, and honeycombing is a feature (in some cases) present only IPF patients (fig. 1.5) 





Figure 1.5 HRCT scan from patients affected by ILD. ILDs presents a high level of overlapping. SSc-
ILD (left) and IPF (right) similarities become limitation in clinical practise (see text). The figure shows 
differences in ground-glass opacity and similarities in subpleural fibrotic development, highlighted 
with white arrow (SSc-ILD left) and black arrow (IPF right)  
 
There is substantial variation in the appearance of fibrosis between individual patients. 
For example, fibroblast foci or honeycomb formations are correlated with more severe 
fibrosis, however they are only present in a minority of IPF patients (Kalchiem-Dekel et al., 
2018).  
ILD biodiversity represents a limit also in experimental biology. Reproducing the wide 
spectrum of fibrotic features of human lung fibrosis within a single animal model is currently 
not possible Therefore, different animal models of lung fibrosis have been developed using 
exposure to toxic molecules, irradiation and gene overexpression (Degryse & Lawson, 2011). 
The single exposure to a profibrotic concentration of Bleomycin remains the most used model 
and perhaps the most established as well. A single intratracheal or oropharyngeal 
administration of Bleomycin leads to  an initial immune phase,  followed by fibrosis (Wynn, 
2011).  
Bleomycin is drug used for treatment of patients with lung cancer, however, the drug is 
used in experimental biology as it induces fibrosis very similar to human lung fibrosis. 
Bleomycin induces both single and double strand DNA breaks (ssDNA or dsDNA) which lead 
to fibrosis. Subcutaneous administration of Bleomycin initiates a SSc-ILD like disease (Murray 
et al., 2012). The intratracheal/oropharyngeal route is the gold standard method to induce 
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lung fibrosis in rodents. Interestingly, Lakatos and collaborator compared intratracheal and 
oropharyngeal silica administration in the mouse, demonstrating that both administration 
routes were equivalent for drug delivery. Oropharyngeal localized in the distal parenchyma, 
while intratracheal more close to the hilum (see 2.2) (Lakatos et al., 2006). Although the 
Bleomycin model of lung fibrosis is fast and quite reproduceable, it has technical limitations 
due to the lack in hyperplastic alveolar type II cells, usually induced by chronic damage. 
Moreover, in rodents, Bleomycin-induced-fibrosis resolves after 21 days from the first 
injection (Mouratis & Aidinis, 2011).  
Another disadvantage is that the Bleomycin model reproduces fibrotic features also 
common to SSc-ILD. This limitation is important in drug development, as drugs for both SSc-
ILD and IPF are tested with a very similar animal model, despite the differences in disease 
aetiology. As mentioned, anti-inflammatory drugs are not recommended in patients with lung 
fibrosis. As a result of limitations in the Bleomycin model, drugs that appeared successful in 
initial animal studies failed in the further studies. Examples of this are INF-ϒ, Pirfenidone, 
Etanercept (TNF mAb) and bosentan (Murray et al., 2012).  
Nevertheless, the Bleomycin model of lung fibrosis remains a fundamental tool in this 
field of research. However, disease variability, with overlap across IPF, PF and SSc-ILD 
represents major limitation of this system. In recent years organoids have become a novel 
model for the study of complex disease, such as lung fibrosis. However, the structural and 
cellular complexity of the lung has so far prevented the development of a suitable organoid 
model system for lung fibrosis. 
 
1.2.1. Diagnosis of Pulmonary fibrosis 
 
In lung pathophysiology, diagnostic uncertainty has been a historical limitation due to 
overlap in disease phenotypes. IPF and PF main distinction is in their aetiology, which is 
unknown for IPF. However, due to conflicting histological reports there is no clear disease 
classification. The high variability among lung fibrotic features, is a big limitation and has to 
be taken in account in both experimental and clinical practice (Kalchiem-Dekel et al., 2018).  
Formulating a straightforward and accurate diagnosis for IPF for clinicians has been a 
challenge. The most common symptoms are considered to be “dry cough”, as well as weight 
loss, fever, and arthralgia (Meltzer & Noble, 2008). IPF symptoms are common to many other 
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lung diseases, such as chronic obstructive pulmonary disease (COPD) and lung cancers. This 
unspecific symptomatology is driven by the magnitude of response to damage, which is typical 
during early stages of the disease. Clearer signs of fibrosis are detectable during the late stages 
of the disease, where treatments cannot revert the fibrotic phenotype. Moreover, there are 
no specific and sensitive routine laboratory test that can univocally diagnose IPF in a patient. 
However, physiologic changes in spirometry parameters, such as lung capacity or lung volume 
are historically well- established methods to detect IPF (Wynn, 2011). Spirometry changes are 
due to changes in lung architecture due to a in decrease in ECM turnover. However, routine 
laboratory tests (blood test) and spirometry evaluations cannot be considered as gold 
standard due to technical limitations. On the other hand, imaging techniques such as high-
resolution computerized tomography (HRCT) have become crucial in IPF diagnosis and is 
considered the gold standard for IPF diagnosis (Martinez et al., 2017). The presence of 
honeycombing is considered a clear hallmark of disease physiology. Honeycomb is a multiple 
unshaped thin fibrotic-like wall cysts which modifies the acinar lung architecture. The result 
of honeycomb formations is an enlargement of both lung bronchiole and epithelial. 
Honeycombs are composed mostly of ECM and they appear translucent at HRCT. Although 
honeycombing shares similarities with emphysema, honeycombing is considered as a clear 
manifestation of fibrosis in later stages of IPF (Arakawa et al., 2011). Nevertheless, only 30% 
of IPF patients present honeycombing in HRCT scans. More invasive tests, such as surgical lung 
biopsies, are generally used to overcome an uncertain diagnosis. Histological stains permit 
identification of clear fibrotic features, such as parenchymal disruption, fibroblast foci, tissue 
scaring and immune infiltration. Limitation to this is the possibility to produce false negative 
results due to the presence of fibrotic lesion only in a localised area. Therefore, as a single 
step diagnosis might fail in the identification of fibrosis, there is an increasing interest to 
develop a multidisciplinary approach. Although the increase in the number of tests also raises 
the possibility of systematic error, a multidisciplinary approach seems to improve the accuracy 
in the diagnostic process. Of note is the discovery of a  number of serum markers such as 
specific microRNAs (X. Yang et al., 2015), metalloproteinases (MMP-1 and MMP-7) (Rosas et 
al., 2008) or proteins (endotelin- 1 and surfactant protein), which might lay the foundation for 
a better diagnosis in lung fibrosis. The clinical challenge is then to set standardized guidelines 
applicable to large scale populations for diagnosis. However, HRCT together with surgical lung 
biopsy remain the clinical gold standard for diagnosis (Martinez et al., 2017). Interestingly, 
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Burgstaller and collaborators identified possible molecular signature in lung diseases 
analysing ECM through a proteomic approach, which might be a new strategy for a fast and 




1.3. Lung Structure and Physiology 
 
The lung is an evolutionary unique organ, a vertebrate adaptation to air for oxidative 
metabolism. The lung provides oxygen to tissues and the release of carbon dioxide during 
each breathing cycle. In alveolar sacs and in transitional bronchioles oxygen is exchanged with 
carbon dioxide and vice versa in a diffusion process (Hsia et al., 2016). Tissues need oxygen to 
complete aerobic respiration, which is fundamental to produce ATP in mitochondria. Carbon 
dioxide is the final product of aerobic metabolism, and it can be considered as “waste”. 
Vertebrates constantly breathe through a controlled mechanism involving involuntary 
innervation. This gas exchange necessary to live, is brought in from the trachea to the 
bronchiole through convention, while gases diffuse through the alveolar and transitional 
bronchiole. This latter is the actual location for gas exchange through circulation and provides 
oxygen and releases carbon dioxide (Hsia et al., 2016). Lung is characterised by an 
inhomogeneous stratified epithelia, composed of a wide range of different cell types, which 
reflects functional differences between proximal and distal regions (fig. 1.6). 
 
Figure 1.6 Cast of human bronchial tree with airways (yellow), pulmonary arteries (red), and 
pulmonary veins (blue) (From Hsia et al., 2016). 
Proximal and distal lung can be then divided in two different compartments based on 
their function and cell population. Regarding cell heterogeneity, Whitsett and his 
collaborators produced in November 2018 a fundamental publication for lung biologist 
(Whitsett et al., 2018). Through single cell RNA analysis and bioinformatic tools they clustered 
each cellular lineage identifying 1) Epithelial cell (Ciliated, Club, alveolar epithelial type I and 
type II) 2) Immune cells (T and B lymphocytes, basophils and macrophages) 3) Mesenchymal 
(smooth muscle cells, pericyte, matrix and lipo-fibroblast and myofibroblast) and Endothelial 
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(lymphatic and vascular endothelial) (fig. 1.7). 
 
Figure 1.7 Hierarchical clustering for major lung cell types predicted from the RNA-sequencing data, from 
Whitsett and collaborator analysis from whole mouse lung. Endo, endothelial cells; Mesen, mesenchymal 
cells; Epi, epithelial cells; Immune, immune cells; FB, fibroblast cells; AT1, alveolar type 1 cells; AT2, 
alveolar type 2 cells; MyoFB, myofibroblast cells; SMC, smooth muscle cells; MatrixFB, matrix fibroblast 
cells. (From Whitsett, Kalin, Xu, & Kalinichenko, 2018). 
Proximal airways are generally referred as conducting airways. Their main role is to 
conduct air in the direction of transition bronchioles and alveoli, generating O2 and CO2 
gradients (Hsia et al., 2016). Conducting airways are composed of cartilaginous cells (trachea 
and bronchi) and a mixture of basal epithelia cells, comprising ciliated, goblet, club, and 
immune cells. In adults, basal cells serve as a pool for epithelial cells, however in distal airways 
basal cells differs from proximal ones in morphology, molecular signature, and molecular 
function (Whitsett et al., 2018). Lung basal cells possess secretory activity fundamental for 
host protection and for production of surfactant molecules involved in gas exchange. The 
basal cell proliferation state depends on interaction with mesenchymal cells through 
production of growth factors (TGF-ß and IL-1). Ciliated, club and goblet cells possess a high 
secretory activity and participate in innate immunity (Schittny, 2017). Brush cells compose a 
first barrier in lung apex. Club, goblet, and brush cells are activated in response to intoxicant, 
and represent the first host defence against pathogens, whereas ciliated cells remove the 
debris. Club and brush cells produce lactoferrin and defensin, while goblet cells mucins 
MUC5A and MUC5B. Club cells produce surfactant protein A and B, but not C, involved in the 
surface tension that allows gas exchange (fig. 1.8). Other cells composing this track are 
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neuroendocrine cells, which are as “gas sensors” (Whitsett et al., 2018). 
 
Figure 1.8 Electron microscopy image of proximal conductive airways. Image are identified as 
Goblet cells indicated by G; Ciliated cells can be identified by flagellum structures. Brush cells 
are identified by black arrows in the lower image. [Image from google image). 
The distal airway, as mentioned above, composes the gas exchange unit and relative 
branches. Gas exchange is achieved through the diffusion of O2 and CO2 between the alveolar 
wall and lung microcirculation. A dense capillary network connected to terminal branches is 
the prolongation of pulmonary arteries and veins. This brings arterial walls and capillaries, 
separated by septa, in proximity favouring gas exchange. To optimize gas exchanges between 
epithelia, the contact surface is spread out over the surface. Capillaries and alveolar walls are 
in close contact, to maximize the volume of air, by contrast conductive airways minimize dead 






Moreover, capillaries are smaller and denser than alveoli, which are also not 
homogenous between them (Hsia et al., 2016). Alveolar epithelium is a mosaic of alveolar 
type-I and II epithelial cells and originate from the same squamous alveolar epithelial 
precursor cell. Those cells originated once the structure of bronchoalveolar duct is formed, 
through myofibroblast ECM deposition. Interestingly, the alveolar epithelia progenitor 
originates from the foregut (endoderm) and are already present during conductive airway 
budding. However, only in the canalicular and saccular phase do they start to differentiate 
into mature alveolar epithelia (Whitsett et al., 2018). After branching morphogenesis, these 
cells accelerate their proliferation, colonizing the scaffold built by myofibroblasts. In the adult 
lung, alveolar epithelial type-II cells originate during cannulation are able to differentiate into 
alveolar type-I cells (Schittny, 2017). Alveolar epithelia type-II cells are in a lower abundance 
and cover less than the 5% of the entire alveolar parenchyma, where they produce and recycle 
lipids to obtain surfactant proteins (Hsia et al., 2016). Surfactant proteins are produced in the 
canicular phase and released in the airways in order to promote increase in gas tension and 
promote gas exchange (Whitsett et al., 2018). Alveolar epithelia type-I cells cover more than 
Figure 1.9 Proximal airway allows the mass flow of air in the conductive airways, while 
alveolar structures allow the gas exchange through a diffusion mechanism. Therefore, 
conductive airway generates a flow, which allows diffusion of gasses due to irregular 
structure of distal airways (from transitional bronchiole to alveoli)(from Hsia et al., 2016).  
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95% of the total alveolar parenchyma and appear as an unaligned leaflet, which extends over 
capillaries surface, where they promote O2 diffusion. Alveolar epithelial cells are separated by 
a thin interstitium from endothelial cells, where the gas exchange takes place (fig. 1.10) (Hsia 
et al., 2016). Lung mesenchymal cells generate the alveolar scaffold in the saccular- alveolar 
phase, while they are involved in wound healing repair in adult life. Mesenchymal cells are 
associated with both the alveolar epithelium and endothelium of the capillaries (fig. 1.10) 
(Whitsett et al., 2018). Lung fibroblasts include lipofibroblasts, myofibroblasts and matrix 
fibroblasts. Lipofibroblasts participate in lung fibre organization and contribute to surfactant 
protein synthesis (McGowan & Torday, 1997). Myofibroblasts are associated with the alveolar 
interstitium, where they are orientated in the direction in which the alveolar walls contract, 
and they express α-smooth actin although they are different from smooth muscle cells. 






Figure 1.10 Electron micrographs of alveolar human lung showing capillaries (C), type-1 alveolar 
epithelium (Ep1) and elements of the interstitium such as collagen (cf) and elastic (ef) fibres and 
fibroblast (fb) that focally can form myofibrils (myo) and serve as myofibroblasts bracing the interstitial 
space. (From Hsia et al., 2016). 
Lung function is maintained during each air cycle thanks to a tree-like structure 
composed of a network of fibres and filament. This structure allows influx and efflux of air and 
to overcome mechanical stretch induced by ventilation, where ventilation is the movement 
of fresh bloom of air (Béla Suki et al., 2011). Conductive airways increase air flow velocity as 
the cross-section area decreases following proximal direction. Once airflow reaches alveoli 
the uneven alveolar geometry induces an increase in cross-section area and a decrease in flow 
velocity (fig. 1.9) (Hsia et al., 2016). Therefore, the new air will diffuse only after energy 
dissipation. For these reasons, lung architecture is defined as a tensegrity structure, where 
stiffer fibres (in conductive airway) support and propagate the mechanical stretch without 
structural collapse (Béla Suki et al., 2011). Tensegrity is a building principle where structures 
that stabilize the shape of a system are in continuous tension or “tensional integrity” rather 




Figure 1.11 Example of Tensegrity represented by Snelson sculpture, where the tensegrity force 
balance is based on local compression and continuous tension (From Ingber, 2003). 
This system can resemble the lung connective component, although a certain amount 
of compression is exerted by respiratory muscles on the pleura (Hsia et al., 2016; Béla Suki et 
al., 2011). The architectural structure of mammalian lungs undergoes a number of volume 
pressure modifications induced by respiratory cycles. Connective tissue elastic properties 
guarantee volumetric variation in lung expansion and recoil. Lung architecture is composed 
of an integral connective tissue continuum that expand from conductive airways into alveolar, 
which spans the entire lung until the pleura (Hsia et al., 2016). Moreover, this scaffold 
connects and separates (as septa) airway epithelium from vascular endothelium. This flexible 
connective tissue presents a hierarchical composition formed by 1) axial fibres that connect 
bronchi and bronchioles continues into the alveolar ducts 2) peripheral fibres from the pleura 
to lung parenchyma 3) septa fibres from the intra-alveolar space to capillaries, this latter point 




Figure 1.12 Schematic cartoon representation of lung fibres architecture. Axial fibres are coloured 
in red and indicated by a. Axial fibres represent ECM that goes from bronchi to alveoli. Peripheral 
fibres are coloured in black and indicated by p. They connect lung edge to the pleura and are also 
attached to fibres that compose alveolar-capillary interface, which is represented by septa fibres 
coloured in green and indicated by letter s (From Hsia et al., 2016). 
This structure allows chest and diaphragm movement to be propagated through fibres 
onto cells composing the alveolar and capillaries tissue. This transmission of stretch pulls 
fibres extending the contact surface between alveoli and capillaries also determining gas 
diffusion. The connective tissue associated with lung is composed by cells and ECM including 
water and biological macromolecules. Pulmonary ECM is organized into two main structural 
types; basement membranes (covers basal side of epithelial and endothelial cells) and 
interstitial matrix. Basal membrane and interstitial matrix together form tissue-specific niches, 
fundamental sources of stem cells (Burgstaller et al., 2017). Interstitial matrix forms lung 
scaffolding fibres, which compose the connective tissue mentioned above. The major ECM 
components that make up lung structure are collagen, elastin, and proteoglycans. Each ECM 
component has a different structural role in response to lung deformation, resulting in 
differences in mechanobiological properties. In addition, ECM contains secreted proteins, 
such as growth factors, ECM-modifying enzymes and other ECM-associated proteins which do 
not contribute to the structure of ECM, but affect its function (Burgstaller et al., 2017). 
Collagen is the most abundant and rigid protein present in the lung, and it is considered 
a determinant factor in lung mechanobiology. Collagen type-I, III and IV constitute around the 
15% of total lung dry weight and are the major protein group (Laurent, 1986). Type-I and III 
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form fibres that support the entire lung parenchyma, where collagen fibres are the most 
abundant component (fig. 1.7). They extend from a central axial fibre network down to 
peripherical alveoli, passing through bronchoalveolar ducts, which also extend from the 
visceral pleura and a parenchymal interstitium that connects the two (Hsia et al., 2016). From 
a biomechanics point of view, collagen fibres are structural filaments that influence the non-
linear elastic behaviour of the lung, expressed as lung hysteresis in cyclic breathing. More 
detailed information on collagen fibres and the role of collagen type-I and III in lung fibrosis 
are discussed in 1.3.1. Collagen type IV is less abundant and forms a sheet layer as part of the 
epithelial basement membrane (Béla Suki et al., 2011). Collagen type-IV forms a network in 
which four molecules are assembled forming tetramers, however its role in conferring stability 
to lung deformation is poorly studied (Ricard-Blum, 2011). 
 
 
Elastin provides elasticity to the lung scaffold and is synthetized as tropo- elastin by 
mesenchymal and endothelial cells. Elastin molecules in combination with other ECM proteins 
(fibulins fibrillin and glycoproteins) form microfibrils in a self- assembling mechanism. In 
addition, separated elastin molecules cross-link through hydrophobic bonds forming fibres of 
elastin (Béla Suki et al., 2011). In alveolar walls, those fibres overlap and bind collagen fibres 
via RGD-motifs (Burgstaller et al., 2017). This matrix composition allows a proper hysterical 
deformation of lung parenchyma, allowing the serial alveolar opening during gas exchange. 
Figure 1.13 mouse lung stained for collagen fibres indicated by the red colour due to the 
staining with Sirius Red, which stains collagen fibres. From the picture it is possible to 
appreciate hexagonal like structure representing alveoli. A major blood vessel can be 
discriminated by an increased stain for Sirius Red and by the presence of red blood cells, in 
which appear as green-yellow in this stain. 
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However, elastic fibres are less important than collagen fibres in properly maintaining lung 
structure. 
Proteoglycans (PGs) or Glycosaminoglycans (GAGs) are the second most abundant ECM 
component in the lung. PGs and GAGs possess a protein core connected to long chains of 
repeated disaccharide units soluble in water and therefore charged. PGs and GAGs dissolved 
in water become the ground substance, which embedded the connective tissue (Béla Suki et 
al., 2011). The main role of PGs and GAGs is to sequester water that might change secondary 
and tertiary collagen structure. In the expiratory phase surfactant molecules together with 
PGs and GAGs avoids the alveolar collapsing through trapping a residual volume of air in the 






The following subparagraphs provide detailed information regarding genes studied in 
this experimental thesis on microRNAs and lung fibrosis. In the experimental sections fibrillar 
collagens, CCN2/CTGF, Snail family associated with EMT, and inhibitory Smad; have been 




Collagens are the most abundant proteins in mammals, and they comprise 28 isotypes 
(Tab. 1.1), numbered with Roman numerals numbers in vertebrates. Each collagen has a 
different role and abundance in each body compartment. They are formed by triple α-chain 













Table 1.1 Collagens type (From Ricard-Blum, 2011). 
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The length of the Amino acid chains varies in number from 622 to 3152 amino acids acid 
per α-chain between the different collagens. Although each collagen has a unique α-chain 
amino acid sequence, there are similarities in the amino-acid sequence with characteristic 
Gly-X-Y repeats, where X and Y are either proline, alanine or hydroxyproline. Collagens can be 
subdivided in into subfamilies based on their super-molecular assemblies: fibrils, beaded 
filaments, anchoring fibrils, and networks (Ricard-Blum, 2011). Fibrillar collagen have a 
dedicated paragraph in this thesis, because of their importance in fibrosis (see below). Fibrillar 
associated collagens do not form fibres, but they are covalently bound to the fibres. Beaded 
filaments, between different epithelial layers composed mostly of collagen type VI, it is 
thought that they can interact with basal membranes and as well to fibrillar collagens. 
Network collagens possess a peculiar structure due to the lack in glycine, as composed by 
collagen type IV, which accounts for different mechanical properties. They form network 
structure through N-C terminal binding. 
 
1.4.1.1.  Fibrillar Collagens 
 
Fibrillar collagens account for the structural environment and hold a key role in lung 
mechanics and fibrosis. They are formed by one major triple-helix structure folded in a zipper-
like fashion. The presence of hydroxyproline in the α- chain of both collagen type-I and type-
III is fundamental for the formation of the fibrils. At the super molecular level, rigidity is 
achieved as in the procollagen molecule (the pro-peptide) the hydroxyproline-lysine of single 
α-chains forms a so called “rope-shape” structure able to resist to mechanical force, thus 
assembling fibres. The lack of hydroxyproline, in both inter and intra molecules binding, 
accounts for the elastic capability, that allow the stretch of the fibres without the disruption 
of the rod-like super molecular structure (Béla Suki et al., 2011). As example, collagen type I 
is longer and more united in the structure than collagen IV, that contains fewer hydroxyproline 
binding sites. Therefore, Collagen type-I can assemble more rigid fibres through triple α-chain 
helix link together by covalent bounds, which would need then a higher amount of energy to 
be broken compared to Collagen type-IV (Shoulders & Raines, 2009). 
Fibrils are assembled as a quasi-hexagonal rod-like structure. This structure is at the 
basis of the mechanical properties of this subfamily. Of particular interest is the lysine-
hydroxyproline-lysin bonds between different triple helix that maintains collagen structure 
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integrity (Orgel, Irving, Miller, & Wess, 2006). Collagen type I and III provide the structural 
component of many body compartments, including bone and muscle, providing physical 
support against mechanical forces. 
The organisation and tensile properties of the collagen fibres in the lung allows 
mechanical forces to propagate from the diaphragm and chest muscles through the major 
airways, and into the alveoli, without triggering a collapse of the organ. 
Lung deformation or mechanical stretch strongly influence fibrillar collagen and it has 
been proposed that lung elastic properties are the result of a balance between collagen 
strength and elasticity. 
Collagen molecules are crosslinked through the Milliard reaction, where a sugar group 
interacts with an amine giving rise to a covalent bond. This cross linking prevents degradation 
of collagen type I by metalloproteinases and it is at the basis of increased collagen during 
ageing, although lung epithelial cells seem to downregulate Col1a1 gene expression during 
ageing. Other fundamental crosslink reactions are disulphide bonds and glycation reduction 
of crosslinks and N- (-glutamyl) lysine iso-peptide, this latter catalysed by transglutaminase-
2. Inhibitors of transglutaminase-2 are currently in currently in phase II clinical trials in kidney 
fibrosis, and if effective could also be used in pulmonary fibrosis (Johnson et al., 2007). The 
level of collagen crosslinking is tissue-specific, with the musculoskeletal system showing 
higher rates of crosslinking in comparison with the respiratory or cardiovascular systems 
(Ricard-Blum, 2011). 
Each collagen α-chain is composed of a N- terminal, a repeated helix and C- terminal 
domains. The N-terminal contains a signal sequence and a globular sequence present as well 
in the C-terminal, rich in Cys, which allow collagens to form Cys-Cys disulphide bridge. The 
level of N-terminal divergence is in the number of exons present in this domain; it is thought 
to be at the basis of collagens diameter size. Cleaved N-terminal is also considered to hold a 
paracrine effect on collagens expression level. C-terminal also contains a globular site 
fundamental for intra and inter-binding interaction between different α-chain of procollagen. 
Both the N- and C- terminal domains are removed from the procollagen peptide, once 
secreted into the extracellular space. This allows multiple molecules of procollagen to bind 
together forming a fibre. 
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The α-chain of fibrillar collagens is synthesized as precursor pro α-chain, after 
posttranslational modifications, three pro α-chain molecules form a procollagen structure. 
Procollagen is synthetized in ER as pro-peptide. α-chain peptides are bound together through 
lysin-hydroxyproline, disulphide bridges. N- and C- terminal proteolytic cleavage through 
metalloproteinases (MMPs) allows the binding of pro-collagen molecules. The majority of 
post-translational modifications in procollagen take place in the Golgi. Hydroxylation, 
disulphide bridge creation and glycosylation are fundamental steps for procollagen correct 
folding that take place in both ER and Golgi. Of note is the pH sensitive transportation from 
ER to Golgi, which involves the heat shock protein 47 (HSP47). This chaperone is able to guide 
only correctly folded α-chains. Depletion of HSP47 in knock out mice lead to retarded body 
development (fig. 1.14) (Ishida & Nagata, 2011). 
 
Collagens are highly conserved between species, even in non-vertebrate organisms such 
as sea urchins (Niederreither et al., 1995). Loss of function of collagen type I or III leads to 
severe disorders such as Osteogenesis Imperfecta (IO) and the Ehler-Danlos syndrome (EDS). 
Interestingly, in EDS the low amount of collagen can lead to pneumothorax (collapse of a 
lung). Mutations in Collagen type-I have been referred to as “procollagen suicide”, as the lack 
in fibrillogenesis is associated with a body weakness (in particular in bones) not compatible 
with a long survival. Col1a1 transgenic models generated by exon depletion in one allele only 
Figure 1.14 Collagen undergoes a number of post-transcriptional modification. 
HSP47 actively participates in the transportation of collagen molecules assembled 




lead to bone weakness, body shortening and a high rate of premature death (Pereira, Khillan, 
Helminen, Hume, & Prockop, 1993). 
Collagen can be seen as structured scaffold that maintains tissues integrity; however, 
collagens have roles beyond structural support as well. Collagens in the ECM play important 
roles in both ECM-ECM and cell-ECM cross-talk. In 1966 Hauschka and Königsberg 
demonstrated that a collagen substrate induces chicken embryo fibroblasts to differentiate 
into myofibroblasts. Fibrillar collagen interacts also with other components of ECM such as 
fibronectin (Hauschka & Konigsberg, 1966). Interestingly, fibronectin can bind different 
collagens overlapping and competing with metallo-proteinase-2 for the same binding site 
rendering the collagens resistant to several proteases (Steffensen, Xu, Martin, & Zardeneta, 
2002). This latter fact may be crucial in early stages of fibrosis when expression of fibronectin 
is increased. Collagens contain RGD motifs which allow interaction with  cells via binding to 
integrins (Burgstaller et al., 2017). 
More than 15% of lung wet weight is composed of collagen fibres, mostly collagen type-
I and III. In lungs, collagen fibres are arranged to form single fibres around alveoli and/or as 
networks of the single fibres (Béla Suki et al., 2011). The lung is one of the most perfused 
organs, as it is the centre of the gas exchange and oxygen delivery. The blood vessels are 
formed by different layers composed mostly of collagen I and III, that give the strength and 
elasticity fundamental for blood to flow. Differences in collagen content reflects lung 





1.4.1.1.1. Collagen Type I 
 
Collagen type-I is the most abundant collagen type, expressed in almost all connective 
tissues and it is the major component in bone, skin, tendon and blood vessels. Type-I collagen 
accounts around ~80% of the total protein present in bone and it is the most abundant protein 
in vertebrates (Henriksen & Karsdal, 2016). Collagen type-I can be found as homo or hetero-
trimer composed of either two α1 and one α2 chains (2:1), or as homotrimer of three α1 
chains. The α1 chain is encoded by COL1A1 and α2 chain by COL1A2 in human, and in mice by 
Col1a1 and Col1a2. Although there is no clear correlation between homotrimer formation and 
pathological phenotypes, the presence of COL1A1 homodimers has been associated with 
tumours and fibrotic lesions (Makareeva & Leikin, 2014). 
The COL1A1 gene is located on the long arm of chromosome 17 in humans, and on the 
long arm of chromosome 11 in mice. This gene consists of 51 exons and it has 13 isoforms in 
humans and 4 in mice, all due to alternative splicing. The length of the Col1A1 gene is ~18kbp 
in both humans and mice (ENSG00000108821). 
COL1A2 encoding for the type-I collagen α2 chain is located on the long arm of 
chromosome 7 in humans, and on the long arm of chromosome 6 in mice. The Col1a2 gene 
has a length of ~36 kbps and is organised in 52 exons. It has 13 isoforms in humans and 8 in 
mice (ENSG00000164692). 
Like for collagen type-III, both α chains of Collagen type-I are highly conserved between 
species and contains repeated sequences as LINE-1 Alu in its genomic sequence. During 
maturation, the collagen type-I protein undergoes several post-translational modification, 
such as hydroxylation of Proline and Lysin residues that allow the correct folding of the pro-
peptide. Glycosylation and other post- translational modifications proceed simultaneously 
with the synthesis in the ER (Engel & Bächinger, 2005). Folding of the collagen type-I triple 
helix is guided by chaperones prevent formation of an unfolded structure. Any unfolded triple 
helixes are degraded in lysosomes through a chaperone-dependent mechanism. For collagen 
type-I the most important chaperone is HSP47, which delivers the unfolded α chains into 
autophago-lysosomes (Makareeva & Leikin, 2014). 
Collagen type-I is secreted a as pro-peptide, followed by proteolytic cleavage to remove 
the N- and C- terminal domains from the pro-peptide, necessary for a correct fibrillogenesis. 
Alteration in Collagen type-I secretion can be also a result of polymorphism in promoter 
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sequences, that have been observed in osteoporosis. 
During foetal development Col1a1 and Col1a2 are highly expressed in the lung. Up-
regulation in COL1A1 and COL1A2 synthesis during the post-foetal period allows correct 
development of the lung. Tissue damage as well as pathological conditions like fibrosis led to 
a collagen type-I upregulation. In those pathological conditions ECM reorganization triggers 
increase in organ stiffness. Physiologically, collagen type-I, as mentioned above, is expressed 
in lung in response to damages, as it is a key protein for wound healing repair. Dysregulation 
in wound healing repair due to repeated damage are able to trigger fibrotic lesion. 
Type-I collagen, in particular the α1 chain, is involved in a number of pathway related to 
cascade coagulation, mitogenesis, inflammation and cell differentiation. In vitro studies have 
demonstrated that TGF-ß modulates type-I collagen expression in a dose dependent manner. 
Concentrations higher than 10 ng/mL trigger a downregulation in Col1a1 expression, in a 
mechanism involving CUX-1, a DNA binding protein (Fragiadaki et al., 2011). Collage type-I 
activates a number of intracellular signalling pathways through cell surface receptors such as 
integrins and tyrosine kinase receptors. 
Ageing is a natural mechanism that impacts type-I collagen metabolism, and ageing has 
been correlated with increased collagen abundance (Kühn, 1987). However, studies on 
Col1a1/Col1a2 demonstrated instead a reduction in collagen synthesis in aged samples 
(Guilbert et al., 2016). This apparent increase in collagen fibre content is due to increased fibre 
crosslinking during ageing. Collagen crosslinks make fibres impervious to degradation by 
MMPs, leading to an increase in collagen protein content (Miller, 2010). Increased collagen 
crosslinking is also thought to be at the basis of the higher incidence of pulmonary fibrosis in 
the elderly population (Burgstaller et al., 2017). 
Interestingly, collagen type-I crosslinking is a result not only of hydroxylation but also of 
Glycosylation, which is thought to contribute even more to collagen insolubility. Glycation end 
products (AGEs) are considered at the basis of fibrotic lesion development and ageing 
(Henriksen & Karsdal, 2016). AGEs can activate the Smad3 pathway, even without TGF-ß 
receptor activation, through a p38 activation (Lan, 2008). 
Collagen type-I makes up more than 10-15% of the entire lung structure and it can be 
found in all pulmonary substructures (from the bronchioles to the alveoli). Assembled in fibres 
together with collagen type-III it provides ECM rigidity to the lung. Moreover, type-I collagen 
is considered as monomers or brick that constitutes collagen fibres, as it is highly represented. 
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Interestingly, Collagen type-I as monomer holds different mechanical properties than collagen 
type-I in fibres, underlaying physiological differences in the supra-molecular structure. Recent 
advances in Atom Force Microscopy (AFM) have highlighted that type-I collagen as single 
molecules possess a higher resistance to tensile stretch compared to a fibrillar collagen. The 
reason lay in the non-covalent bounds on the fibrillar collagen (0.5 GPa of force to be broken), 
whereas a single molecule of type-I collagen to be broken need a higher force to “unwrap” a 
secondary structure as it contains more covalent bounds (11 GPa) (Shoulders & Raines, 2009). 
This molecular organization is at the basis of energy dissipation during breathing. Moreover, 
it is thought that they can control contractile movement or organ and also cells via binding 
specific receptors as dimeric discoidin receptors DDR1 and DDR2, which possess an active 
tyrosine kinase activity (Ricard-Blum, 2011). 
 
1.4.1.1.2. Collagen Type III 
 
Collagen type-III was first identified by Miller et al in 1971 and it constitutes between 5-
20% of all collagen in mammals. 
Collagen type-III is a homotrimer formed of three collagen type-III α-chains encoded by 
the COL3A1 gene, in humans located on the long arm of the chromosome 2. Collagen type-III 
is highly conserved among species, in particular in mouse and dog. The 38kbp gene in both 
human and mice contains 51 exons, with an amino acid sequence composed of Gly-X-Y 
repeats similar to all other fibrillar collagens and fundamental for super molecular structure 
and crosslink formation (see above). Alternative splicing mechanisms or use of alternative 
promoters, leads to 6 transcript variants in human and 7 in the mouse (ENSG00000168542). 
Collagen type-III is synthetized as pre-peptides, which undergo post- translational 
modification, between ER and cis-Golgi. Triple helix formation is obtained through disulphide 
and hydroxyproline-lysine bonds of three identical - chains. The pro-peptide is secreted as 
tropocollagen, containing a globular N- and C- terminal, which are further cleaved, allowing 
the formation of fibrillar structures (see above). 
Collagen type-III is highly expressed in hollow organs and in developmental organs as 
placenta and endometrium and it is one of the most important components of blood vessels. 
We found high levels of Col3a1 expression in lung fibroblasts isolated from C57BL/J mice. 
Collagen type-III, as mentioned above, plays a key role in tensile stress and it is the 
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second major component of collagen fibres. Fibrillar collagen, as mentioned above, possess 
the ability to form covalent bond that crosslinking together different collagens, giving rise to 
fibres. A collagen fibre is composed mostly of collagen type-I (around 85%) which is 
considered as the “brick-module” of fibres, whereas collagen type-III accounts for 10-15%. 
Collagen type-III is localised in the peripheral part of the fibres suggesting a more regulative 
role. Thus, collagen type-III presence confers a variability to the supra-molecular structure, 
regulating fibril diameter and also interactions between fibrils and other ECM components. 
The peripherical localization is considered to influence fibre formation during the wrapping of 
the fibre (Fleischmajer, Douglas MacDonald, Perlish, Burgeson, & Fisher, 1990). 
Collagen type-III displays a high overlapping with collagen type-I expression, although 
the molecular mechanism underlying this is not clear (Niederreither et al., 1995). 
TGF-ß, Wnt/ß-catenin, p38 mitogen-activated protein kinase (MAPK) and hypoxia-
inducible factor 1a (HIF-1a) generally activate collagen type-III expression. However, Col3a1 
expression can be influenced by ageing, cell origin, and concentration of Col3a1-inducing 
cytokines, resulting in differential and complex regulation. As example, HIF-1a leads to Col3a1 
expression decrease in chondrocytes, whereas it increases Col3a1 expression in primary 
endothelial rat fibroblasts (Kuivaniemi & Tromp, 2019). The only clear mechanism able to 
induce Col3a1 expression is through the neural precursor cell expressed (NEDD9), which has 
been demonstrated to regulate vascular remodelling and pulmonary hypertension (Haley et 
al., 2018). 
Accumulation of collagen type-III is strongly involved in several fibrosis mechanisms, but 
also accounts to systemic sclerosis and liver cirrhosis. The role of Col3a1 in pulmonary fibrosis 
is not entirely clear, as in lungs, type-III collagen accounts for the elasticity of the fibres. 
Moreover, Col3a1 reduces stiffness, and biopsies from patients affected by IPF showed a 
reduction in production of type-III collagen (Seyer, Hutcheson, & Kang, 1976; D. Tschumperlin, 
Boudreault, & Liu, 2011). In 1997 Liu and collaborators, discovered that Col3a1 knock out mice 
showed a dysregulated fibrillogenesis, where the triple helix of collagen type-III was replaced 
by collagen type-I, resulting in an increase in rigidity of collagen fibres, lacking in Col3a1. This 
latter highlights the possibility of an anti-stiffness, and therefore anti-fibrotic role of Col3a1. 
Therefore, the balance between collagen type-I and type-III may be very important in the 




1.4.2. Connective Tissue growth factor (CCN2/CTGF) 
 
Connective Tissue growth factor or CCN2 (CTGF was changed to CCN2 in 2015 by the 
HUGO Gene Nomenclature Committee HGNC) is a protein discovered in 1991 and originally 
named “fibroblast-inducible secreted protein-12”. CCN2 is a member of the CCN family of 
proteins, that comprises six subgroups with similar structural and mitogenic characteristics. 
Historically, CCN2 was discovered as a matricellular protein associated with organ fibrosis and 
angiogenesis. (Gonzalez & Brandan, 2019). The CCN2 gene is located on the long arm of 
chromosome 6 in humans, and on the long harm of chromosome 10 in mice. The human 
encodes a single 349 amino acid protein. Mouse Ccn2 expresses three mRNA splice variants; 
two of 23 kbps and one of 34 bps, which encode for a 348, 293 and 80 amino acid proteins 
respectively (ENST00000367976). 
CCN2 is composed of an insulin-like growth factor -binding domain (IGF-BP), a von 
Willebrand domain (VWC), a thrombospodin-1 domain (TSP) (similar to non- fibrillar 
collagens) and cysteine knot domain. The IGF-BP domain possesses only structural similarity 
as it has very low affinity for insulin. The VWC domain is fundamental for interaction with 
αvß3/ß5 integrins (present on mesenchymal cells) and with growth factors such as TGF-ß and 
bone morphogenic proteins (BMPs). The TSP domain is fundamental for interaction with ECM, 
MMPs, VEGF and LRP1. The C- terminal contains the Cys knot domain, homologous to a 
number of growth factors, which mediates interaction with elastic ECM components 
(Takigawa, 2018). 
To address the role of CCN2 in vivo different transgenic mice have been developed, 
either with overexpression or deletion of CCN2. A transgenic mouse model, where the CCN2 
gene was under control of Col1a2 promoter, leading to fibroblast- specific overexpression of 
CCN2, showed several fibrotic features in skin, lung, kidney and vasculature (Sonnylal et al., 
2010). On the other hand, systemic CCN2 knock out prevents mice from Bleomycin induced 
skin fibrosis (S. Liu et al., 2011). Taken together these two studies demonstrate a key role of 
CCN2 in fibroblast-mediated tissue fibrosis. 
CCN2 is expressed during development in the thin wall surrounding bronchioles and 
alveoli. CCN2 knock out litters were very small in number; the high incidence of mortality was 
thought to be due to lung problems. The surviving mice showed poor susceptibility to 
bleomycin induced fibrosis, whereas CCN2 over- expression leads to thickening in alveolar 
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space between alveoli due to cell proliferation and secretion. Interestingly, foetal regulation 
of CCN2 expression is controlled differentially by different genetic enhancers, which show 
time and tissue specific regulation (Frost et al., 2018). CCN2 has both a regulatory and 
structural roles in lung. CCN2 is one of the earliest transcripts induced by TGF-ß r and it has 
autocrine and paracrine effects on the expression of major ECM genes (Col1a1, fibulin-1, 
PDGFR) (Kendall & Feghali-Bostwick, 2014). 
 
1.4.3. Snai1 (SnaiL) and Snai2 (Slug) 
 
Snail family proteins are zinc-finger DNA binding proteins involved in several 
mechanisms during foetal development and in epithelial to mesenchymal transition (EMT). 
They are composed of a highly conserved C-terminal region, which contains from four to six 
zinc-finger region and a N-terminal with differences between species. Snail proteins are 
expressed in the nuclei where they function as sequence specific transcription factors, where 
they o repress target genes. They were discovered first in Drosophila melanogaster mesoderm 
and subsequently discovered in different vertebrate and non-vertebrate organisms, including 
mouse and human (Nieto, 2002). 
The human and mouse genomes encode two snail proteins: Snail (or Snai1) and Slug (or 
Snai2). Snail is a 17 kbp gene in both human and mouse, located on the long harm of 
chromosome 20 long in human and on the long harm of chromosome 2 in mouse. Both genes 
encode a protein of 264 amino acid which is the only protein translated (ENSG00000124216). 
The Slug gene consists of 24 kbp and is located on the long harm of chromosome 8 in 
human and on the long harm of chromosome 16 in mouse. The human gene encodes 4 
translated variants from alternative splicing events, whereas mouse Slug encodes only for the 
full-length protein of 268 amino acids (ENSG00000019549). 
Snail family proteins bind to DNA in a sequence specific manner (consensus sequence: 
CAGGTG) through a basic helix-loop-helix motif, similar to the E-box common to a variety of 
transcriptional factors. Snail superfamily in vertebrate consists of Snail and Slug subgroups, 
with different roles in embryonic development (mesodermal for Snail and neural crest for 
Slug) (Thiery et al., 2009). 
Snail and Slug compete for the same binding sites in the DNA. This competition leads to 




Epithelial to mesenchymal transition (EMT) is a mechanism historically associated with 
development, where characteristic transition in surface proteins from E-cadherin to N-
cadherin is a sign of change in cell polarity. This mechanism is fundamental during 
embryogenesis for the creation of the germinal layers, during gastrulation. The genetic 
regulation in development identified the different roles of Snail and Slug in mesoderm and 
neural crest location (Kalluri & Weinberg, 2009). However, EMT is not confined only in germ 
layer development, but also in angiogenesis and wound healing, and pathological events such 
as organ fibrosis and metastasis in cancer. 
Snail and Slug are induced by TGF-ß in epithelial cells where this activation mediate the 
inhibition of caveolin and sequestration of TGF-ß receptor 1 recycle. Both mechanisms are 
connected with EMT and are thought to participate to lung fibrosis, resulting in EMT for ATII 
(Hwangbo et al., 2016). In conclusion, Snail and Slug are thought to play an important role in 
the development of IPF by increasing the size of the fibroblast pool through induction of EMT. 
In addition, Slug and Snail may trigger increased mobility in mesenchymal cells, as has been 
observed in cancer cells. Mobility is a key characteristic of myofibroblasts in fibrosis. 
 
1.4.4. Mothers against decapentaplegic homolog 6 and 7  
 
Inhibitory Smad proteins constitute the inhibitory feedback loop in the Smad activatory 
pathway. Inhibitory Smads present similarity in structure with activatory Smad, 
(https://www.omim.org/entry/600993). Differences in the protein structure from other 
activatory Smads are located in the N-terminal domain, where inhibitory Smads lack a TGF-ß 
phosphorylation site (X. Yan et al., 2009). All Smad proteins are composed of two main 
domains (MH1 and MH2) that compete in the DNA binding activity, where Smad proteins 
compete to give rise to expression of distinct sets of mRNA (X. Yan et al., 2009). 
SMAD6 is a 38 kbps gene located on the long harm of chromosome 15 in human and of 
30 kbps located on the long arm of chromosome 9 in mouse. The human gene encodes a 496 
amino acid long protein in its full-length translation and 5 other splice variants, whereas 
mouse presents 3 splice variants (ENSG00000137834) 
Smad7 is a ~44 kbps gene located on the long harm chromosome 18 encoding for a 426 
amino acid full-length protein in both human and mouse, with 8 splice variants in human and 
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5 in mouse (ENSG00000101665). 
As mentioned above, both inhibitory Smads mediate activatory Smad inhibition through 
three major mechanisms, which reflects similarity in the supramolecular structure: 1) 
competition in phosphorylation cascade to activatory Smads after TGF-ß receptor 1 
dimerization. 2) Phosphate removal through a phosphatase activity. 3) E3-ubiquitin- 
dependent lysosomal degradation of TGF-ß1 receptors achieved through Smad-Specific E3-
ubiquitin ligase 1 and 2 (Smurf1 and 2) (X. Yan et al., 2009). Another possible mechanism of 
inhibition of TGF-ß signalling pathway demonstrated in vitro for Smad7 highlighted a 
transcriptional factor activity for this protein. Atomic Force Microscopy (AFM) experiments 
aiming at investigating interactions between SBE and PAI-1 oligonucleotide consensus 
sequences with Smad7 showed a similar force of binding compared to activatory Smad. 
Interestingly, Smad7 was able to bind SBE in a 17 nucleotide sequence different from Smad4 
(Shi et al., 2008). Although it is not clear if there is an exclusive relationship in this binding, it 
results in a decrease in effector gene expression (Zhang et al., 2007). Another possible 
mechanism still not well understood is the indirect inhibition of TGF-ß and BMP pathways, 
through inhibitory SMADs combination with histone deacetylases (Bai, Shi, Yang, & Xu, 2000). 
The mechanism proposed referred that Smad6 regulates ECM gene transcription in 
combination with Hoxc-8, mediating an inhibition on Smad1 DNA binding activity.  
Smad-dependent signalling affects fibrosis through the regulation of myofibroblast 
activation, synthesis and secretion of matrix proteins, T cell cytokine upregulation, and 
mesenchymal differentiation. Therefore, as Smad6 Smad7 limit TGF-ß-induced Smad 
signalling, they may play an important role in fibrosis.  
Excess synthesis and secretion of collagen is a major feature of lung fibrosis, and TGF-ß 
strongly increases Collagen expression. Therefore, TGF-ß has been a major target for the 
development of anti-fibrotic therapies (Chaudhary, Schnapp, & Park, 2006). However, none 
of strategies so far have succeeded in reverting lung fibrosis. Increasing inhibition of Smad 
signalling by increasing Smad7 has shown to ameliorate the Bleomycin model of fibrosis, 
indicating that Smad7 is a promising candidate for targeting fibrosis (Bonniaud et al., 2014). 
 
1.4.5. Platelet derived grow factor receptor  (PDGFR) 
 
Platelet-derived growth factor receptor alpha (PDGFRα) belongs to the platelet-derived 
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growth factor receptor family. PDGFR signalling plays an important role in wound healing 
repair. 
PDGFR encodes a 6kbp gene located on the long arm of chromosome 5 in humans and 
the long arm of chromosome 4 in mice. The PDGFR protein serves as a tyrosine kinase 
receptor for PDGF. PDGFR encodes 10 splice variants in humans and 2 isoforms and 9 splice 
variants in mice (ENSG00000134853). 
The PDGFR protein consists of a c extramembrane domain for ligand binding, a 
transmembrane domain and an intra-cellular tyrosine kinase domain that undergoes 
transphosphorylation inducing the subsequent intracellular signalling cascade. 
PDGFR activation can lead to uncontrolled cellular proliferation and increased matrix 
production (Mori et al., 1993). Two phosphorylation sites are located in the insert-region 
between the actual kinase subdomains. Those sites are rich in Ser and Thr, which upon 
ubiquitination mark the protein for proteasomal degradation (P. H. Chen, Chen, & He, 2013). 
PDGFR selective knock-out experiments shows that PDGFRß can compensate the lack 
of PDGFR, forming homodimers able to activate the same signalling cascades (P. H. Chen et 
al., 2013). 
Binding of the PDGF ligands induces tyrosine autophosphorylation of PDGFR , leading 
to activation of a number of SH-adaptor transducers such as Sos, Grb, which can then 
transduce to downstream kinase/phosphatases such as PI3k and PLC (Tallquist & Kazlauskas, 
2004). 
PDGFR is a common marker for mesenchymal cells and variation to its activation or 
expression level is strongly associated with a variety of pathological states including fibrosis. 
Anomalies in activatory pathways can be cell-specific and can also induce changes in cell 
polarity as in EMT. 
 
 
1.4.6. Granzyme ß (GRMß) 
 
Granzyme ß (GzmB) is a serine protease enzyme mostly known for its pro- apoptotic role 
in epithelial and in cytotoxic T and natural killer lymphocytes. It mediates the cell-mediated 
killing in combination with perforin, which forms a transient pore in cell membranes allowing 
targeting of Grmß. Granzyme ß has been associated with a number of immunological 
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mechanisms and it is at the basis of acute phases lung injury (Russo et al., 2018). 
Granzyme ß is encoded by GZMB gene, located on the long arm of chromosome 14 in 
both humans and mice. GZMB is a 10 and 14 kbp gene, respectively in humans and mice. The 
protein is 247 amino acid long and it presents 8 additional non-coding splice variants only in 
human (ENSG00000100453). 
Although GzmB plays a fundamental role in apoptosis, this enzyme when is not targeted 
through perforin can mediate cellular receptor cleavage and ECM degradation. The serine 
protease activity is at the basis of GzmB role in apoptosis, as it cleaves a variety apoptotic 
target proteinssuch as caspase 3 leading to programmed cell death. (Heibein et al., 2000). 
Organ fibrosis is characterised by insufficient apoptosis of mesenchymal cells, and excessive 
apoptosis in the lymphocyte population (Wynn, 2011). Excessive lymphocyte cell death leads 
to an increase of inflammatory mediators. Among all those molecules, perforin and GzmB are 
thought to play an important role in acute lung injury (Miyazaki et al., 2004). Excessive and 
prolonged lung injury is a common mechanism in lung fibrosis. In this context apoptosis is a 
key mechanism for mesenchymal removal after the replacement of the scar tissue, whereas 
an excessive immune cells apoptosis increases the level of perforin/GzmB. As demonstrated 
by perforin knock out mouse, GzmB and perforin might be involved not only in the acute 




1.5. Lung biogenesis 
 
Lung development is a complex mechanism that reflects the high level of cellular 
heterogeneity mentioned above. Lung is derived from both endoderm and mesoderm 
through a mechanism involving sequential signalling interactions between epithelia and 
mesenchyme, composed of four phases; embryonic, pseudoglandular, canalicular and 
saccular-alveolar (Whitsett et al., 2018). 
In the embryonic phase, the foregut divides into oesophagus and trachea, forming the 
future inner lung parenchyma as two buds. Mesodermal cells interact with endodermal 
foregut cells (fig.1.15), leading to laryngotracheal track and pleura formation (Schittny, 2017). 
In more detail, mesenchyme in embryogenesis creates the lung pleura and the cartilaginous 
ring surrounding the trachea and bronchi. During lung embryogenesis, vascular and 
neuroectoderm tissues associated to lung develop at the same time (Schittny, 2017). Thus, in 
embryogenesis, there is the formation of the trachea, main stem, lobar and segmental 
bronchi, and hilum, through a process generally referred to as branching morphogenesis 
(Schittny, 2017). Epithelial-Mesenchymal interactions are finely controlled during the 






Figure 1.15 Differentiation of the embryonic foregut endoderm. Dorsal ventral axis is represented 
in blue (SOX2) and lung in red tubules (NKX2). While the mesenchyme is represented in green 
(FOXF1)(From Whitsett et al., 2018). 
The pseudoglandular phase is characterised by branch formation from lung buds, which 
resemble a classical lung tree-like structure. From each “father” segment two “daughter” 
segments will form in a process dominated by inhomogeneous dichotomy. Inhomogeneous 
dichotomy is characteristic of lung biogenesis only for bipedal apes, where branches grow as 
separated units, each newly formed branch is defined as a “generation” (fig.1.9) (Hsia et al., 
2016; Whitsett et al., 2018). 
 
 




From a father branch two structural different daughter branches will be formed, 
resulting in the inhomogeneous structure. By contrast, rodents show a monopodial 
inhomogeneous branching formation, where one daughter branch is formed from a father 
main branch (Schittny, 2017). The diverse branching development between bipedal apes and 
rodents represents one of the main structural difference between these two species. 
Transition from the embryogenic to the pseudoglandular stage is governed by Sox2 and 
Sox9 expression, where Sox2 activates epithelial cells for the branching, while Sox9 is active 
during budding and in later stages of saccular acinar formation (see below). Other key genes 
in this process are Transcriptional terminator factor, which control the embryogenic phase 
and FGF10 which serves as signal from mesenchyme to epithelia promoting branching 
morphogenesis (Whitsett et al., 2018). 
Following branching, the canalicular phase starts with formation of the first respiratory 
unit (Schittny, 2017). From this phase on, developmental mechanisms vary between 
mammalian species, and the following description applies only to humans. The canalicular 
phase is characterised by epithelial differentiation in the proximal airways, while respiratory 
epithelia start to form the terminal buds, with formation of the early respiratory units. A 
respiratory unit is composed by airway epithelia and capillaries, which permit gas exchange. 
Airway epithelia are still generated through a branching morphogenesis with inhomogeneous 
characteristics, while capillaries form trough angiogenesis. Interestingly, in branch 
morphogenesis before the canalicular phase, each generation shows a progressive 50% 
reduction in the diameter for conducting airways, while in respiratory units this relationship 
is lost. Newly formed respiratory bronchioles show a decrease in diameter length through 
generation resulting in a reduction in lung capacity, which will allow O2 diffusion through 
bronchioles walls (Hsia et al., 2016). Pre-respiratory units generated in the canalicular phase 
originate from small buds, which differentiate giving rise to alveolar epithelial cells type-I and 
II (Whitsett et al., 2018). Alveolar epithelia type differentiation marks a discontinuity in 
epithelia layer, resulting in an evident morphological change from conducting airways to 
respiratory unit. The respiratory unit starts from the bronchioalveolar duct junction, which 
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represent a connection point of conductive airway with respiratory airway (fig.  1.17) 
(Winkelmann & Noack, 2010). 
 
Bronchioalveolar duct formation lays the basis for saccular-alveolar development from 
transitional bronchiole units. As mentioned, angiogenesis forms capillaries from primitive 
blood vessels. Pericyte and smooth muscle are recruited on vessels edge to extend their 
networks, ending in capillary formation at the end of respiratory units. Endothelial cells 
migrate internally newformed vessel, to remodel basal lamina producing a proper vascular 
lamina, in a process regulated by VEGF-A (Schittny, 2017; Whitsett et al., 2018). 
In humans, branching morphogenesis ends at the start of the saccular stage when 
alveorization begins. In human, rat and mouse, the saccular stage starts shortly before birth 
and leads to the formation of the first alveoli. From bronchoalveolar ducts, squamous 
epithelial cells, precursors of alveolar epithelia type-I and II, determines an epithelia growth 
in length and width, forming a pre- alveolus. Both type-I and II cells are derived from the same 
undifferentiated cuboidal squamous progenitor, which serves as a stem niche (Schittny, 2017). 
As mentioned above, microvasculature follows airway progression, depositing 
connective tissue, which separate endoderm and mesoderm. At the saccular stage smooth 
muscle cells produce a thick, immature septum that covers type-I and type-II epithelia cells 
around double layer capillaries. Maturation of capillary layers and alveolar septa is thought to 
take place in parallel, at the start of alveorization (Schittny, 2017). Lipofibroblasts and 
myofibroblasts build alveolarsepta (see below) and boost alveolar epithelial expansion 
Figure 1.17 Scanning electron micrograph of human lung parenchyma. Alveolar 
ducts (d) are surrounded by alveoli (a). Alveoli represent lung section with the 
highest diffusion capability due to the reduce structure. In the figure it is possible 
to appreciate the differences in size and structure between alveolar ducts and 
alveoli. Bronchioalveolar duct development provide the structural basis for alveolar 
development in canalicular-alveolar phase (From Hsia et al., 2016). 
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through FGF10 release in alveorization (Whitsett et al., 2018). Alveorization is a 
developmental mechanism starting after birth and continuing as long as lung is growing, 
consisting in alveolar formation (Schittny, 2017). Microvasculature developing in here is 
driven by VEGF and TGF-ß and by hypoxia, which can retard or accelerate lung development 
(Whitsett et al., 2018). This phase in lung biogenesis is characterized by the gas exchange unit 
ultimate generation. New septa generated by mesenchyme, lift up the primary septa 
deposited during canalicular phase, separating capillary from pre-alveolar space. Then, 
smooth muscle cells release ECM components forming the fibrillar alveolar structure. Then 
the septum rises up to its full length and a proper alveolus is formed. In this process, septa 
thinning and the two capillaries fuse to form a single layer capillary network in the septum 
(Schittny, 2017). This allows formation of a respiratory unit, which continues in human until 






Figure 1.18 Morphological development of the lung parenchyma during the pseudoglandular, 
canalicular and saccular stage. In the pseudoglandular stage, epithelial tubules branches 
penetrate into the surrounding mesenchyme (a). The canalicular stage (b) is characterized by 
a differentiation of the epithelial cells into type I and type II epithelial cells (e, f), forming the 
future airways. Capillaries maturation starts once the mesenchyme is close contacts to the 
epithelium (b, e) and by the formation of first future air–blood barriers (e, f). Thick immature 
inter-airspace septa is formed by mesenchyme ECM expression, which in the terminal ends of 
the bronchial tree represent air-blood phase (Schittny, 2017). 
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1.6. Lung Biomechanics 
 
Pulmonary fibrosis repair impairment alters organ function, resulting in variation to the 
Volume/Pressure ratio. Fibrosis is characterised by volume decrease and pressure increase in 
terms of air during each breathing cycle, resulting from the increase in ECM (Bela Suki, 
Stamenovic, & Hubmayr, 2011). This fact inevitably alters lung mechanical properties.  
Lung movement is controlled by chest muscles and diaphragm, which control lung 
expiration and inspiration through involuntary innervation. This creates a tension which is 
then further propagated to ECM and finally this force is transferred from ECM to cells 
cytoskeleton. Inflammatory signals and cytokines key in fibrosis, such as TGF-ß and TNF-, 
prompt cytoskeletal remodelling that alters cell-generated forces and cellular mechanical 
properties (D. J. Tschumperlin et al., 2018). Tissue damage alters normal tissue “mechanical” 
homeostasis, with collagen deposition by myofibroblasts that increases tissue stiffness. 
Transition from a lower to a higher level of stiffness seems to propagate collagen deposition 
and crosslink. Stiffness, or rigidity, of a material is based on how well a material resists to a 
force applied on it. This resistance depends on ECM composition, which varies between body 
compartments, and is altered in a wide range of pathological conditions (Handorf et al., 2015).  
Interestingly, stiffening seems to amplify mesenchymal activation. Normal tissue repair 
decreases stresses in the wound bed, through signals that bring myofibroblasts to either a 
quiescent state or induce myofibroblast apoptosis. By contrast, stiffer ECM, generated by 
impairment in wound healing repair, increases collagen deposition and myofibroblasts 
activation (D. J. Tschumperlin et al., 2018). One possible explanation to this mechanism is that 
stiffer materials increase activation of Focal Adhesion Kinases (FAKs). FAKs are activated by 
integrins and growth factor receptors, which can respond to changes in the extracellular 
space. Those change possibly can be transduced to FAK, which might activate Rho/Rock 
signalling pathways, triggering cell polarity activation and results in myofibroblasts persisting 
in their activation state (Handorf et al., 2015). Moreover, acquisition of cell polarity seems to 
trigger myofibroblast migration towards stiffer matrix. Marinkovic and collaborators 
demonstrated that lung fibroblasts from IPF patients were more responsive when cultured on 
rigid Col1a1 based matrix, whereas soft matrix inhibits fibrotic phenotype, in terms of cells 
contractility (Marinković, Liu, & Tschumperlin, 2013). Therefore, tissue biomechanics 
influences fibrosis outcome. Although most of the evidence regarding these behaviours rely 
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on in vitro studies, the interest in this field has largely increased.  
Stiffness is not the only variable used in biomechanics; mechanical stress (force per unit 
area) is a key parameter to take in account to understand fibrotic response over time. 
Mechanical stress (or stretch) changes biomaterials size and shape, when a force is applied 
onto an elastic material (Béla Suki et al., 2011). When a force has a direction, stretch is equal 
to the product of material length increase = (l-l0)/l0 with Young’s modulus of elasticity, Y. 
Where l0 refers to material starting length and l to the length after a force is applied. Young’s 
modulus refers to material elastic properties (Béla Suki et al., 2011). In addition, Young’s 
modulus is indirectly proportional with tissue flexibility. Soft tissue possesses a lower Young’s 
modulus compared to rigid materials. Increase in tissue stiffness, as in fibrosis, augments 
parenchyma rigidity, resulting lung volume pression changes ratio. Therefore, fibrotic ECM 
possess a higher Young’s modulus compared to healthy ECM. Therefore, the tension or force 
required (considered as mechanical work during time) to stretch highly crosslinked ECM fibres 
is higher. 
This increase in tissue stiffness seems to generate a positive feedback on collagen 
deposition and crosslinking. Biomechanics have extensively proved that all tissues respond to 
mechanical changes, through sensors of biomechanical alterations. Cell to cell and cell to ECM 
interactions represent a fine-tune system that controls tissue biomechanics and senses 
alterations.  The understanding of molecular mechanisms beyond bio-mechanic can lead to 
new pharmacological strategy aiming at as example inhibition of mesenchymal movement 
towards stiff ECM (which increase ECM production, see above). 
Adhesion molecules play a key role in cell-cell communication. FAKs and cadherins 
prompt cytoskeletal changes due to mechanical stimulation. Cadherins are adhesion 
membrane proteins that connects adjacent cells. Those adhesion molecules allow cells to 
sense and transfer information regarding alteration in shear force and stretch, resulting in 
cytoskeleton remodelling. Mechanical stimulation increases actomyosin tension, inducing 
acquisition in cell polarity and collective migration (D. J. Tschumperlin et al., 2018). 
Modification to cytoskeletal tension is thought to participate activate mechanism as EMT in 
response to damage. VE-cadherin in the vasculature represents a well-studied example of 
mechano-transduction. On cell surface a complex formed by VE-cadherin, PECAM-1, and VEGF 
receptor type II and III form a well-studied mechanosensitive system. Mechanical forces and 
fluid flows trigger PECAM-1 interaction with vimentin, which activating Src kinase family, 
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regulating vasculature tone. In addition, this mechanism leads to increase in VEGF receptor 
activation; inhibitors for this vascular tyrosine kinase receptor appear promising novel 
pharmacological strategy against fibrosis as they promote myofibroblast “deactivation”. 
Another intracellular sensor for mechanical forces is represented by the Notch and Rho/Rock 
signalling pathways, whose seem to prompt vimentin and -smooth actin expression in 
response to mechanical stimulation, mechanisms occurring also EMT (D. J. Tschumperlin et 
al., 2018). Interestingly, this relationship might underlie a synergistic mechanism on EMT, 
where the acquisition of cell polarity, perhaps, depends on mechanical stimulation.  
Cell-matrix forces are sensed mostly though integrins, ß heterodimer transmembrane 
cells surface receptors (D. J. Tschumperlin et al., 2018). Integrins are important in 
biomechanics as they bind specific ECM domains, activating signal transduction in response 
to mechanical stimulations. RGD motif represents a high conserved aminoacidic triplet 
presents in fibronectin, vitronectin, osteopontin, fibrinogen and von Willebrand factor, which 
possess affinity for a wide range of integrins (Burgstaller et al., 2017). Integrin-RGD interaction 
allow mesenchymal cells population to move across connective tissue and epithelium. 
Activated integrins are bound to actomyosin system through dynamic association with 
integrin- or F-actin binding protein. This association transfers information regarding matrix 
stiffness from fibronectin to cytoskeleton. Another cell-matrix force sensor recently identified, 
is Thy-1, a GPI-anchored glycoprotein, which seems to amplify or attenuating stiffness sensing 
to cell-matrix adhesions. Proteomic analysis have identified more than 500 individual protein 
in the “adhesome” (adhesion proteins omic) influenced by changes in mechanical 
environment, which might contain future target against fibrosis (D. J. Tschumperlin et al., 
2018).  
At the intracellular level, the transcriptional factors YAP and TAZ were identified as 
mechano-sensors in endothelial and mesenchymal cells. YAP and TAZ might regulate gene 
expression in response to mechanical stress through indirect association with other 
transcriptional factors implicated in fibrosis, such as SMAD and Notch/ß-catenin (D. J. 
Tschumperlin et al., 2018). Another important mechano-sensor intracellular transcription 
factor family associated with fibrosis is MRTF, which after activation induced by TGF-ß, moves 
to the nucleus where it activates SNAIL2. Through this mechanism MRTFs induce cytoskeletal 
remodelling occurring in EMT (Thiery et al., 2009).  
Biomechanics present technical limitation as most of those studies have been 
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conducted in vitro through tension force microscopy or similar techniques. There is the 
necessity to corroborate this evidence in experimental animal models. Multidisciplinary 




1.6. Genetic factors influencing pulmonary fibrosis 
 
Understanding the genetic and epigenetic factors involved in IPF is a powerful tool for 
both diagnostic and therapeutic advances. IPF is a multifactorial disease where genetic 
predisposition and environmental cause the IPF phenotype. Therefore, pulmonary fibrosis 
does not act as a classical Mendelian disease “one gene : one phenotype”. 
Despite the fact that there is not a single predominant mutation associated with the 
disease, inheritability of IPF, known as familial IPF, has been documented. Familial IPF is 
characterised by higher incidence in the younger population, without a significant 
environmental cause triggering IPF. Where classic IPF predominantly affects the elderly, 
familial IPF predominantly affects people in the 18-25 year old age bracket (King et al., 2000). 
Familial IPF is transferred in an autosomal dominant fashion with high penetrance. 
Only a few mutations have been associated with an early age IPF and with a worsening 
of the fibrotic phenotype (Leslie et al., 2012). Familial IPF seems to follow the “double hit 
theory”, where the inherited genetic factors lead to a higher susceptibility to environmental 
conditions. As example, in a study using a cohort of 111 families with familial IPF, only 8% of 
people were un-affected. However, those subjects showed subclinical manifestation of the 
disease (Steele et al., 2005). Therefore, they might be predisposed to develop IPF. 
Studies into the genetic basis of fibrosis have revealed several genes associated with 
pulmonary fibrosis.  
Polymorphisms are changes in the genome that occur in more than 1% of the population 
Genome wide studies have identified polymorphisms in the MUC5B gene, which encodes a 
lipoprotein fundamental for gas exchange, related to a poorer IPF prognosis in Hispanic and 
Caucasian cohorts (Borie et al., 2013). Moreover, this MUC5B variant was not associated with 
SSc-ILD but only with IPF. SNPs in interlukin-1 (IL-1) and in tumour necrosis factor α (TNFα) in 
Italian and British cohorts have been associated with higher susceptibility to IPF. However, 
those SNPs were found only in a small number of patients, and hence cannot be used for 
diagnostic purposes (Borie et al., 2013). 
Gene mutations in telomerase as well as mutations leading to telomere shortening have 
been reported to be correlated to IPF (M. Armanios, 2012).  Telomerases are polymerase 
enzymes with a reverse transcriptase activity specialised in chromosome end duplication. In 
mammals, telomerases are composed of two components: a catalytic unit named hTERT with 
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a reverse transcriptase activity and an RNA unit (hTR in humans) which contains the RNA 
template (TTAGGG)n for telomere repeat addition (Ramlee, Wang, Toh, & Li, 2016). Healthy 
somatic cells decrease in telomere length as a normal process during ageing. Deficiencies in 
the normal duplication of telomeres give rise to a series of diseases, known as 
telomeropathies. Telomeropathies have been extensively associated with pulmonary fibrosis. 
Primary telomeropathies are due to mutations in the genes related to telomere maintenance, 
such as mutations in DKC1 and hTERT. While secondary telomeropathies are due to 
dysregulation of the DNA repair system that leads to impairment in telomere length, as can 
occur in progeria and cancer. Mutations in either telomerase gene or in gene related to 
telomerase biogenesis gives rise to Dyskeratosis congenital (DC) (M. Y. Armanios et al., 2007). 
In DC, telomere shortening generates an early cell death or an early cell cycle arrest; 
pathological features of DC are bone marrow failure and pulmonary fibrosis. For DC patients, 
IPF is the second most common cause of death after bone marrow failure (M. Y. Armanios et 
al., 2007). One explanation why DC can lead to IPF lays in the high cell turnover of lung 
epithelial cells. A high cell turnover implies that lung cells at each replication will present 
mutation in telomeres, which will reduce the cell turnover. This might then increase 
susceptibility to damage, with a stronger dysregulation in wound healing repair system. In 
general DC patients present clinical features similar to familiar IPF, such as the high 
penetrance in young adults (M. Armanios, 2012). 
Mutations in the DCK1 gene, a gene fundamental for correct telomerase biogenesis, 
lead to the most common form of DC with IPF. Patients with DCK1 mutations often develop 
IPF after bone marrow transplantation due to treatment with immunosuppressive that are 
toxic to the pulmonary system (M. Armanios, 2012). Unfortunately, bone marrow 
transplantation is the only available treatment in severe DC. Adjustment in anti-rejection 
therapies only slow IPF development, which is the main cause of death in these patients. IPF 
can also arise in DC patients without bone marrow failure. Mutations, in hTERT and hTR 
(telomerase genes) create a more severe type of DC with anticipated IPF (similar to familiar 
IPF). The transmission follows, as for familiar IPF, an autosomal dominant heritability. Usually 
mutations in hTERT and hTR lead to loss of function of telomerase, which triggers either IPF 
or bone marrow failure or a combination of the two (M. Y. Armanios et al., 2007). Loss of 
function mutations in those genes show a more severe phenotype, although mutations 
leading DC do not present a fully progeroid phenotype. Young patients show “symptoms of 
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ageing”, such as, hair loss, liver cirrhosis, and osteoporosis. Ageing is a multifactorial 
mechanism in which both genetic and environmental events can deregulate its normal 
progression (Lidzbarsky et al., 2018). Telomere shortening is one of the most studied 
mechanisms related to ageing. Therefore, clarifying this overlap between DC and IPF might 
provide new insight into the role of ageing in IPF, and may explain why IPF is more common 
in the elderly. 
One of the most interesting genetic insights into IPF comes from Nogee and 
collaborators, who in 2001 identified a series of point mutations in the surfactant protein C 
gene (SFTP-C) (Nogee et al., 2001). SFTP-C is a key protein for lung stability and for lung 
embryonic development. SFTP-C is expressed and secreted only by Alveolar epithelial cell type 
II (AECII) and it maintains lung integrity (Whitsett et al., 2018). When secreted, SFTP-C, 
together with mucins, shields alveolar parenchyma from irritants and pathogens. Moreover, 
SFTP-C is required for correct lung inflation and recoil, as through reducing lung surface 
tension, it prevents lung collapse. Unfolded mutant SFTP-C protein accumulates in the 
alveolar parenchyma where it induces epithelial injury. Those injuries in the parenchyma then 
lead to familial IPF (Van Moorsel et al., 2010). 
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1.7.  Environmental factors influencing pulmonary fibrosis 
 
Environmental factors can contribute to the development of IPF. Although there is not 
a univocal correlation between a single identified environmental factor and IPF, a number of 
risk factors have been described. Exposure to asbestos, smoke from cigarettes, and silicosis 
seem to accelerate IPF progression from a ILD phenotype, in particular for subjects constantly 
exposed to a toxic environment (Olson, Gifford, Inase, Fernández Pérez, & Suda, 2018). Other 
factors that increase the risk of IPF regards to workers exposed to metal, stone and wood 
dust, hair dressing and farming products. Microbial agents such as viral infection by EBV or 
cytomegalovirus have been identified in alveoli from patients with IPF and it was considered 
as a source of risk. However, current treatment for IPF uses drugs with immunosuppressive 
effect, which can influence the analysis (King et al., 2000). 
UK is the country with the highest incidence of IPF per inhabitant in Europe. Gribbin and 
collaborators found a 100% increase in the number of cases from 1993 to 2003, with higher 
incidence in the male population (Gribbin et al., 2006). The male predominance may be 
caused by the fact that specific professions (such as miner), are historically associated with 
males, possess a higher risk to develop IPF. Moreover, the number of smokers is higher in 
males than females, according to “Facts on Gender and Tobacco” from the World Health 
Organization. 
 
1.8. Ageing in pulmonary fibrosis 
 
Ageing is a multifactorial biological process, in which genetic and environmental factors 
contribute to its progression. Genetic mechanisms driven by age progression are telomere 
shortening, decreased cell turnover and autophagy. Unhealthy life-styles, such as smoking, 
have shown to accelerate ageing and decrease life-span (Lidzbarsky et al., 2018). Age 
increases susceptibility to several diseases due to cellular senescence and organ structural 
deterioration, which influences fibrosis (Lidzbarsky et al., 2018). An example is represented 
by IPF, which mostly affects the elderly population with high significant increase after 75 years 
old compared to 40-60 aged (King et al., 2000). As mentioned in the paragraph Genetic factor 
influencing IPF, mutations in DKC1 and telomere shortening are genetic conditions that 
correlate age with pulmonary fibrosis (M. Armanios, 2012). Ageing leads to accumulation of 
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damages over time, and this can result in changes in matrix biosynthesis and modification of 
cell-ECM and ECM-ECM interactions (Kurtz & Oh, 2012). Furthermore, during ageing there is 
an increase in the alveolar space, which is not related to inflammation or alveolar wall 
destruction (Miller, 2010). This changes lung mechanics perhaps influences ECM composition 
and turnover in aged subjects. Collagen type-I and III are strongly influenced qualitatively and 
quantitatively by age, although it is debatable whether age quantitatively increases fibrillar 
collagens. Collagen fibre turnover decreases with age in particular for type-I collagen (Parola, 
2016). One possible explanation for this could be that collagen crosslinking increases with age 
or that ageing increases advanced glycosylation end products (AGE) (Reiser, Hennessy, & Last, 
1987). Therefore, ageing determines a more “favourable” environment for fibrosis, which 
might explain the lack of response to antifibrotic therapies in the elderly (Raghu et al., 2011). 
Understanding the impact of age alone and in combination with other fibrotic stimuli may 
clarify the role of ageing in pulmonary fibrosis. 
Age-related disease phenotypes are difficult to reproduce due to the low efficacy in 
reproducing such phenotypes. There are a wide range of animal model that can be used for 
age-related research, rodents have been extensively used for this propose. However, 
understanding the genetic variability of mouse strains is important to generate a consistent 
model, because each strain possesses specific genetic characteristics, which can translate to 
variation to the desired model. The C57BL/6J mouse strain represents the genetically most 
well-characterised animal used in experimental biology. Models of progeria syndromes, 
models of accelerated or retarded ageing are well-established animal model, able to 
reproduce complex age-related features (Kõks et al., 2016).  
Mouse and human organs age differently at different rates. For ageing studies, the age 
at which a mouse is considered “aged” for the organ or tissue under study is generally chosen 
by comparing the ageing-related features in the mouse by those in humans. This age can vary 
considerably between organs. For example, the age range used to study age-related 
osteoarthritis in mice is 15 to 17- months , while in vivo models for studying ageing lungs 
require mice older than 19 months (Kõks et al., 2016; Schulte et al., 2019, Mühlfeld, & 
Brandenberger, 2019).  
Interestingly, Schulte and collaborators have pointed out the key role of age for the 
development of mice animal models of lung disease. They have reported a clear significant 
increase in inspiratory capacity, compliance, hysteresis, and lung volume, while tissue 
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resistance, tissue elastance and alveolar cellular volume showed significant decrease from in 





microRNAs are small non-coding nuclear RNAs with a length of 17-22 base pairs, 
involved in gene regulation (Cai et al., 2009). microRNAs play a key role in transcriptome 
regulation through a 3’-UTR binding repression mechanism on mature mRNA, which stops 
ribosome translation. Only the central part of a mature microRNA sequence is actually bound 
to its 3’-UTR binding site on the target mRNA. This part of the sequence is composed of 8-9 
base pairs, whereas the rest of the sequence is key for ribozyme-like interaction with protein 
co-factors involved in the microRNA repression mechanism (see below). A single microRNA 
can modulate the expression of many genes. As well as of directly decreasing the expression 
of target mRNAs, microRNAs can also indirectly regulate gene expression by inhibiting the 
expression of transcription factor. The inhibition of a inhibitory transcription would in 
principle increase the expression of genes repressed by this transcription factor. The actions 
of microRNAs are based on sequence complementarity between the microRNA and its target 
mRNAs (see below). 
microRNAs are named using a specific nomenclature, where the first three letters 
identify the species (“hsa” for human and “mmu” for mouse). microRNA coding sequences 
are located in both intronic and exonic regions, where polymerase II transcribe a pre-form of 
microRNAs from a single or polycistronic unit. microRNAs located in intronic regions are 
expressed from a single open reading frame (ORF), while the ones located in exons are co-
expressed with the relative gene (Cai et al., 2009). The coordinated expression of microRNAs 
is strongly regulated at the epigenetic level. DNA methylation accounts for 10% of changes in 
the entire microRNA expression during some forms of cancer (Cai et al., 2009). DNA 
methylation represses gene transcription and therefore microRNA expression. microRNAs 
located near CpG island tend to be most affected by hypermethylation (Cai et al., 2009). For 
instance, miR-34b and miR-34c showed expression suppression related to hypermethylation 
of a nearby CpG island. This mechanism has been extensively studied as the miR-34 family 
targets p53 expression, a fundamental cell cycle gate keeper. Changes in p53 expression as a 
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result of miR-34a inhibition, have been shown to be linked with cancer cell proliferation.  
however, in the Bleomycin model of lung fibrosis  miR-34a inhibition appears to reverse lung 
fibrosis (Disayabutr et al., 2016; Hermeking, 2010).  
microRNAs were first detected in C. elegans in 1993 by Ambros and Ruvkun, who 
identified an inhibitory element involved in larval development in lin-4. It is now estimated 
that microRNAs compose around 1% of the mammalian genome (Bartel, 2009). 
As mentioned, microRNAs are transcribed by polymerase II as either a cluster or as a 
single microRNA unit, produced as pri-miRNAs. miR biogenesis is classified as either canonical 
or non-canonical (O’Brien et al., 2018). In canonical biogenesis, after polymerase 
transcription, pri-miRNAs assume a secondary hairpin structure and undergo a first catalytic 
cleavage mediated by DGCR8 and Drosha. While DGCR8 recognises a N6-methyladenylated 
GGAC motif, Drosha operate the endonuclease cut forming a 2 nt 3’ overhang, generating a 
pre-miRNA. Once the pre-miRNA is obtained, the exportin-5/RanGTP complex exports the 
miRNA to the cytoplasm, where further cleavage by the RNase III endonuclease activity of 
Dicer results in mature microRNA (O’Brien et al., 2018). This mature duplex sequence 
represents a mature ds microRNA, the direction of the two strand determines the name of 
the mature single strand microRNA. The 5p strand arise from the 5’-end of the pre-miRNA 
hairpin while the 3p strand originates from the 3’-end. Both strands can be loaded in a protein 
complex known as microRNA-induced silencing complex (miRISC), which is mainly composed 
















However, only one strand is favoured in this preferential binding on the RISC. Therefore, 
only one strand can operate the inhibition of a target mRNA and the two strands have 
different targets, based on sequence complementarity. Interestingly, microRNAs compete not 
only for the RISC complex, but also for the binding at the target mRNA. The competition 
between the 5p and 3p depends on thermodynamic stability of the 5’-ends of the miRNA 
duplex or by the presence of a 5’ Uracil at nucleotide position 1 of mature miRNA. Lower 5’ 
stability or 5’-uracil are inducing events leading to a preferential microRNA strand loading 
(O’Brien et al., 2018). Therefore, miRNA binding to the inhibitory complex is influenced by the 
sequence. Interestingly, 5’-end low stability loading, permits AGOII conformational changes 
occurring in miRISC-dependent recognition and degradation (Bartel, 2009). 
Non-canonical microRNA biogenesis results from different combinations of proteins 
involved in the canonical biogenesis. There are two distinct mechanisms grouped as 
Figure 1.19 microRNA biogenesis. See text for details 
See text for the details (From O’Brien et al., 2018). 
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Drosha/DGCR8-indipendent and Dicer-independent biogenesis. First group resemble on Dicer 
substrates, which are directly exported to the cytoplasm without cleavage. Dicer-independent 
miRNAs are processed by Drosha from short hairpin RNAs (shRNA), which can be directly 
exported in the cytoplasm and loaded on AGOII (O’Brien et al., 2018). 
Modification at the post-transcriptional level, such as RNA editing, or SNPs can influence 
microRNA target interaction. This because change in the sequence can change both binding 
to RISC complex and target mRNA binding (Bartel, 2009). Approximately 16% of human pri-
miRNAs are subject to A-to-I editing, where an adenosine is transformed in an inosine (Cai et 
al., 2009). This modification alters normal microRNA:mRNA interaction, creating wobble base 
pairing, which is considered to trigger inosine-cytosine interaction. Single base pair 
polymorphism alters microRNAs sequence determining, as well as for the A-to-I editing, 
changes in recognition between microRNA-mRNA microRNA interferes with translation 
through a selective binding at complementary sequences in the 3’-UTR of a mature mRNA. 
Although microRNA-mRNA interaction is not the only mechanism affecting mRNA expression, 
it accounts for most of transcriptional repression (O’Brien et al., 2018). Other less frequent 
mechanisms are a 5’-UTR binding, which can even induce transcription through microRNA 
binding at a gene promoter (Rocha et al., 2007). 
Nevertheless, transcription repression consists in a sequence specific mechanism, 
where AGOII recognizes an mRNA through microRNA-mediated binding, which acts as an RNA 
guide. AGOII or AGO2 is the endonuclease composing miRISC complex. In the microRNA 
repression, the core sequence, composed of 7-8 nucleotide represent the RNA guide that 
guides AGO2 to cleaves and degrades mature mRNA and stop translation. AGO2 is 
overexpressed in several pathological conditions, which sees increase in microRNA repression 
machinery, as in cancer. In those cases, AGO2 overexpression results in repression (or 
suppression) in the translation of a set of gene by miRISC complex. Diseases phenotypes 
induced by alteration to those mechanisms are still not clear, but they might in future 
exploited for molecular therapies. AGO2 augmented expression potentiates microRNAs or 
siRNAs repression rate, as it increases the number miRISC complexes activity in the cytoplasm 
(Ye, Jin, & Qian, 2015). When the microRNA guide binds mature mRNA, it destabilizes AGOII 
association with microRNA at the 3’-end, activating a conformational change that activates 
enzyme nuclease activity. Thus, miRISC-dependent degradation starts after GW182 
recruitment, which act as mediator between AGO2 and PAN2-PAN3. This protein together 
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with CCR4-NOT complex mediates poly-A de-adenylation, which follow the 5’-mRNA de- 
capping by exonuclease DCP2, resulting in mRNA degradation (O’Brien et al., 2018). 
The regulatory function of microRNAs depends on target identification, which is based 
on Watson and Crick rules. microRNAs from metazoans differ from those in plants in the 
repression mechanism, as the first one does not need a perfect match between sequences to 
repress a transcript. By contrast, in plants microRNAs translational inhibition can result only 
from perfect complementarity between sequences. Nevertheless, microRNA core and mRNA 
3’-UTR interaction can repress translation only when the binding between nucleotides is 
energetically favourable. Therefore, interaction between mRNAs 3’-UTR and miRs core can be 
predicted from sequence complementarity. However, those predictions need experimental 
procedures, either measuring both microRNA and mRNA expression levels or 
immunoprecipitating mRNA:microRNA complex to prove such interaction. Through 
transcriptomic techniques a complex network of interactions was discovered, where each 
microRNA has multiple targets. This fact also means that family of protein with a similar 3’-
UTR can virtually be inhibited by the same microRNA. An example of this is represented by 
miR-29a, which shows sequence complementarity for fibrillar collagens and for collagen IV, in 
the basal membrane (Montgomery et al., 2014). Moreover, these sequences (both mRNA and 
miR) show a remarkable evolutionary conservation between species in metazoans. 
Interesting, several studies in the last 10 years have proven that groups of microRNAs have 
pathway-related preferential expression correlated to biological mechanism, such as ageing, 
cancer, development, and fibrosis (Bartel, 2009). Therefore, in metazoans microRNAs regulate 
mRNAs translation through a partial sequence complementarity, which is additionally highly 
conserved between species. The 7-8 bp long core microRNA shows for many microRNA:mRNA 
interactions an homology in the interacting sequence, also conserved in most model 
organisms. Although microRNA expression is governed by epigenetics, increased microRNA 
levels result from stimuli of different origin. miR upregulation increases the probability of 
interaction with a set of target mRNAs, which can ultimately lead to pathology. microRNA 
networks influence cell cycle arrest, apoptosis, proliferation, ECM metabolism, development, 
and diseases. This means that microRNAs have the potential to be important for both 
diagnosis and treatment of diseases. In humans hsa-miR-19a and hsa-miR-34a were 
significantly increased in ageing and muscle wasting. miR-34a also showed an age dependent 
expression in muscle. The mechanism proposed is a repression of VEGF-A and decrease in 
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endothelial growth. In this clinical study, the miR-34a increase was correlated mostly to SIRT1 
decrease, which might trigger mitochondrial degeneration in the aged cohort (Zheng et al., 
2018). miR-34a is a perfect example of a microRNA with multiple targets and involvement in 
different biological mechanisms. Increased miR-34a expression in lung epithelial cells in 
response to TGF-ß is thought to be at the basis of EMT in fibrosis. TGF-ß, EMT and ageing are 
three mechanisms that at the molecular, cellular and organism level are connected with 
fibrosis, where miR-34 is thought to possess a key role (Cui et al., 2017; Takano et al., 2017). 
miR-21a comprises two isoforms known as miR-21a-3p (or miR-21-1) and miR-21a-5p (or miR-
21-2); and represents another microRNA involved in multiple biological mechanisms. The 
gene is transcribed from the vacuole membrane protein-1 (VMP-1) ORF. Transfection with 
this ORF sequence has been used to induce miR-21a-5p expression in cancer cells (Ribas et al., 
2012). miR-21a-5p levels were found increased in the bronco-alveolar lavage from patients 
with IPF together with miR-155 (Li et al., 2013). miR- 21a is highly conserved between species, 
and its expression is increased in the Bleomycin model of lung fibrosis (Xie et al., 2011). This 
miR appears to play a role in the regulation of EMT in alveolar epithelial cells, and in 
fibrinogenic activation in fibroblasts, two mechanism related to fibrosis (Yamada et al., 2013). 
Moreover, increased miR-21a expression has been documented in several forms of tissue 
fibrosis at both the inflammatory and tissue remodelling stages.  
Through translational repression microRNAs can change the proteomic composition of 
cells, and through this can alter cellular and physiological functions. Bartel in 2009 has 
summarized microRNA repression activity on proteins as switch interaction, tuning 
interaction, and neutral interaction. In switch interaction, a microRNA is upregulated in 
response to augmented protein level, which, as example, can prevent a pathological outcome. 
Switch interaction in some cases can be accounted for a “failsafe” target where  protein 
repression is important for survival (Bartel, 2009). An example is miR-9a expression during 
embryogenesis in Drosophila melanogaster epithelial cells, which prevents from extra-neural 
differentiation. Tuning interaction is similar to switch interaction, but in a more dynamic way, 
as based in microRNA sinusoidal expression to compensate a transient protein increase. The 
possibility to tuning microRNAs expression is also a good strategy in experimental microRNAs 
validation. Neutral interactions reduce protein expression for proteins that do not have 
functional role. microRNA protein repression is considered a two-step mechanism. First 
microRNA binds on the 3’-UTR accounting for a moderate 2-fold change decrease in mRNA 
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translation. From this moment on, protein synthesis by ribosome gradually reduces, reaching 
a final 10-fold repression (Bartel, 2009). This model takes in account AGOII conformational 
changes and the 3’-end pairing, which might explain why 6-mer bindings are also a possible 
alignment. 
Major rules that govern miR-mRNA interactions are based on sequence homology and 
conservation between species. A number of different open source bioinformatic software 
systems have been developed to identify possible targets for specific miRs. Assumptions 
regarding binding probability are based on experimental evidence of microRNA-mRNA 
interactions (Agarwal, Bell, Nam, & Bartel, 2015). microRNAs showing a high level of 
conservation between species have been observed to be more likely to effectively repress 
mRNA translation. microRNA-target interactions are classified on the basis of the type of 
interaction between miR core sequence and mRNAs 3’-UTRs. microRNA-mRNA recognition 
results from a match between these two sequences, where the position 1 and the last match 
shows to be more important. Thus, binding nomenclature states 8mer and 7mer interactions 
accounting for matches in position 2-8; 7-mer A1 accounting for 2-8 match position followed 
(as match in the last nt) by an adenosine in the mRNA sequence and then 6-mer with 2-6 base 
pair complementarity (rarely taken in account) (Agarwal, Bell, Nam, & Bartel, 2015). Another 
important determinant which can influences positively microRNA action is the supplementary 
3’-pairing. When a 7 or 8-mer interaction presents also a 3 base pairing, it has more probability 
to repress that target (Bartel, 2009). This latter mechanism results in more stable mRNA 
binding to the miRISC. During classical miR:MRE without mismatches, the binding in position 
2-8 is strong enough to trigger mRNA degradation. 
 
As mentioned above, microRNAs participate in a number of biological process, and it is 
now agreed that microRNA expression profiles are cell and organ specific. As a consequence, 
a microRNA could affect different targets depending on the tissue studied. Moreover, it 
appears that microRNAs possess paracrine and autocrine functions. Because of their small 
size, microRNAs are more resistant to endonucleases, and they can be found either complexed 
with exosomes or free in the tissue environment. Although it is not totally clear how this 
affects the tissue transcriptome, microRNAs complexed with exosomes appear to participate 
in cell communication (O’Brien et al., 2018). It has been postulated that through distribution 
through the circulation microRNAs can affect distant organs, however this mechanism might 
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be true only for body compartments in close proximity. In lungs, capillary-alveolar epithelial 
cross talk seems an interesting possibility that can be applied to microRNAs. The progress in 
this understanding is highlighting the possibility to use microRNA to diagnose diseases, based 
on microRNA expression variance. Tests based on microRNA profiling, from blood serum or 
bronco-alveolar lavage, have produced interesting results for microRNAs as diagnostic 
parameter in a wide range of diseases (G. Yang et al., 2015). As mentioned, miR-21a and miR-
155 were found upregulated in broncho-alveolar lavage from patients affected by IPF, while 
miR-34a was found downregulated in patients affected by lung cancer. However, to develop 
diagnostic applications, miR profiling in large cohorts are necessary to establish the actual 
predictive capability of those tests. This diagnostic possibility becomes an interesting 
possibility to apply to lung fibrosis pathology, in particular for early stages of the disease, when 
the fibrosis is more reversible. 
 
1.10. Antifibrotic Therapies 
 
As mentioned in the first chapter of the whole spectrum of lung fibrosis, IPF appears the 
most resistant to treatment.  IPF is resistant to all major antifibrotic treatments, and current 
drugs only reduce disease symptoms, and in some cases, slow disease progression(Fujimoto 
et al., 2015). There are currently no treatments that are able to revert disease outcome, 
although to some extend fibrosis appears to be reversible. However, depending on the stage 
of disease the response can vary dramatically. For more severe cases, the only successful 
therapy is lung transplantation (Fujimoto et al., 2015). However, lung transplantation is an 
invasive and risky procedure, which can result in transplant rejection. Therefore, it is a 
strategy to consider only for high risk cases. 
One of the main reasons why antifibrotic therapies are not successful in IPF is because 
of its unknown underlying cause. The removal of causal factors resulted in disease 
amelioration in several similar lung fibrotic phenotype(Fujimoto et al., 2015). IPF has long 
been classified as an inflammatory-related disease, which explains why the first treatment for 
IPF was with corticosteroids and other immunosuppressives. One example is represented by 
the failure of a therapy using prednisone and azathioprine with or without NAC (N-
acetylcysteine). Unfortunately, this therapy led to 23 cases of premature hospitalization and 
did not show any disease amelioration (King et al., 2000).  
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Pirfenidone and Nintedanib are at the moment approved for the treatment of IPF and 
other lung fibrotic diseases in the EU, Japan, and the USA. Pirfenidone is a low-molecular-
weight compound that showed anti-inflammatory and antifibrotic effects, with inhibition of 
fibroblast proliferation, collagen biosynthesis and reduction in the positive TGF-ß feedback 
effect (Troncone et al., 2018). Nintedanib blocks the activity of VEGF and FGF, resulting in 
improved lung respiratory function. These two compounds have been also compared for their 
efficacy by the FDA, which reported that Nintedanib showed a stronger effect against acute 
symptoms, while Pirfenidone improved survival time (Fujimoto et al., 2015).  
Interestingly, new leads using monoclonal antibodies (mAb) against profibrotic proteins 
might be more successful strategies, of note is a mAb targeting CCN2/CTGF which is in phase 
II clinical trials for IPF (FDA). It is still necessary to develop new effective therapies to improve 
the quality of life of patients affected by lung fibrosis. The strategies currently employed have 
benefitted from a better understanding of the molecular mechanisms involved in lung fibrosis. 
Examples of this are represented by monoclonal antibody and synthetic nucleotide therapies, 
including miRNA, siRNA, Crisper/Cas9, Tales; which might represent the future of 
pharmacology (Ramazani et al., 2018). However, most of those novel drugs have so far failed 
in clinical trials, due to differences between animal models and humans.  
 
microRNAs represent a good strategy for diseases that that affect parts of an organ, 
such as fibrosis or cancer. In cancer an intra-tumoral injection of miRNA directly into the 
pathogenic site could enhance target specificity, efficacy and minimize side effects (Hanna et 
al., 2019). microRNAs have been shown to be differentially expressed during fibrosis 
progression and in many other pathologies such as cancer, diabetes, neuropathy. Moreover, 
drugs used in clinical practise against cancer, such as cisplatin or doxorubicin show a response 
in a set of microRNAs, which have been identified at the basis of drug resistance to those 
systemic drugs. Moreover, as many of those compounds are considerably toxic a resistance 
can worsen the clinical outcome. microRNA repression activity correlated to drug resistance 
have been explained by inhibition of ATP-binding cassette proteins (ABC). Drug resistance to 
cisplatin, widely used for non-small lung cancer adenocarcinoma, through miR-495 repression 
to ABCG2 protein, involved in drug trafficking. (Hanna et al., 2019). Although a promising 
possibility, none of the microRNAs at the moment have passed to phase III  clinical trials, also 
for evaluation in the cost and profit in drug development, as for miR-21 (RG-012) used to cure 
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Alport syndrome, which is a fibrosis related kidney disease and suspended for apparently no 
scientific reasons (Ivan G. Gomez et al., 2015). However, there are promising results from 
mirmimic miR-34 for the treatment of liver and lung cancer, mirmimic miR-29 for scar tissue 
(and maybe fibrosis); and antagomir strategy using LNA-based miR-92 for a broad range of 
cancers. Of note microRNA therapy for mesothelioma represents a promising possibility to 
cure one of the most lethal diseases (Hanna et al., 2019). The main issues are possible off-
target effects, possibility to inhibit RNA binding protein motifs, long-terms effects, effective 
absorption and distribution, and Toll-like receptor activation. However, because the lung is a 
highly vascularised tissue, miR Adsorption, Distribution, Metabolism and Excretion (ADME) is 
probably less of a problem in the lung than in many other tissues. Another option for effective 
drug delivery to the lung is the use of aerosols, which might be a future strategy for microRNA 
treatments. Interestingly, non- invasive inhalation of polyplexes formed by mRNA complexed 
with hyperbranched polyesters were adsorbed by lung epithelial cells and expressed in mouse 
lung lobes (Patel et al., 2019). Considering that microRNAs are at least 10 times smaller in 





1.11. Aims  
 
There is currently no treatment for IPF that can cure the disease or stop progression. It 
is therefore essential to identify novel targets for the development of new drugs. microRNAs 
might be a potential novel strategy to treat IPF and other types of fibrosis.  Therefore, the 
overall aim of my thesis was to identify microRNAs that can be targeted to cure or stop 
progression of IPF. The achieve this, I addressed the following specific aims:  
 
Aim 1: Analyse the expression patterns of microRNAs in the Bleomycin model of IPF.  
 
Aim 2: Study the effects of the microRNAs identified in Aim 1 in in vitro models of fibrosis.   
 
Aim3: Study the effects of extracellular matrix composition, mechanical forces and ageing on 
expression of the microRNAs identified and fibrosis-related-mRNAs in in vitro models of 
fibrosis. 
 
Aim 4: Test miRmimics and antagoMirs for the most promising miRs identified in the first two 









Table 2.1. Reagents  
Reagent Catalogue number Company 
Alexa Fluor 488 A32723 Life technologies, USA 
Alexa Fluor 555 A32727 Life technologies, USA 
Alexa Fluor 594 A32740  
Blocking buffer (TBS)927-50010 LICOR, UK 
Chloroform C2432 Sigma Aldrich, UK 
Collagenase, type 1a C9891 Sigma Aldrich, UK 
Custom miRIDIAN 
Hairpin Inhibitor 
MIMA000530 Dharmacon, GE, USA 
Custom miRIDIAN 
MIMICS 
MIMAT000530 Dharmacon, GE, USA 
Cutom miRIDIAN 
Negative Control 
IN-001005-01-50 Dharmacon, GE, USA 
DMEM 21885025 Gibco, UK 
DMEM F-12 D9785 Sigma Aldrich, UK 
DMSO 0231 VWR, USA 
Fetal Bovine Serum S1810 Biowest, USA 
EDTA E6758 Sigma 
Ethanol Absolute E7023 Honeywell, USA 
Ethanol (histology)  Fisher scientific 
EvoScript Universal 
cDNA Master 
07912455001 Roche, Switzerland 
Glacial acetic acid 305238 Scientific Laboratory Supplies, UK 
HBSS 14025 Life Technologies, USA 
HEPES H3874 Sigma Aldrich, UK 
Isopropanol 278475 Sigma Aldrich, UK 
Lightcycler 480 probes 
master 
04887301001 Roche, Switzerland 
Lipofectamine 2000 11668019 ThermoFisher, USA 
   
miRScript II RT Kit 218161 Qiagen, UK 





1027271 Qiagen, UK 
miScript miRNA Mimic 219600 Qiagen, UK 
miScript SYBR Green PCR 
Kit 

















2.2 In vivo Procedure 
 
2.2.1 Animal information and power calculations 
 
C57BL/6J were purchased from JAX, male mice were used for all in vivo procedure, while 
female mice for all in vitro procedure. C57BL/6J employed for the Bleomycin model of lung 
fibrosis in chapter 3 were housed in a pathogen free facility; C57BL/6J used for miR-21a-5p 
inhibition in the Bleomycin model of lung fibrosis in chapter 6 were housed in the Centre for 
Preclinical Imageing (CPI) facility, both at the University of Liverpool. All procedures were in 
accordance with the Animals (Scientific Procedures) Act 1986 and the EU Directive 
2010/63/EU and after the local ethical review and conducted under the PPL of Prof. Bou-
Gharios after the approval of Liverpool University’s Animal Welfare and Ethical Review Body  
(AWERB). 
Sample size for both in vivo experiments were conducted in order to find the optimal 
number of animal to use, as requested by the 3R (replacement, reduction, and refinement). 
Power calculation for sample size were performed using OpenEpi an free on-line platform for 
calculation as advised in “How to calculate sample size in animal studies?”, published by 
Journal of Pharmacology and Pharmacotherapeutics (Charan & Kantharia, 2013). Although in 
Neutral buffer 
formalin 
HT501128 Leica, UK 
Non-immune goat 
serum 
S-1012-50 Vector, USA 
Paraformaldehyde #P6148 Sigma Aldrich, UK 
PBS D8537 Sigma Aldrich, UK 
Penicillin/Streptomycin P4333 Sigma Aldrich, UK 
Qiazol 79306 Qiagen, Germany 
SDS L4509 Sigma Aldrich, UK 
Sodium hydrogen 
carbonate 
S6014 Sigma Aldrich, UK 
Sirius Red (Picric Acid) STPSRPT StatLab 
Recombinant TGF-β1  100-21 Peprotech, USA 
Tween 20 P7949 Sigma Aldrich, UK 
Vectashield mounting 
medium with DAPI 
H1200 Vector, USA 
Xylene X0250 Fisher scientific, USA 
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this publication authors advise a sample size for each group equal or higher than 10, the level 
of confidence should be the most important value to take in consideration. However, this 
value for novel drug, as a treatment with microRNA, should be quite low, to prevent an 
unnecessary pain to an animal.  
For Bleomycin experiment in chapter 3, I used a level of bilateral confidence of 90% as 
the method was efficient in reproducing the desired phenotype. As the experiment aim was 
to reproduce fibrosis in term of progressively increase of disease hallmarks, an expose to non- 
expose ratio equal to 0.25 was used. A percentage of outcome in the control group was set at 
3% as no treatment was administered in control group, as PBS being a liquid might induce a 
parenchymal damage.  
 
Table 2.1 Power calculation used for Bleomycin experiment 
Bilateral confidence  90% 
Power 80% (as adviced by 
OpenEpi) 
Expose/ not Expose (ratio)  0.25 
Not Exposed with outcome  3% 
 
OpenEpi calculated a total number sample size of 19 mice divided in 15 for treated group 
(Bleomycin) and 4 for control group.  
For miR-21a-5p mirmimic and antagomir treatments the confidence was set as 25%, as 
literature, in silico, and in vitro evidence suggested changes in the system due to the 
treatment. Not exposed versus expose ratio was set at 0.5 as it was necessary to evaluate 
miR-21a background effect. Therefore, the percentage adverse event in control group was set 








Table 2.2 Power calculation used for miR-21a experiment 
Bilateral confidence  25% 
Power 80%  
(as adviced by OpenEpi) 
Expose/ not Expose (ratio)  0.33 
Not Exposed with outcome  20% 
 
OpenEpi calculated a total number sample size of 12 mice divided in 4 for treated group 
(Bleomycin) and 4 for control group 
 
2.2.2 Bleomycin model of lung fibrosis 
 
As mentioned in the previous chapter, Bleomycin is not the only method use to induce 
fibrosis in experimental models. Administration of silica or asbestos, irradiation of gamma 
rays, infections with adenovirus overexpressing TGF-ß, or other techniques are equally 
valuable methods able to reproduce a fibrotic phenotype. All of them present benefits and 
drawbacks, however as the model was already established by Dr Ke Liu, from Bthe ou-Gharios 
group, it has been easier to follow his method rather than optimise a new one.  
Bleomycin is an antibiotic produced by Streptomyces verticillus and was discovered by 
the Japanise scientist Hamao Umezewa in 1969. Bleomycin induces cell death through single 
and double strand DNA breaks. Bleomycin activity is particularly high in lung due to a lack in 
the inactivating enzyme, Bleomycin hydrolases, which trigger an higher cell death in lung 
parenchyma (Mouratis & Aidinis, 2011). The main benefit in the use of Bleomycin is the low 
cost of the entire procedure, the reproducibility in a wide range of model organism (from 
mouse to primates). Bleomycin allows to reproduce a fibrotic phenotype in short therapeutic 
window, of 14-28 days, despite the induction of fibrosis is more acute than chronic, as in all 
ILDs with fibrotic characteristic. Moreover, Bleomycin has been extensively reported that in 
rodents the fibrotic Bleomycin-induced phenotype is rescued after 28 days, consisting in the 
major limitation of this technique (Mouratis & Aidinis, 2011).  
The second thing that was important to consider was the route of administration, as in 
an interesting paper from 2006, H. Lakatos and collaborators compared the efficacy of 
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oropharyngeal and intratracheal administration routes to induce fibrosis (Jun & Lau, 2018). 
Although in this study researcher used silica instead of Bleomycin, this paper highlighted for 
oropharyngeal route a localization of damage in distal lung, while intratracheal administration 
was more effective in the proximal lung. (Lakatos et al., 2006). Intratracheal administration is 
also a more complex technique, as the catheter is surgery installed might trigger pathogen 
infections, which will alter the response to a drug, as example. Therefore, oropharyngeal 
administration was used to induce a lung fibrotic phenotype in experimental animal. 
7 mg of Bleomycin was dissolved in sterile PBS to achieve a concentration of 1 mg/mL 
and stored at -20°C. Anesthetised mice were suspended by the cranial incisors on a thin 
rubber band, animal tongue was gently extracted in order to close through forceps and the 
Bleomycin was administered in the posterior pharynx at the base of the tongue (fig. 2.1). A 
single dose treatment of Bleomycin was used in all procedure, the volume of drug to 
administer was calculated based on weight in order to reach a concentration of 0.15 mg/mL 
for each experimental animal. As Bleomycin referred to a moderate procedure in ASPA for the 
level of pain induced in the experimental animal, I monitored at different intervals changes in 
body weight (see appendix 1) and any sign of distress. 
 
Figure 2.1 Methodology for oropharyngeal aspiration. Anesthetised mice were suspended by the 
cranial incisors on a thin rubber band, animal tongue was gently extracted in order to close through 





2.2.3 microRNA treatment in mice 
 
Customised sequences and hairpin inhibitor from the miRIDIAN product line (GE 
Dharmacon) were used for miR-21a gain and loss of function in the in vivo model of Bleomycin 
induced lung fibrosis. Customised sequences contained a phosphonothioate group 
(containing a sulphite group instead of a phosphoric group in nucleic acid backbone) in the 
terminal ends of the sequence, a cholesterol group at 3’-RNA (synthetic) and also a 2-OMe 
substitution. mirmic sequence referred to miR-21a-5p, while scramble sequence was random 
generated and as the sequence used did not match with any other miRNA. miRIDIAN hairpin 
inhibitor consisted of a double strand sequence able to inhibit miR-21a-5p expression, which 
present specific chemical changes that are covered by industrial secret. 
 
Mice received a 2 µg/mg dose of microRNAs every 7 days, according to treatment half-
life. microRNAs were injected via tail vein by Dr. Sharkey from CPI unit from University of 
Liverpool facility.  
Mice were preconditioned with miR-21a treatment at time starting of the experiment 
(day 0), and at day 8, while Bleomycin was administered at day 2 as described in 2.2.2. After 
18 days from the starting of the procedure mice were sacrificed (fig. 2.2). 
  




Figure 2.2 Treatment timeline. microRNAs treatment for miR-21 mirmimic, antagomir and 
scramble were performed before the administration of Bleomycin in order to reach a 
concentration in the animal bloodstream before the acute damage induce by Bleomycin. 
The day after (day 1) Bleomycin was administered as described in 2.2.2. To maintain an 
effective miR-21a concentration, another microRNA treatment was performed at day 8. 
Mice were culled after 18 days from the first treatment and 17 days after the treatment 
with Bleomycin, to avoid a rescue of phenotype (which is usually 21 days after the single 
dose of Bleomycin). 
 
2.2.4 Dissection and inflation of lung 
 
Mice were culled through intraperitoneal injection (IP) of 0.2 mL of Pentobarbital, then 
the abdominal cavity was opened using sterile scissors and forceps and skin was removed. 
Liver portal vein was cut, and diaphragm removed. Chest ribs were then opened without 
touching lung and heart through transversal cutting using blunt scissors. Neck muscles were 
removed leaving trachea opened. A sterile string was then passed underneath and then up 
tracheal space through the use of blunt forceps and wrapped around tracheal rings, leaving 
an opened knot. A blunt syringe filled with air was then placed in the tracheal space and the 
knot was closed around syringe blunt needle. Air was then pushed in the lung space for the 
procedure used in Chapter 3; O.C.T. at 30% v/v Sucrose/PBS was used instead for procedure 
in Chapter 6. Once the lung was inflated, syringe was gently removed, and the knot closed. 
Lung was dissected out from the dorsal cavity as inflated lung. Knotted lungs filled with air 
(Chapter 3) were placed in a 7 mL bijou containing 4°C PBS supplemented with 3% of 
Potassium Iodine and imaged by µCT ex vivo. Post-caval lobes were dissected out for histology 
while all other lobes were stored at -80°C for RNA extraction. Samples used for histology were 
placed in PBS supplemented with 4% of PFA and placed at 4°C. After less than 24 hours, PBS 




The left lobe was dissected out from lungs filled with O.C.T.at 30% v/v of Sucrose/PBS 
(Chapter 6) for RNA extraction while right and post-caval lobes were snap frozen with Iso-
Pentane and stored in -80°C and used for Histology. 
 
2.2.5 Ex vivo lung imageing with µCT scan 
 
Lung filled with air and in PBS supplemented with 3% of Potassium Iodine and scanned 
by µCT using Skyscan1272 system (SKYSCAN, Belgium) with a resolution of 20 µm, using a 0.25 
mm aluminium filter and 0.3° rotation step. Images were reconstructed using Skyscan 
“NRecon” software (SKYSCAN, Belgium), which allows scans reorientation and to define a 
volume of interest for the analysis. Using “CTAN” software (SKYSCAN, Belgium) the data set is 
then analysed with a macro measuring the lung volume. Ex vivo scans allows to produce 
tomographic images extremely precise, due to an accuracy of the order of micrometres. 
However, for lung application ex vivo CT has limitation due by a considerable intrasample 
variability as the amount of air in the explanted lung can dramatically vary during the 
dissection.  
 
2.2.6 In vivo live imageing with µCT scan 
 
Mice used for the experiment conducted in Chapter 6 were imaged by in vivo µCT using 
a Quantum GX-2 system (PerkinElmer, USA). In vivo µCT allow to produce images from a living 
organism, which are key in preclinical studies, as they provide evidence in real time on the 
effectiveness of a treatment. Mice were imaged at day 0, at day 8 to obtain information on 
the early stage of disease, and at 12 and 18 for the late stage of disease. The machine produces 
two image one; regarding to inspiration and expiration phase of each breathing cycle, 
producing a volumetric image, representing the lung in all three dimensions through 
synchronising of single images collected during inflation and expiration.  
An X-ray filter of copper (Cu) 0.06mm and aluminium (Al) 0.5mm was used for lung 
scans. Live CT view allowed then to position the camera in the region of interest before the 
starting of the CT scanning. Lungs were scanned with a 50 µm voxel size and at high speed (4 
minute). Post-scan sorting of respiratory phases was used to produce inhalation and 
exhalation images. Once the scan of a lung was finished, mice were acclimatised in a dedicated 
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2.3.1 Paraffin wax histology 
 
Lungs fixed with PBS at 4% of PFA were after dehydrated using Et-OH at 70% and 
embedded using Leica EMTP6 tissue processor following the following protocol: 









70% Et-OH 30 min Ambient 80 
90% Et-OH 30 min Ambient 80 
100% Et-OH 10 min Ambient 80 
100% Et-OH 10 min Ambient 80 
100% Et-OH 10 min Ambient 80 
100% Et-OH 15 min Ambient 80 
Xylene 10 min Ambient 120 
Xylene 20 min Ambient 120 
Xylene 30 min 40°C 120 
Wax 4 h 60°C 140 
 
Lungs were then embedded in wax using a Leica EG1150 Tissue Embedder with a caudal 




2.3.2  Cryogenic histology 
 
Lungs filled with O.C.T. at 30% v/v of Sucrose/PBS were place in -20°C 20 minutes before 
cryostat and then cut with a Leica CM1850 cryostat producing slides of 5-7 µm. 
 
2.3.3 Picosirius red Staining 
 
PFA fixed sections were dewaxed through Xylene for 5 minutes and hydrated through 
decreasing ethanol concentrations, while cryosections were incubated for 1 minute in PBS. 
PFA sections were incubated with Weigert’s haematoxylin for 8 minutes allowing 
nuclear staining. Slides were then washed in running tap water. This step was not used for 
Cryosections as the procedure destroyed tissue architecture. Slides were then incubated for 
1 hour in Picrosirius red, which colours collagen fibres. Sections were washed through two 
dips in water with 1% of Acetic Acid. Slides were dehydrated in ethanol, cleared in xylene and 
mounted in a resinous medium with a coverslip. Slides were then incubated for 1 hour in a 
fume hood at room temperature to evaporate traces of xylene. 
 
2.3.4 Histology imaging 
 
Slides were imaged using an Olympus BX60 microscope with or without a polarized filter 
(Nikon) as Brightfield microscopy and polarized light microscopy. Slides were imaged at 4X, 
10X and 20X magnification with or without polarised filter. Polarised light was obtained 
positioning the polarising filter at 90° orientation. This technique was used as it allows to 
image repeating structures with a refractive index, such as collagen fibres (Wolman & Kasten, 
1986). 
Quantitative measurement of the dichroism was calculated through ImageJ Fiji using a 





2.4 Cell culture 
 




A549 adenocarcinoma alveolar lung cells were purchased from the American Type 
Culture Collection (ATCC) cultivated with DMEM F-12 (Sigma-Aldrich) supplemented with 10% 
foetal bovine serum (FBS) (Gibco) and 1% Penicillin/Streptomycin (Sigma-Aldrich) in a 
humidified incubator at 37°C and 5% CO2. Cells at passage lower than 20 were defrosted from 
liquid nitrogen tanks and first pre-cultured in a T75 flask for 3-4 days until confluency was 
reached. Then, cells were split in a 1:10 ratio.  
Cells were washed with sterile Phosphate buffered saline (PBS) to remove any trace of 
conditioned media and incubated with 1.5 mL of TripLE express (Gibco) per T75 flask for cells 
detachment for 5 minutes. Subsequently, cells were visualised at phase contrast microscope 
(Nikon TiE) to confirm surface detachment. Cells were washed using 7-8 mL of complete 
DMEM F-12, used to neutralise TripLE express action, and resuspended and collected in a 15 
mL tube (Falcon). Cells were spun down at 300 g for 5 minutes, allowing pellet formation. 
After supernatant removal, cells were resuspended in 10 mL of complete DMEM F- 12 and 




MRC5 immortalised lung fibroblast cell lines at passage 5 were kindly donated by Dr 
Kazuhiro Yamamoto (Institute of Ageing and Chronic disease) and after amplification were 
stored in liquid nitrogen. MRC5 at passage lower than 10 were cultured with DMEM (Gibco) 
supplemented with 10% FBS and 1% Penicilin/Streptomycin in a humidified incubator at 37°C 
and 5% CO2. Cells were cultured until confluency was reached and then washed with 
Phosphate buffered saline (PBS) to remove any trace of conditioned media and incubated with 
1.5 mL of TripLE express (Gibco) per T75 flask for cells detachment for 5 minutes. 
Subsequently, cells were visualised at phase contrast microscope (Nikon TiE) to confirm 
surface detachment. Cells were washed using 7-8 mL of complete DMEM F-12, used to 
neutralise TripLE express action, and resuspended and collected in a 15 mL tube (Falcon). Cells 
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were spun down at 300 g for 5 minutes, allowing pellet formation. After supernatant removal, 
cells were resuspended in 10 mL of complete media and used for cell expansion or in 
experiments. 
 
2.4.2 Primary cells 
 
2.4.2.1 Primary mouse lung fibroblasts culture 
 
Primary mouse lung fibroblasts were cultured in complete DMEM in a humidified 
incubator at 37°C and 5% CO2. Lung fibroblasts after 5 days of culture were transferred to a 
T75 flask (see 2.4.3). After overnight incubation cells reached full confluency of the flask and 
were then used for further experiment. Cells were sub-cultured according to 2.4.1.  Cells used 
for all in vitro procedure were then at a passage 2. 
 
2.4.2.2 Primary mouse lung fibroblasts isolation 
 
Three different methods were attempted to obtain the best fibroblasts cellular yield. 
For the first method slices of around 1 mm2 of lung tissue were cut. Slices were placed 
in a sterile incubator at 37°C and 5% CO2 with 1-2 mL of complete DMEM for 30 minutes. 
Media volume was increased until reaching 7-8 mL and half replaced every 1-2 days after first 
incubation (fig 2.3), until fibroblasts had grown out of the tissue. 
 
Figure 2.3 Possible primary fibroblasts culture obtained using the second method described (see 
text). Cells at 4X magnification (A) and at 10X magnification (B). Please note that we refer as 
“possible primary fibroblasts culture” as we did not test the efficiency of this isolation. Images were 
obtained using phase contrast microscopy. [scale bar 2 mm]. 
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Next, I tried a method developed by Seluanov and collaborators, but using collagenase 
instead of Liberase (Seluanov, Vaidya, & Gorbunova, 2010). Liberase is a mixture of 
collagenase and other proteases which was developed to obtain a better cell release from 
ECM. However, as it was reported that there is no change in terms of cellular yield, using 
liberase or collagenase (Hyder, n.d.), we used collagenase. Moreover, I compared Seluanov 
method of isolation with another method provided by Dr Vanja Pekovic-Vaughan (IACD). The 
substantial difference between the two methods lay in the use of Hanks Buffer supplemented 
with at 0.47% of NaHCO3, 1% of Hepes buffer and 1% of Penicillin/ Streptomycin and with 10% 
w/v of Collagenase, instead of using 10% w/v Collagenase in DMEM media. Testing the two 
methods in parallel showed that after 5 days of culture we consistently were able to obtain a 
much higher yield using modified Hanks buffer, leading to a fully confluent culture of primary 
cells (fig. 2.2). 
 
 
Figure 2.4 Primary fibroblasts isolation methods comparison. Figure shows images from primary 
mouse lung isolation protocols using the method provided by Dr V. Pekovic- Vaughan (A 4X 
magnification and B 10X magnification) and Seluanov method (C 4X magnification and 10X 
magnification). [scale bar 100 and 50 µm]. 
The method developed from Dr. Pekovic-Vaughan resulted in a better yield and 
therefore was used for all procedures (fig. 2.2). In detail: lungs were placed in a Petri dishes 
and dissected to remove hearts and trachea. Using a sterile scalpel, tissues were chopped 
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producing slices of ˜1 mm2. The tissue fragments were then incubated for 1.5 h in a modified 
Hanks buffer supplemented with at 0.47% of NaHCO3, 1% of Hepes buffer 1% of Penicillin/ 
Streptomycin and 10% w/v of crude collagenase Type 1 (Sigma-Aldric) from Clostridium 
histolyticum. The Petri dish was then washed with 1-2 mL of the enzyme to obtain the best 
yield. Cell suspensions after resuspension, were filtered through a 100 µm cell stretcher, to 
avoid larger pieces in the following isolation steps. Subsequently, the mixture was centrifuged 
at 300 g for 5 minutes, to obtain a cellular pellet. The cell pellet was resuspended in in 
complete Hanks buffer, and centrifuged gain at 300g. After centrifugation, the supernatant 
was discarded, and the pellet resuspended in complete DMEM. The cells were cultured in 
complete DMEM at 37°C and 5% CO2 for five days, in order to obtain a fully confluent culture, 
as shown in figure 2.3. Next, cells were harvested using trypsin, as macrophages are resistant 
to trypsin digestion. The resulting cell suspension was then spun down at 300 g for 5 minutes 
and resuspend again in DMEM media at 10% FBS 1% Penicillin/Streptomycin. After 16h of 




To characterise the cells isolated, 0.5X103 lung fibroblasts were cultured on sterile 
25mm circular coverslips in a 12 well plate for 1.5 days in complete DMEM at 37°C and 5% 
CO2. Once cultures were reaching 50-60% confluency of the coverslip, medium was removed, 
cells washed with PBS, and the cells fixed for 10 minutes with cold 4% v/v of 
paraformaldehyde in PBS. Cells were subsequently washed 3 times for 10 minutes with sterile 
Figure 2.5 Cultured mouse fibroblast isolated from the lung five days after the isolation. 
Figure A shows the culture at 4X magnification while B is showing 10X magnification. 
Images were obtained using phase contrast microscopy. [scale bar 100 and 50 µm]. 
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PBS at 4°C. Fixed cells were then stored at 4°C to avoid protein degradation and used for 
immunocytochemistry. 
As fibroblasts do not possess a unique marker that allows to distinguish this cell 
population, a panel of 3 positive and 1 negative marker were used (tab. 2.3). - Smooth actin, 
vimentin and HSP/47 were used as positive markers as these are highly expressed in 
fibroblasts, while F4/80 was to verify macrophage/monocyte contamination. 
 
 
Table 2.5 Table 2.4 Primary and secondary antibodies list used to validate primary 
fibroblasts isolation. 
Ab Target HOST Concentration used Second Ab 
a-SMA Mouse 10 g/mL AF594 Goat anti-mouse 
Vimentin Rat 10 g/mL AF555/AF594 Goat anti-rat 
F4/80 Rat 10 g/mL 555 Goat anti-rat 
HSP47 Rabbit 10 g/mL 488 Goat-anti-rabbit 
 
Coverslips were removed from 12-well plates and placed on a parafilm layer and 
incubated with PBS at 4°C supplemented with 0.5% v/v Tween 20 for 20 minutes to 
permeabilise fixed cells. Coverslip were then washed with PBS at room temperature. Fixed 
cells were then incubated with goat blocking serum at room temperature (VECTOR) for 45 
minutes. Subsequently, coverslips were incubated overnight (16 hours) at 2-8 °C with one of 
the primary antibodies shown in Table 1. Primary antibodies were diluted at 1 in 100 v/v in 
goat blocking serum. After the overnight incubation, coverslips were washed with PBS at 4°C, 
then incubated with the secondary antibody at 1 in 100 dilution in Goat Blocking serum for 1 
hour at room temperature in the dark to prevent loss of fluorescence. 
After the incubation with the secondary antibody, coverslips were washed in PBS at 4°C 
in the dark. After this step, except for mF4/80 immunostaining, a second primary antibody 
was incubated overnight again to produced double stained specimens. The combination of 
first and second antibody to evaluate fibroblast markers was based on fluorophore excitation 
spectrum and species compatibility. Negative control without employing antibodies was used 
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to measure background fluorescence for vimentin, -smooth actin and HSP47. Images were 
produced using a LSM800 laser confocal microscope (Zeisss) at 10X and at 20X magnification. 
All images with the confocal microscopy were 512 x 512 pixels at 16 bit obtained through a 
bidirectional scanning of the coverslips. 
 
 
Figure 2.6 Lung fibroblasts isolation efficiency (1): Immunocytochemistry (ICC) from primary 
Macrophages positive control for F4/80. Macrophages were kindly provided by my colleague 
Jacqueline Lim, imaged using confocal microscopy with a 20X magnification lens from ZeissLSM800 
for: (A) F4/80 conjugated with AF555 in green (A); (D) DAPI for nuclear stain and with DAPI (B); and 















Figure 2.7 Lung fibroblasts isolation efficiency (2): Immunocytochemistry (ICC) from 
primary lung cells imaged negative control. Primary cells were imaged using confocal 
microscopy with a 20X magnification lens from ZeissLSM800 for: DAPI for nuclear 
stain (C); vimentin negative control conjugated with AF555 in green (A) and with DAPI 
(D); -smooth actin negative control conjugated with AF594 in red (B) and with DAPI 






Figure 2.8 Lung fibroblasts isolation efficiency (4): Immunocytochemistry (ICC) from primary lung 
cells imaged using confocal microscopy with a 10X magnification lens from ZeissLSM800 for: DAPI 
for nuclear stain (C); Vimentin conjugated with AF555 in green (A) and with DAPI (D); -smooth 
actin conjugated with AF594 in red (B) and with DAPI (E); and a merge of the three antibodies used 







Figure 2.9 Lung fibroblasts isolation efficiency (5): Immunocytochemistry (ICC) from primary lung 
cells imaged using confocal microscopy with a 20X magnification lens from ZeissLSM800 for: DAPI 
for nuclear stain (C); Vimentin conjugated with AF555 in green (A) and with DAPI (D);  -smooth 
actin conjugated with AF594 in red (B) and with DAPI (E); and a merge of the three antibodies used 




Primary mouse lung fibroblasts were positively stained for vimentin and α- smooth 
actin. Both cytoskeleton proteins are considered markers for fibroblasts as expressed in 
mesenchymal cells. Vimentin is associated with microtubules and with tubulin, whereas α-
smooth actin to actin filaments. Primary cells show an abundant cytoskeletal presence for 
both fibroblast markers, with merged images highlighting a cytoskeletal co-localization 
(orange colour in fig. 2.8 and 2.9). 
 
 
Figure 2.10 Lung fibroblasts isolation efficiency (6): Immunocytochemistry (ICC) from primary lung 
cells imaged using confocal microscopy with a 20X magnification lens from ZeissLSM800 for: DAPI 
for nuclear stain (C); Vimentin conjugated with AF594 in green (A) and with DAPI (D); HSP47 
conjugated with AF594 in red (B) and with DAPI (E); and a merge of the three antibodies used (F) 
[scale bar = 50 µm]. 
HSP47 is a chaperone protein fundamental in collagen α-chain transportation from 
endoplasmic reticulum, therefore it can be used as marker for mesenchymal cells. Vimentin 
showed again a cytoskeletal localization, although less bright than in other samples, while 







2.4.3 TGF-ß treatment 
 
TGF-ß is one of the most important cytokines to reproduce experimentally a fibrotic 
environment. TGF-ß alone is able to induce EMT in epithelial lung cells, and activate fibroblast 
activation in myofibroblasts. Human recombinant TGF-ß from Peprotech was used for all in 
vitro application as human and murine TGF-ß share more than 80% of sequence similarity in 
DNA and protein sequence homology (from Blast).  
Therefore, the following methodology was used for TGF-ß treatments in A549, MRC5 
and primary lung fibroblast. Cells were detached from a T75 fully confluent flask as described 
in section 2.4.1. 1x105 cells per well were seeded on either RGD-motif or collagen I coated 
plate purchased from Flexcell. In each experiment, four 6-well plates, paired for each 
substrate condition, were used at the same time. After 48 hours cells were reaching 60-70% 
of confluence. Complete media (DMEM for fibroblasts and DMEM F-12 for A549 only) was 
replaced for 16-18 hours with DMEM or DMEM F-12 (A549) at 1% Penicillin/Streptomycin and 
1% of defined serum replacement specific for human (TCH) or mouse (TCM) cells. Next, 3 wells 
per plate were treated with 2 ng/mL of recombinant TGF-ß and other 3 wells with BSA at 0.1% 
in PBS. The 2 ng/mL concentration was used as TGF-ß at concentration equal or higher than 
10 ng/mL can suppress collagen expression via CUX-1 (Fragiadaki et al., 2011). Moreover, from 
a trial test I have conducted at the beginning of my PhD it appears that 2 ng/mL was the 
concentration with less variability in the system (however, data cannot be included in this 
thesis as this test was performed in 3T3/NIH, with different kit for mRNAs extraction, retro-
transcription, and qPCR).  
Two 6-well plates out of 4 were placed in a Tension system for cell stretch (Flexcell) in a 
dedicated sterile humidified incubator at 37°C and at 5% CO2. Tension was then set at 6% of 
stretch and at 1 Hz of frequency using a continuous stretch for 6 hours. After completion, the 
plates were removed from the physical support, imaged using phase contrast microscopy 
(Nikon TiE), washed with sterile PBS for 2 times and lysed using Trizol, and the lysate collected 






2.4.4 Flexcell tension system 
 
The Flexcell Tension system allows coated plates to stretch. Stretch is the percentage of 
total surface elongation, and it is expressed as percentage of increase from starting state. The 
main purpose of this experimental procedure was to evaluate stretch contribution to gene 
expression in a system that include fibrotic stimulation in terms of cytokine and ECM. Flexcells 
plates surface can be functionalised with ECM components, such as RGD-motif, collagen I or 
IV, laminin and fibronectin. The experimental plan for this procedure was to evaluate 
difference in mRNAs due to different ECM coat. Therefore, the effect of collagen over RGD-
motif were evaluated, assuming collagen type I coating fibrotic-like. As explained in 1.6, in 
fibrosis there is an increase in the organ stiffness, due to dysregulation in wound healing 
repair, which dramatically augments collagen content. Collagen is among protein in the 
mammalian with the highest Young’s modulus (Young’s modulus monomer is 7 GPa), 
therefore a quantitative increase in course of fibrosis might be act as stimulation on 
expression of gene and microRNA involved in fibrosis (Shoulders & Raines, 2009). The rational 
in the use of the Flexcell system was to produce interdependent data on the role of collagen 
and stretch. However, the system cannot provide information regarding tissue stiffness which 
appears (as mentioned in 1.6) more important than stretch in a context of lung fibrosis. This 
was a limitation due to the system used. 
The Flexcell Tension System is composed by a loading coated post, plates are physically 
placed and a controlled vacuum pump. Pumps compressing air in the space between the 
loading post and the coated surface creates the vacuum, which allows to mechanical stretch 
the culture as indirect movement of the loading post (fig. 2.10). To avoid air leaking, which 
cause a weaker stretch (as vacuum cannot be created), Vaseline was spread around the 
physical support. The Flexcell Tension System was inserted in a dedicated humidified 






2.4.5 In vitro microRNA treatments 
 
Primary mouse lung fibroblasts were growth in T-75 and detached as described in 2.4.1. 
2X105 cells per well were seeded in 6-well plates. Once cultures reached full confluency, the 
DMEM was removed, and fibroblasts incubated for 30 min in sterile PBS in a humidified 
incubator at 37°C and at 5% CO2. For each mouse donor 3 different conditions were 
established. A scramble sequence for control, containing a random sequence not associated 
with any specific microRNAs; a mirmimic for the gain and a synthetic hairpin inhibitor for loss 
of function. 
Primary mouse lung fibroblasts were treated with synthetic sequence for miR-29a at 
0.05 µM. Treatments for miR-21a-5p used scramble at 0.1 µM, mirmimic at 0.05 µM and 
antagomir at 0.15 µM. Primary cell transfection was achieved using Lipofectamine 2000. After 
48 hours of incubation in a humidified incubator at 37°C and at 5% CO2 cells were washed with 




Figure 2.11 Schematic representation of Flexcell Tension System. The plate is placed with a 
brown rubber on top of a black support as shown in A. An air pump then creates vacuum, the 
air removal allows the plate surface to extend over the loading post, producing a stretch of 
surface as shown in B. (Please note that the figure in B contains the world strain although it 
should be stretch. The figure was not altered as taken from Flexcell website). 
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2.5 Molecular Analysis 
 
2.5.1 Lung Homogenization  
 
Lungs were homogenised using liquid Nitrogen (N2) and a mortar, and the resulting tissue 
powder was lysed in 0.5 mL of Trizol and vortexed for 5 min at maximum speed. 
 
2.5.2 Total RNA extraction 
 
0.5 mL of Trizol (Thermofisher) was added to cells in 6-well plates for 5 minutes for each 
well and the lysate collected with the use of a sterile scraper and stored in Eppendorf tubes 
at -80°C. After defrosting, 0.12 mL of Chloroform was then added to each tube and the tubes 
centrifuged at 12,000 x g for 15 min at 4°C. Only the aqueous phase, containing the total RNA, 
was collected for further steps. Next, 0.2 mL of Isopropanol was added to each tube and mixed 
with the lysate and incubated for 30 minutes in -80° C. Tubes were centrifuged at 12,000 x g 
for 10 min at 4°C to precipitate the RNA. The liquid phase was then discarded, and the pellet 
washed with 0.5 mL of molecular grade 75% ethanol and centrifuged at 7.500 x g for 5 min at 
4°C. The ethanol phase was discarded, and the pellet was air dried for 5 min at room 
temperature. RNase free water (volume depending on pellet size) was then added and the 
tubes incubated in a thermo-block at 55°C for 10-15 min. Total RNA concentration was then 
determined using a Nanodrop from Thermofisher. RNA with a 260/280 and a 260/230 ratio 
respectively higher than 1.65 and 1.4 were used in further applications. 
 
2.5.3 Reverse transcription 
 
Per sample, 1 µg of total RNA was used for all reverse transcriptase reactions. Evoscript 
from Roche LifeScience was used as it contains both random hexamers and oligo-dT as 
primers. Next, 4μl of 5x concentrated Reaction buffer and PCR grade water to a final volume 
of 18μl was added. Tubes were mixed well, centrifuged briefly and incubated for 5 minutes at 
room temperature. After incubation, 2μl of 10x concentrated Enzyme mix was added and 
mixed well. Tubes were then placed in a SimpliAmp Thermal Cycler (Thermo Fisher, USA) and 
incubated using the protocol in Table 2.5. 
Per sample, 100 ng of total RNA was used for all miRNA reverse transcriptions. Reverse-
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transcription was performed using miScript II Hispec technology. A mastermix composed of 
2:1 of 5X miscript Buffer with 10X miscript Nucleic Mix was added to the RNA. After 5 minutes 
of incubation, 1 µL of miScript reverse transcriptase mix was added to the solution. Tubes 
were then placed in a SimpliAmp Thermal Cycler (Thermo Fisher, USA) and incubated using 
the protocol in Table 2.6. 
Table 2.6 Reverse-transcription run program mRNAs. 
Step Temperature Time 
1st 42°C 15 min 
2nd 85°C 5 min 
3rd 65°C 15 min 
4th 4°C ∞ 
Table 2.7 Reverse transcription run program microRNAs. 
Step Cycle Temperature Time 
1st Incubation 1 37°C 60 min 
2nd Incubation 1 95°C 5 min 





2.5.4 Quantitative Polymerase chain reaction 
 
Genes were analysed using primer-probe sets from either Real Time Ready Assay© or 
Universal probe library©, while microRNAswas analysed using validated primers from 
miRScript technology. First the number of reactions were calculated according to the 
following formula: 
𝑛° 𝑜𝑓 𝑟𝑒𝑎𝑐𝑡𝑖𝑜𝑛 = (𝑛° 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒𝑠 + 1) × 3 + 1 
 
Formula 1: Calculation of number of reactions 
 
The resulting number was multiplied for each reagent single volume according to the 
following tables: 
Table 2.8 Master mix ingredients and volumes used for Universal probe library© 
Reagent Volume (µL) 
MasterMix 5 
Fw Primer 0.4 






Table 2.9 Master mix ingredients and volumes used for Realtime Ready Assay©. 
Reagent Volume (µL) 
Mix 5 
miR Primer 0.5 
Water 3.5 
 
Table 2.10 Mastermix ingredients and volumes used for mirScript ©. 
Reagent Volume (µL) 
Syber Green 5 
miR Primer 0.7 
Universal primer 1 
Water 2.3 
 
Each reagent was mixed together and 9 µL of the mix was loaded in each well in a 96 
well plate. Then, 1 µL of cDNA per well was added in triplicate for each sample. For miR-qPCRs 
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I used a Roche LightCycler480 (Roche, Switzerland) with the following protocol: 
 
Table 2.11 miR-qPCR protocol used for Roche LightCycler480. 
Step Cycle Temperature Time 





95°C 15 sec 
56°C 30 sec 
71°C 30 sec 
Cooling 1 4°C ∞ 
 
while for qPCRs a LightCycler96 (Roche, Switzerland) with the following protocol: 
Table 2.12 qPCR protocol used for Roche LightCycler96. 
Step Cycle Temperature Time 





95°C 10 sec 
60°C 30 sec 
72°C 1 sec 
Cooling 1 4°C ∞ 
 
Results were analysed with two different dedicated software packages, depending on 
the machine used. 
Relative miR expression was calculated using SNORD68 as housekeeping gene as 
suggested in the miRScript manual. Only miR-qPCRs results showing similar melting profile 
were used for further analysis as prove of technical specificity. Table 






Table 2.13 microRNA primers list. 




miR-21_2 MS00011487 5'UAGCUUAUCAGACUGAUGUUGA3' 
miR-34a_1 MS00001428 5'UGGCAGUGUCUUAGCUGGUUGU3' 
miR-29a_1 MS00001372 5'UAGCACCAUCUGAAAUCGGUUA3’ 
miR-378_1 MS00032781 5'UAGCACCAUCUGAAAUCGGUUA 
 
 
Relative mRNA expression was calculated using ß2-microglobulin for all in vitro 
experiments and HMBS for all the in vivo experiments. This is because HMBS showed a stable 
expression between samples, while ß2-microglobulin expression was stimulated by Bleomycin 
treatment. Mouse Col1a1 primers were the only using Universal probe library© technology 
(Tab. 2.12). Table 2.13 lists information regarding the validated Primer/Probe used for qPCRs.  
All qPCRs calculation for microRNAs and genes of interest followed delta CT relative 
expression, this allowed to compare each experiment in a more absolute way than relative to 
the control. To accomplish that housekeeping gene should not vary more than two between 
all technical replicates. Relative expression is therefore equal to the quadratic difference of 
housekeeping gene and gene of interest, obtained from each sample average from three 
technical replicates.  
The reason why I used two different qPCR machines for my experiments lay in the 
possibility to exploit peculiar characteristic of each qPCR machines. LightCycler 480 can be 
customed with temperature, time and in the trend of increase or decrease in the temperature. 
Therefore, it suited better with SYBR GREEN technology as the custom setting for melting 
temperature allowed to choose more accurate temperatures of annealing. 0.5 °C variation in 
temperature can results in not specific signals, as fluorescence depends by the number of 
probe molecule attached to DNA minor groove. By contrast, LightCycler 96 has a more rapid 
execution time, which fitted better with Taqman technology, more specific and sensible than 
SYBR GREEN. 
Table 2.14 Universal probe library© mus musculus Col1a1 primer information. 
GENE ID FORWARD (5’-3) REVERSE (5’-3’) PROBE SEQ AMPLICON BP 
Col1a1 CTCCTGGCAAGAATGGAGAT AATCCACGACCCTGA CCTCCTGG 91 
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Table 2.15 Real Time Ready Assay© primer/probe list. 




COL1A1 H. sapiens 
 
OI4 






CTGF H. sapiens 
CCN2, HCS24, IGFBP8, 
MGC102839, NOV2 






SNAI1 H. sapiens 
dJ710H13, SLUGH2, 
SNA, SNAH 

















SMAD7 H. sapiens 
CRCS3, FLJ16482, 
MADH7, MADH8 
SMAD family member 7 
[Source:HGNC 
Symbol;Acc:6773] 




















Snai2 M. musculus 
 
Slug, Slugh, Snail2 







Snai1 M. musculus 
 
AI194338, Sna, Sna1, 
Snail, Snail1 







Ctgf M. musculus 
Ccn2, fisp-12, Fisp12, 
Hcs24, 
connective tissue growth 





Smad6 M. musculus 
 
Madh6, Smad 6 







Smad7 M. musculus 
 
Madh7 







B2m M. musculus 
beta 2 microglobulin, 
beta2-m, beta2m, Ly- 
m11 



















2.6 Bioinformatics tools 
 
microRNA target discovery was performed with TargetScan 7.2 
(http://www.targetscan.org/vert_71/), while general information about each microRNA used 
were obtained from miRBase database (http://www.mirbase.org/). This database provides 
specific information regarding microRNA nomenclature, hairpin structure, sequence peculiarity 
and a list of related publications. Moreover, it distinguishes the mature microRNA in seed 
sequence and passenger strand, which present an asterisk after the name. This is because pre-
microRNAs are composed of a stem hairpin united dsRNA, where the two strands are separated 
by exonuclease cleavage, as only mature microRNA can be assembled in the RISC complex (Cai et 
al., 2009). Although both strands can operate a transcript inhibition, only the “seed strand” is 
usually considered for target analysis (O’Brien et al., 2018). In this study, only microRNAs 
conserved between human and mouse were taken in consideration. 
TargetScan 7.2, as many other target discovery platform, allows target discovery in most 
studied model organisms trough either microRNA or gene ID or name, as shown in figure 2.14. 
 
Then, in case of mRNAs target discovery from a microRNA name, TargetScan generates a 
table representing a list of mRNAs that satisfy algorithm requirements (Tab. 1 in Chapter 6 and 
Figure 2.12 TargetScan 7.1 open page screen shot 
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Chapter 7). For search from a gene name or ID, the platform produces a diagram, illustrating the 
entire 3’-UTR (as 5’-3’) with coloured boxes regarding the location and type of binding (fig. 2.15). 
 
This selection system is based on a number of assumptions that are quite often expanded, 
as new mechanisms or inhibition preference are discovered. TargetScan follows Watson and 
Crick pairs complementarity between microRNA seed sequence and corresponding 3’-UTR. The 
seed sequence represents the inhibitory core in the ribonucleic complex and therefore, 
represents the most important selection requirement. Selection requirements are based on the 
analysis of preferential conserved miRNA binding motif presents in the 3’-UTRs, which identify 
several classes of target sites. An 8-mer site is a match on miRNA of interest in position 2-8 with 
an adenosine on mRNA opposite to position 1, a 7-mer A1 site matching in position 2-7 with an 
adenosine on mRNA opposite to position 1, a 7- mer site matching in position 2-7 and a 6-mer 
site matching in position 2-7 with lower efficacy (Agarwal et al., 2015). Adenosine in microRNA 
sequence at position 1 regarded to increase in affinity in the binding, seen in mammalian species 
and therefore present only in algorithms for vertebrates (Bartel, 2009). Other parameter 
affecting microRNA binding included position 11-15 in the miR sequence, which promote binding 
when in contiguous complementarity to the mRNA sequence. Moreover, 3’-UTR accessibility is 
quite important parameter that can influence microRNA-mRNA interaction for steric reasons. 
miR-binding at the central of gene 
3’-UTR occurs less as the silencing complex might be destabilised by ribosomal rRNA 
(Bartel, 2009). With that TargetScan7.2 provided reliable predictions for mRNA and microRNA 
target identification. However, Fromm and collaborators extensively explained that TargetScan 
prediction algorithm main limitation are due to wrong or redundant annotation from microRNAs 
Figure 2.13 TargetScan output from mRNA name search. The output provides information 
regarding selected gene 3’-UTR gene (in this case Smad7 in mouse, on top) and location 
(below gene UTR) and type (see legend in the central box) of predicted binding site 
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databases (Fromm et al., 2015). Moreover, confused, and false positive functional analysis can 
result from an extensively use of simulation over experimental procedure.  
The wisest approach in this case is to refer not only to microRNAs databases but also to 
better annotated databases, such as ensemble! and UCSC. miR genomic location, and epigenetic 
regulation are all important information to obtain a successful prediction. 
 
2.7 Statistical Analysis 
 
Statistical tests were used to discern between different experimental groups, using Student 
t-test for comparison between two groups, and 1 and 2-way- Analysis of variance (1-way ANOVA 
and 2-way ANOVA) for more than 2 groups. Student t-test was then used for direct comparison 
regarding gene regulation change induced by fibrotic stimuli (TGF-ß, substrate and stretch) and 
also for single comparison in gain and loss of function experiments. 1-way-ANOVA was used for 
multiple comparison for analysis between experimental samples greater than 2, the analysis was 
also accompanied by Tukey Post-Hoc test for comparison between pairs of columns. 2-way-
ANOVA was used to investigate differences induced by fibrotic stimuli in two different age 
populations.  
All statistical analyses were performed using Prisms. Information regarding power 














Reproducing the entire disease complexity in in an animal model is still impossible. No 
models so far have been able to fully recapitulate lung fibrosis characteristics univocally. 
However, strategies such as administration of asbestosis, silica and Bleomycin, or cytokine 
overexpression (overexpressing TGF-ß, TNF-α or IL-1) represent robust methods to use for 
research propose (Mouratis & Aidinis, 2011). Among animal fibrotic models, the Bleomycin 
model of lung fibrosis is one of the better characterised and established in fibrosis research 
(Moore et al., 2013). Using a single intratracheal administration of Bleomycin, it is possible to 
reproduce both inflammatory and fibrotic patterns. Bleomycin induces either single or double 
strand DNA breaks (ssDNA or dsDNA) which lead to tissue injury due to cell apoptosis or necrosis. 
The intratracheal route limits the tissue damage to the lung. Furthermore, the low expression of 
Bleomycin metabolising enzymes increases the drug half-life and effectiveness with increase in 
cell damage. Bleomycin treatment leads to 1) Cell death 2) Inflammation 3) Fibrosis, which 
together recapitulate the main events of IPF. The main limitation of this model is that it resembles 
more an acute injury than a chronic disease such as fibrosis (Hatley et al., 2010). Moreover, 
murine lungs can recover from disease after 28 days (Degryse & Lawson, 2011). 
Despite the limitations, the method has proved to be indispensable for drug discovery for 
antifibrotic therapies and to improve our understanding of the diseases. 
As mentioned in the aim section, comprehensive analysis at different time point in the 
Bleomycin model of lung fibrosis identified in clusters of microRNAs interesting possible target 
for the developing of therapy against fibrotic diseases. Therefore, microRNAs of interest were 
selected based on their potential future therapeutic role (Xie et al., 2011). However, this study 
was based on arrays, therefore there was the necessity to validate the analysis with qPCRs in a 
lung fibrosis phenotype.  
After the phenotype was confirmed at molecular and histopathological level the microRNAs 
target discovery began. As mentioned in the introduction, the main focus of this work was on 
three major microRNAs, miR21-a, miR-34a and miR-29. Obviously, all cited microRNAs represent 
already interesting lead at the moment in clinical trial.  
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miR-21a has been strongly associated with kidney fibrosis and a synthetic analogue of miR-
21a has proved to be a possible cure for Alport disease, which can evolve to kidney fibrosis. 
Therefore, miR-21a might be involved in the first phase of fibrotic development, which represent 
most interesting therapeutic window for patient affected by the disease (Ivan G. Gomez et al., 
2015). miR-34a has a lung tropism, with significant increase in ageing and in cancer, as it induce 
lung epithelial survival by p53 repression (Disayabutr et al., 2016; Hermeking, 2010). miR-29a is 
considered fundamental in scar formation, this miR can potentially repress most of collagens and 
represent one of the most interesting target for microRNAs discovery (Slusarz & Pulakat, 2015). 
Another microRNA included in this experience was miR-378, because of its role in the response 
to tissue damage and involvement in EMT (Jieun Kim, Hyun, Wang, Lee, & Jung, 2018). 
 
The main aim of this chapter was to identify microRNAs with unique expression profiles in 




3.2 Materials and methods 
 
C57BL/6J male were treated with Bleomycin to induce a fibrotic phenotype as described in 
2.25. 
C57BL/6 mice (N=5 per group) were treated with either Bleomycin (mg/g) or vehicle (PBS 
control group). Mice were grouped in four groups based on the time of culling, such as control 
group, which received PBS and 3, 10 and 21 days after the intra-tracheal injection of a Bleomycin. 
C57BL/6 were sacrificed by intraperitoneal injection of pentobarbital sodium. Euthanasia was 
then confirmed by the end of the circulation and by no sign of reflex. Lungs were dissected and 
inflated for ex vivo lung μCT scans. After inflation, lungs were immersed in a solution at 3% of 
potassium iodide, used as contrast reagent, and imaged at 20 μm through Skyscan1272 μCT. 
Next, post-caval lobes were removed for histological analysis, and the remaining lung tissue used 




Bleomycin administration holds an obvious limitation due to interindividual biodiversity, as 
any treatment to any biological organism. The purpose of this chapter was to obtain results on 
microRNA from lung showing fibrotic phenotypes. For this reason, lungs were analysed at both 
mRNA (qPCR), protein (histology) and organ level (µCT) to assess the presence of a fibrotic 
phenotype. The reason why fibrosis was evaluated at different levels was to develop a robust 
system to correlate fibrosis development with microRNAs expression. To assess this correlation, 
samples were collected at 3, 10 and 21 days after treatment with Bleomycin, which represent 
inflammatory phase, apex of and end-point of fibrotic response, respectively. The main reason 
of this methodology lay in mice capability to rescue the healthy phenotype after 28 days from 
Bleomycin administration.  
 
3.3.1 µCT Analysis of lungs 
 
Total inflated ex-vivo lungs were imaged with a µCT following the setting cited in 2.2.3.  
To quantify the fibrosis, X-ray attenuation of lung parenchyma was measured. Increased X-
ray attenuation corresponded to a higher amount of soft tissue in the specimen and therefore 
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indicator of lung density. Major blood vessels were excluded from the analysis (Wheeler, Jones, 
& Ikonomidis, 2014) Lung parenchyma disruption induced by the treatment, should start a scar 
formation with having a higher quantity of collagen fibres augments the density of the organ. 
Density was calculated through dedicated software, which can calculate an object density from 
the different levels of grey in the reconstructed CT image (fig. 3.1 and 3.2). Therefore, the amount 
of fibrosis was evaluated as the average X-ray attenuation of the lung tissue (fig. 3.2). However, 
2 scatter points in the control group and 1 in the 10 days one were missing due to mistake in lung 
inflation procedure. 
Scans from control group shows a general bright appearance which reflected a healthy lung 
architecture (fig. 3.1 top left), while in the 3 days Bleomycin group there were fibrotic events 
(highlighted by the red arrow in fig. 3.1 top right). In progression from the 3 days group, 10 and 
21 days Bleomycin groups showed a general increase in voxels with high X-ray attenuation, 
indicating fibrosis. Moreover, it is possible to appreciate an increase in density around main 
airways for the 10 and 21 group samples (3.1 bottom). 
From qualitative point of view 10 days samples appeared the most fibrotic as it showed 
darker area compared to 21 days group, which was expected to have the highest degree in 
fibrosis. However, 3D scans reconstructed images allow a complete vision of the ex vivo lung 
allowing the possibility to quantify the levels of grey for each lung section (fig. 3.2).  
Lung density showed a significant 2.3-fold increase from control in 10 days Bleomycin group 
and a 1.5-fold increase in 21 days Bleomycin group (fig. 3.2). Analysis of the density histogram 
showed X-ray attenuation for control and 3 days group were mostly represented at lower density 
range (between 0- 49) while the 10 days and 21 days Bleomycin groups showed a shift to higher 
X-ray attenuation values (between 87-166, fig.3.3).  
The results suggested the presence of fibrosis after 10 and 21 days after treatment with 
Bleomycin, with a pronounced increase in tissue density around major airways as highlighted by 





Figure 3.1  Section of mouse lung imaged in X (upper), Y (central) and Z (right) axe. Images 
were generated and reconstructed from µCT software (Burkel) and saved as snapshot. 
Diverse colour results from different X-ray adsorption across the tissue. In the figure can 
be appreciated different level of grey, where the darker indicates area with higher tissue 
density and whiter area less tissue density. The images are reconstruction of this density 
map in the three dimensions from Control, 3 days (top) 10 days and 21 days (bottom) after 




Figure 3.2 µCT analysis of average lung density after intratracheal administration of Bleomycin. Lungs 
were obtained after 3, 10 and 21 days after the treatment. The density measurement are on a scale 
where 0 indicates pure air, and 255 solid soft tissue. Results shown in the figure were significant for 1-
way-ANOVA with an overall p-value < 0.001. Turkey post- hoc test was used for single column 
comparison **: p-value < 0.01 ***: p-value < 0.001. 
 
3.3.2 Collagen fibre analysis 
 
Picric Acid (Sirius Red) was used as stain for collagen fibres. Lungs were imaged with both 
brightfield microscopy and polarized light microscopy (shown respectively as A and B) for a 
qualitative analysis. PLM images were further analysed quantitively. From each sample 3 alveolar 
areas were arbitrary selected, the area transformed from coloured into scale of grey as 8-bit, 
collagen fibres in alveoli were then measured as levels of grey (fig 3.8). To produce an unbiased 
analysis capillary contains higher quantity of collagen fibres were excluded from the areas of 
interest (as indicated by the yellow arrow in 3.4B). The brightfield image allowed to evaluate the 








Figure 3.3 Control lungs stained with Sirius Red. Same image obtained using bright- field 
microscopy (A) and Polarized light microscopy (B). Black and yellow box indicates areas 
of interest imaged at 4X (left), 10X (centre) and 20X (right) magnification. Lungs show a 
normal appearance with circular dichroism around capillary (highlighted by RBC stained 
in green-dark yellow) [scale bar 1.000, 750, 500 µm respectively]. 
Figure 3.4 Section from 3 days after Bleomycin group, stained with Sirius Red. Same image 
obtained using bright-field microscopy (A) and Polarized light microscopy (B). Blackand 
yellow box indicates areas of interest imaged at 4X (left), 10X (centre) and 20X (right) 
magnification. Images show increase in cell population in the selected area, which might 





Control lungs showed a normal lung architecture, with a normal distribution of collagen 
fibres (fig.3.3A). Polarized light microscopy image (fig. 3.3B) did not show any event of dichroism 
Figure 3.5 Section from 10 days after Bleomycin group, stained with Sirius Red. Same 
image obtained using bright-field microscopy (A) and Polarized light microscopy (B). Black 
and yellow box indicates areas of interest imaged at 4X (left), 10X (centre) and 20X (right) 
magnification. Collagen fibres stains showed a pronounced circular dichroism in alveolar 
tissue parenchyma. [scale bar 1.000, 750, 500 µm. respectively]. 
Figure 3.6 Section from 10 days after Bleomycin group, stained with Sirius Red. Same 
image obtained using bright-field microscopy (A) and Polarized light microscopy (B). Black 
and yellow box indicates areas of interest imaged at 4X (left), 10X (centre) and 20X (right) 
magnification. Collagen fibres stains showed a pronounced circular dichroism in alveolar 
tissue parenchyma. [scale bar 1.000, 750, 500 µm. respectively]. 
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of note. Sections from lungs 3 days after Bleomycin treatment showed a typical hexagonal shape 
of lung parenchyma, with an increase in cell density around the alveolar walls, which could reflect 
the possibility of immune infiltration (fig. 3.4A). Polarized light microscopy showed a little 
increase in collagen fibres deposition (fig. 3.4B). Ten days after Bleomycin, lungs showed a 
disrupted lung parenchyma with a significant increase in cell density around alveoli (fig. 3.5A). 
Polarized light microscopy identified an increase from the control group in terms of dichroism 
around alveoli (fig. 3.5B). 
Twenty one days after Bleomycin treatment, lung sections showed an abnormal lung 
parenchyma (fig 3.6A). Polarized light microscopy showed increase in collagen fibres deposition 
highlighted by the dichroism (fig. 3.6B). 
 
 
Figure 3.7 Quantification of collagen fibres content from 3, 10 and 21 days after Bleomycin treatment 
(n=3). Results in the figure were significant for 1-way ANOVA with an overall p-value < 0.01. Turkey 
post-hoc test was used for single column comparison with control **: p-value < 0.01. 
 
The percentage of area with events of dichroism confirmed the increase in collagen fibre 
deposition for the 10 and 21 days Bleomycin group, with a significant 3-4-fold increase in the 
stained area from control sections (fig. 3.7). 
Histology confirmed the pronounced fibrosis for lung of 10 and 21 days, confirming 
tomography results. The level of collagen suggested the peak of fibrosis after 10 days from 




3.3.3 ECM gene expression profile 
 
The effect of Bleomycin was studied by analysing the expression of Granzyme ß (GzmB), 
Col3a1, Col1a1 and Ccn2/Ctgf by quantitative polymerase chain reaction (qPCR) as described in 
2.5.4. Col1a1, Col3a1 and Ccn2/Ctgf represents key component of ECM, involved in the response 
to chronic damage and fibrosis. The rational was to monitor expression of ECM to further confirm 
fibrosis development at mRNA level. GzmB was included as suggestion from Prof. Bou-Gharios, 
to provide further information regarding a possible immune infiltration found in the histological 
sections for the 3 days group (fig. 3.4). 
 
 
Granzyme ß (GzmB) showed significant 2 and 4-fold increase from control 3 and 10 days 
after Bleomycin treatment respectively. After 21 days GzmB level returned to levels close to the 
Figure 3.8 Gene expression analysis of Granzyme Beta (A) Collagen 3a1 (B) 
Connective tissue growth factor (C) and Collagen 1a1 (D) in the Bleomycin model of 
lung fibrosis. Results shown in the figure were all significant to 1-way ANOVA with 
an overall p-value < 0.01, p- value < 0.001, p-value < 0.001 and p-value < 0.01 
respectively for GzmB, Col3a1, CTGF/CCN2 and Col1a1. Turkey post-hoc test was 
used for single group comparison with control (n=4). 
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control group (fig. 3.8A). 
Collagen 3a1 (Col3a1), one of the most abundant proteins in the lung, showed a 3-fold 
increase 3 days after the treatment with Bleomycin. This further increased after 10 days, with a 
6-fold time increase in Col3a1 expression from control. Col3a1 expression levels decreased 21 
days after Bleomycin treatment with a 3-fold increase relative to control and a 45 % decrease in 
Col3a1 expression compared to the 10 days group (fig 3.8B). 
Connective tissue growth factor (Ctgf/Ccn2) showed a significant 2-fold increase from 
control 10 days after treatment with Bleomycin. Ctgf/Ccn2 levels slightly decreased (20% not 
significant) from levels at 10 days to 21 days after Bleomycin (fig. 3.8C). 
Collagen 1a1 (Col1a1) expression showed a significant 4-fold increase in 10 days group 
compared to control (fig 3.8D). 
Despite pair comparison did not show consistently significance at different time points, all 
ECM genes showed a progressive increase with a peak at 10 days, indicating that ECM production 
does not stop despite the pathological appearance. GzmB increase at 3 days after damage 
induction through Bleomycin further suggests a possible activation of inflammatory machinery. 
 
3.3.4 microRNA expression profiles 
 
The effect of Bleomycin treatment on the expression of miR-34a-5p, miR-21a-5p, miR-29a-
3p and miR-378-3p was studied by quantitative polymerase chain reaction (qPCR). Snord68, a 
small non-coding RNA was used as housekeeping gene. Relative expression was calculated as 
exponential difference between housekeeping gene and gene of interest (figure 3.9). 1-way 




Figure 3.9 miRs expression analysis of miR-34a-5p (A), miR-21a-5p (B), miR-29a-3p (C) and miR-378a-
3p (D) in the bleomycin model of lung fibrosis. Results shown in the figure were all significant for 1-way 
ANOVA with an overall p-value < 0.0001, p-value < 0.001, p-value < 0.0001, p-value < 0.001, respectively 
for miR-34a-5p, miR-21a-5p, miR-29a-3p and miR- 378a-3p. 
 
Expression of all four miRs increased after Bleomycin treatment, with miR- 21a-5p 
expression already significantly increased three days after Bleomycin treatment, and all miRs 
studied significantly increased at days 10 and 21 after Bleomycin treatment. 
miR-34a-5p showed a progressive increase in its expression with a 55 and 77-fold increase 
respectively at 10 and 21 days after Bleomycin treatment from control (fig 3.9A). 
Bleomycin progressively increased miR-21a-5p expression with significant 3, 3.7 and 4-fold 
time increase respectively for 3, 10 and 21 days after Bleomycin treatment from control (fig. 
3.9B). 
miR-29a-3p expression displayed significant 2.4 and 2.7-fold increase respectively at 10 and 
21 days after Bleomycin treatment from control (fig. 3.9C). miR-378a showed a gradual increase 
in its expression after Bleomycin administration, with significant 4 and 6.6-fold increase 








Bleomycin sulphate is an antibiotic from Strptomyces verticullus and is used to reproduce 
IPF features in experimental model of fibrosis (Mouratis & Aidinis, 2011). 
The main aim of this chapter was to identify microRNAs with unique expression profiles in 
the Bleomycin model of lung fibrosis. Four microRNAs (miR- 21a, miR-29a, miR-34a, and miR-
378a) showed progressive increase in their expression following major fibrotic features such as 
an increase in lung density and ECM. To obtain information regarding the progressive IPF 
characteristic, three time points representing start, progression and end stages of fibrosis were 
selected (3, 10, 21 days after Bleomycin treatment). 
In PF, healthy lung parenchyma is replaced by denser scar tissue made of ECMs and an 
increase in tissue stiffness. Tomography represents the golden standard in clinical practise and 
represent an incredible tool in experimental biology. CT reconstructs an organ structures as 3D 
density map, offering the possibility to identify fibrosis progressions and discern between 
structure at diverse density (capillary, alveoli, bronchioles, etc.). In 2013 Chris Scotton and 
collaborators developed a preclinical ex-vivo methodology for evaluation of drug efficacy using a 
Bleomycin model of lung fibrosis. The study was supported by gsk who had interest in this 
method to test compound against IPF (Scotton et al., 2013). Therefore, the idea was to replicate 
the method developed by Scotton and collaborator to use for microRNAs discovery. However, 
biological biodiversity together with dissection difficulty were source of variability in my 
experience and represented limitations that I found in the application of this method. In addition, 
in the ex-vivo procedure lungs are filled with diverse volumes of air, which can result in variation 
in lung total volume. Depending on the amount of air lung might appear more open or close and 
less or more fibrotic. This limitation was the reason why two lungs were excluded from this 
analysis as the inflation was not successful. To sum, results from the ex-vivo µCT showed an 
increase in the soft tissue after Bleomycin administration. The increase in soft tissue increased X-
ray attenuation from a specimen placed between radioactive source and a detector. However, 
morphological changes found in fibrotic samples, as the increase in lung stiffness are features 
common to all Interstitial lung diseases (Nogee et al., 2001). Densitometric analysis of µCT images 
showed a progressive increase following fibrosis progression. Moreover, higher level of grey, 
indicating in the analysis X-rays more attenuated by the specimen, were higher represented in 




The three-day group did not show any form of fibrosis, as this time point represents a pro-
inflammatory phase of IPF (Mouratis & Aidinis, 2011). Fibrotic lung undergoes an acute Th2-
immune response characterised by increase in TGF-ß, IL-1ß and TNF- (Wynn, 2011). Effects of 
this increase are fibroblast/myofribroblast activation and ECM secretion in the later stage 
increase (Kendall & Feghali- Bostwick, 2014). In the model developed, GzmB upregulation and 
the increase in the amount of nucleated cells population in the 3 days group are indicator a pro- 
inflammatory phase. Moreover, GzmB expression level remained high also in the 10 days group, 
which is in line with results obtained in the perforin knock out mice subjected to Bleomycin 
treatment Miyazaki (Miyazaki et al., 2004). However, more detailed evidence (measurement of 
inflammatory cytokines at transcript and protein level and further IHC for identification of the 
single nucleate population) are necessary to further confirm this result. 
In later stages of fibrosis (10 and 21 days after treatment), stains showed a progressive 
disruption of hexagonal shape lung parenchymal, clear sign of an unsolved scar. PLM microscopy 
confirmed a fibrotic appearance of the lungs, highlighted by dense collagenous structure, in line 
with the increase in fibrillar collagen in IPF (Wynn, 2011). 
The fibrotic appearance found in histology was also confirmed at expression level through 
qPCRs for Col1a1, Col3a1 and Ccn2/Ctgf. Results for both Col1a1 (α1 chain of type-I) and Col3a1 
showed significant increase in 10 and 21 days groups, with peaks for both genes at 10 days (fig. 
3.9B and D). Col1a1 and Col3a1 decrease at 21 days from 10 days group may represented a 
possible lung atrophy. In support of this possibility Sirius red staining from 21 days samples 
showed a marked disruption of lung parenchymal, worse than in 10 days group. Ccn2/Ctgf 
showed a trend similar to Col1a1 and Col3a1 with significant increase 10 days after bleomycin, 
with a similar progressive trend. This molecular behaviour in response to Bleomycin is in line with 
previous study from Leask and collaborators, who suggested a profibrotic role of Ccn2/Ctgf (S. 
Liu et al., 2011; Sonnylal et al., 2010). 
Results obtained from CT scans, histology and gene expression designated in 10 and 21 
days, as more fibrotic. 
 
Therapeutic use of miRs is a relatively new strategy in the field of fibrosis, as mentioned in 
1.5. The idea beyond the pharmacological administration of those small non-nuclear RNAs, is the 
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manipulation of their expression to reverse disease outcomes. miRs expression have been found 
altered in a broad range of disease. One example is represented by repression of miR-34a, now 
at phase II of clinical trial, against solid lung tumour (Beg et al., 2017). microRNAs can have a 
single or multiple target, which can regulate a signalling pathways entirely (Avraham & Yarden, 
2012). In the Bleomycin model of lung fibrosis all four microRNAs showed a progressive increase 
in their expression following the gradual fibrotic increase. 
miR-34a-5p high relative expression represents the characteristic lung tropism of this 
microRNA, which showed to be influenced by TGF-ß (Takano et al., 2017). miR-34a has been 
shown to regulate mechanisms such as apoptosis, senescence, and ageing, which are in line with 
the increase found in the Bleomycin model of lung fibrosis. Interestingly, Huachun Cui and 
collaborators showed an amelioration in lung physiology in a conditional epithelial knock out for 
miR-34a after Bleomycin administration (Cui et al., 2017). Our results are then in line with 
previous publications, which identify miR-34a-5p as a possible profibrotic microRNA. 
miR-21a-5p shows an interesting expression profile in our experimental model of lung 
fibrosis with a progressive upregulation with highest levels of expression at 10 days (fig. 3.10 B). 
miR-21a-5p showed a lung tropism, showing a high expression already in the untreated group. 
After Bleomycin treatment miR- 21a-5p expression gradually increased reaching the highest 
expression level among all miRs tested. This increases in expression from a healthy lung shows 
that miR- 21a-5p is a possible pro-fibrotic microRNA. Results are in line with a study from Yamada 
and collaborators, who showed a similar increase in miR-21a-5p expression in the Bleomycin 
model of lung fibrosis (Yamada et al., 2013). 
miR-29a-3p is increased in the expression at later stages of fibrosis, with significant increase 
at 10 and 21 days after Bleomycin administration (fig. 3.10 C). Our experimental data are not in 
line with the work of Montgomery who found a suppression in miR-29a-3p expression in the 
same animal model of fibrosis (Montgomery et al., 2014; Xiao et al., 2012). To further investigate 
miR-29a-3p role in lung fibrosis, I tested miR-29a-3p expression using mirmimic and antagomir 
approach in primary mouse lung fibroblasts (Chapter 6). 
miR-378-3p has been involved in muscle differentiation and induction of subsequent 
apoptosis (Wei et al., 2016). The increase in miR-378a-3p expression indicates possible role for 
this miR in pulmonary fibrosis. 
All microRNAs showed possible profibrotic role in the Bleomycin model of lung fibrosis, 
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however only miR-21a-5p and miR-34a-5p showed a clear progressive increase in their 
expression. Another fundamental reason why I focus this experimental study on those two 
microRNAs regards their relative expression level. miR-34 and miR-21 showed in control lungs CT 
values arounds 20-22, indicating that at 20th or 22nd cycle there was the exponential increase of 
the expression. By contrast, miR-378 had a relative expression of smaller order, which might be 
not identifiable after inhibitory treatments. This, I think is a key parameter to consider as 
pharmacologic use of microRNAs uses suppression or mimicking their ability as gain and loss of 
function.  
In conclusion, my results show that expression of all four microRNAs studied increased in 
bleomycin induced lung fibrosis. miR-21a-5p may be of special interest as it already increased at 
an early stage of the disease before major fibrosis has occurred. It is therefore a potential target 




4 Effect of fibrotic ECM substrate in a dynamic culture of 




In pulmonary fibrosis environmental aspects such as unhealthy lifestyle or cigarette 
smoking, are believed to be important inducers of pulmonary fibrosis (Borie et al., 2013; Ramlee 
et al., 2016). These stimuli trigger prolonged and continuous parenchymal damage or chronic 
damage, which is considered at the basis of organ fibrosis (Wynn, 2011). In vitro systems are at 
the moment able to reproduce organ structure and cells, thanks to the latest advantages in 
organoids and stem cells. Wilkinson in 2014 have been able to obtain human lung epithelial 
leaflet through a complex procedure, with the aim to develop a strategy for personalised 
medicine (Dan C. Wilkinson et al., 2014). Despite the latest advantages in 3D culture and their 
reliability, none of the systems that have been developed so far can fully mimic lung complexity. 
However, in vitro studies can provide information regarding cell behaviour and ECM-cell crosstalk 
in a number of pathologies, such as organ fibrosis. 
In organ fibrosis several cell types can contribute to the development of the disease, 
including immune cells (Th2 response), fibroblasts and myofibroblasts, and epithelial cells that 
undergo a transition into mesenchymal cells (EMT) (Meltzer & Noble, 2008; Wynn, 2011). 
Cytokine treatment with TGF-ß at a concentration lower than 10 ng/mL is currently the most 
used in vitro strategy to reproduce disease hallmarks (Fragiadaki et al., 2011). TGF-ß treatment 
determines TGF-ß receptor activation and a further increase in ECM expression. ECM is a 
reservoir of growth factors that are trapped in that; in fibrosis, ECM remodelling can be followed 
by a pathological release of active forms of TGF-ß (Burgstaller et al., 2017). Then, TGF-ß activating 
its canonical pathway will increase secretion of ECM. 
TGF-ß is considered a major regulator of EMT (Kalluri & Weinberg, 2009). EMT accounts for 
acquisition of polarity and movement, achieved through the loss of epithelial surface markers 
and acquisition of mesenchymal ones. This results in an increase in the mesenchymal cell pool 
(fibroblast/myofibroblast) at the site of damage. EMT is not a pathological mechanism and its 
correlation with fibrosis has only been shown in the kidney, lung, and intestine (Kalluri & 
Weinberg, 2009). These three organs share similarity in high cell turnover, cell heterogeneity and 
embryonic origin, and all three form physical barriers against pathogens. It was calculated that 
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in kidney fibrosis between 15-30% of myofibroblast secreting collagens were originating from 
epithelial cells (Kalluri & Neilson, 2003). Apart from TGF-ß, several other cytokines, such as WNT, 
EGF, FGF and others can activate EMT, as described in 1.2 (Kalluri & Weinberg, 2009). However, 
one transcriptional repressor family sensitive to TGF-ß, Snail, seems to be a master regulator of 
EMT in all types. Then, transformation of an alveolar cell into a mesenchymal one would 
dramatically affect the amount fibroblast/myofibroblast and ECM secretion, which can ultimately 
worse or induce a fibrotic phenotype. Emerging evidence has demonstrated that EMT is strongly 
influenced by mechanical forces (Gomez, Chen, Gjorevski, & Nelson, 2010). These findings latter 
may have important implications in the context of lung fibrosis. 
Through an involuntary innervation, movement of the diaphragm and chest muscles leads 
to a below-like movement of the lung. This leads to deformation of the lung tissue which is 
propagated to lung cells through their attachment to the ECM. During fibrosis lung increase in 
thickness, due to an increase in collagen content. As mentioned in the introduction collagen has 
incredibility strength power, with a Young modulus of around 11 GPa, which is the force 
necessary to unbound a collagen brick covalent bound (Shoulders & Raines, 2009). In addition, 
stiffer matrix seems to attract and activate myofibroblast to increase collagen and other ECM 
components (D. J. Tschumperlin et al., 2018). Although stiffness seems to be more important 
than stretch in fibrosis, I preferred to focus more on this latter, as I was more interested in 
verifying the effect of a diverse ECM in a dynamic system. Therefore, my idea was to compare 
two substrates, one representing a healthy ECM using RGD-motif and a profibrotic one using 
collagen matrix, with or without motion or stretch. The aim was to verify if any of those 
parameters had an effect on key genes involved in the pathogenesis of lung fibrosis. Moreover, I 
thought that stretch might have a positive effect on miR-21a, as Li and colleagues had suggested 
that MRTF-A, considered the transcription factor mechano-sensor, can promote miR-21a in 
mesenchymal cells (D. J. Tschumperlin et al., 2018). The possibility that microRNAs are also 
involved in the regulation of the mechanical stimulation is an interesting possibility that I wanted 





4.2 Materials and Methods 
 
A549 or MRC5 cells per well were seeded on either RGD-motif or collagen coated 6 well 
FlexCell plate, as described in 2.4. RDG-motif was used to mimic a healthy ECM, while collagen 
was used to mimic a fibrotic ECM. Cells were cultured for 1.5 days and FBS free media was then 
added to the culture once 60-70 % confluency was reached. TGF-ß at 2 ng/mL was added to the 
culture to mimic a fibrotic cytokine environment while BSA at 0.1% in PBS was used as vehicle in 
control groups on both substrates. Mechanical stretch was achieved through Flexcell Tension 





4.3.1 Effect of stretch in A549 and MRC5 cells 
 
 
Figure 4.1 A549 seeded on RGD-motif (in A) and Collagen (in B) after treatment. Stretched 
cells appeared elongated after 6 hours of cyclic stretch using Flexcell system. Treatment with 




For both cell lines, the treatment with TGF-ß or with BSA did not induce visible changes in 
cell appearance. Cells receiving stretch showed changes in cell shape (more elongated and 

















Figure 4.2 MRC5 seeded on RGD-motif (in A) and Collagen (in B). After 6 hours 
of cyclic stretch using Flexcell system, cells appeared elongated. Treatment 
with TGF-ß or BSA (Vehicle) did not affect cell morphology [scale bar 100 µm]. 
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4.3.2 A549 Gene expression profile  
 
The effects of substrate, stretch and fibrotic cytokine environment (TGF-ß) on the adherent 
adenocarcinoma alveolar cell A549 were studied analysing genes of interest expression (Tab. 2.13 








Table 4.1 2-way ANOVA statistic was applied to calculate significative differences induced 
by the treatments (TGF-ß and stretch; used as row) and the substrate (used as column) for 
Col1a1 (A), CCN2/CTGF (B) SNAI1 (C) and PDGFRα (D). Top of the figure gives numerical 
percentage indication on the weight of the single variable including interaction, while 
bottom figure shows statistical significance where * p-value < 0.05, ** p-value < 0.01 and 





































































































































































































































































































































































































































































Without any stimulation cells cultured on collagen showed higher mRNA expression for all 
genes studied compared to RGD-motif (fig. 4.2).  
Treatment with TGF-ß at 2 ng/mL for 6 hours resulted in significant increase in expression 
level for all genes analysed, as visible in figure 4.3. Moreover, TGF-ß increased the expression of 
COL1A1 and CCN2/CTGF of 15 and 6 fold approximately. This response to TGF-ß treatment 
demonstrated that not only mesenchymal cells, but also epithelial alveolar cells participate in 
ECM turnover, however, this experiment did not show evidence on protein level.  
COL1A1 expression was significantly affected by TGF-ß, treatment resulted in upregulation 
of COL1A1 expression from control condition on both substrates, with a higher 17-fold time 
relative increase in the RGD-motif group compared to the 12-fold time increase in collagen group. 
However, the absolute level of COL1A1 expression was again higher in the collagen group, 
including TGF-ß together with stretch group (Fig 4.3A and Table 4.1A). Under all conditions, 
COL1A1 expression was higher in cells cultured on collagen than in cells cultured on the RGD 
motif. TGF-ß treatment resulted in upregulation of CCN2 expression with higher 6-fold increase 
from control for collagen group versus a 5-fold increase in RGD-motif group (4.3 B). TGF-ß 
Figure 4.3 (bis) CCN2/CTGF expression level in A549 (n=7). Red circles 
indicate A549 seeded on RGD- motif, whereas blue squares on 
collagen. Effect of stretch on cells without TGF-ß (A) and after 
treatment with TGF-ß (B) for CCN2/CTGF. 
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treatment induced a proportional similar increase in SNAI1 expression in both substrates from 
control. After TGF-ß treatment SNAI1 expression was 38% higher in the collagen group compared 
to RGD-motif (fig 4.3 C). PDGFR expression resulted in a 3.5-fold time relative increase from 
control in both substrates induce by TGF-ß (fig 4.3 D). 
Stretch did not change COL1A1 expression level from controls, and stretch did not affect 
TGF-ß induced expression of COL1A1 in either the collagen group or cells cultured on the RGD-
motif (fig. 4.3 A). Mechanical stretch leads to increases in CCN2/CTGF expression on both 
substrates, however, this was only significant for cells cultured on the RGD-motif (fig. 4.4A). 
Stretch condition showed a 54% increase in collagen group compared to the RGD-motif. Stretch 
did not affect TGF-ß-induced SNAI1 expression (fig. 4.3 C). Stretch at 6% did not significantly 
affect PDGFR expression from controls (fig 4.3 D) 
Stretch with TGF-ß showed significant increase from control for all genes. However, for 
COL1A1, SNAI1 and PDGFR this effect was triggered by the TGF-ß only (fig. 4.3). By contrast, in 
CCN2/CTGF the combination of the two stimulations resulted in a significant decrease from the 
TGF-ß group, as effect of stretch over TGF-ß (fig. 4.4 B). 
Interesting, 2-way ANOVA analysis showed significant interaction for COL1A1, CCN2/CTGF 
and PDGFR, demonstrating that the two stimulation trigger a different response based on which 
















4.3.3 A549 microRNAs expression profile 
 
The effects of substrate, stretch and fibrotic cytokine environment (TGF-ß) on the adherent 
adenocarcinoma alveolar cell A549 (Tab. 2.11 in 2.5) was studied by analysing expression of 
microRNAs of interest (miR-21a-5p and miR-34a-5p) by Quantitative polymerase chain reaction 
(qPCR). 
Table 4.2 2-way ANOVA statistic was applied to calculate significative differences induced by the 
treatments (TGF-ß and stretch; used as row) and the substrate (used as column) for miR-21a-5p (A) 
and miR-34a-5p (B). Top of the figure gives numerical percentage indication on the weight of the 
single variable including interaction, while bottom figure shows statistical significance where * p- 







Figure 4.5A and C shows miR-21a-5p expression level in A549 cells. Table 4.2A shows 2-way 
ANOVA results for miR-21a-5p, highlighting that only substrate influenced miR-21a-5p 
expression. Neither TGF-ß nor mechanical stretch affected miR-21a-5p expression in A549 cells. 
miR-21a-5p expression level showed a highly statistically significant 18% increase in the collagen 
group compared to the RGD- motif. 




































































































































































































level in A549. No significant effects of either treatment or substrate were indicated by 2-way 
ANOVA (Tab. 4.2B and fig. 4.5B). 
Results on microRNAs demonstrated that epithelial cells are strongly influenced by the 
substrate, while other treatments did not result in any effect detected. 
 
In A549, COL1A1, CCN2/CTF, SNAI1, PDGFR showed a responsiveness to TGF-ß, while 
collagen as substrate trigger upregulation from RGD-motif in all genes analysed plus miR-21a. 
Interestingly, only CCn2/CTGF showed a responsiveness to stretch, highlighting a possible role of 




4.3.4 MRC5 Gene expression profile 
 
At this point, I wanted to evaluate the response from the same stimulation in mesenchymal 
cells, as in general they are considered more important in a context of organ fibrosis. 
Mesenchymal cells regulate connective tissue homeostasis, sensing and responding to wide a 
range of stimuli, such as cytokines, chemokines, neurotransmitters, oxygen reactive species, 
hormones, and microRNAs (Kendall & Feghali-Bostwick, 2014). Therefore, using the same setting 
used for A549 I studied the expression of COL1A1, CCN2/CTGF, SNAI1 and SMAD7 by Quantitative 
polymerase chain reaction (qPCR). SMAD7 was included in this analysis as its fundamental role 
in repression ECM secretion in mesenchymal cells. Unfortunately, for time reason I was not able 











Table 4.3 2-way ANOVA statistic was applied to calculate significative differences 
induced by the treatments (TGF-ß and stretch, used as row) and the substrate (used as 
column) for Col1a1 (A), CCN2/CTGF (B) SNAI1 (C) and SMAD7 (D). Top of the figure gives 
numerical percentage indication on the weight of the single variable including 
interaction between variables, while bottom figure shows statistical significance where 




































































































































































































































































































































































































































Figure 4.7 Effect of different substrates on SMAD7 expression in MRC5 (n=34). SMAD7 delta CT values 
were divided in two groups and student t-test for pair comparison showed a significant increase in the 
collagen group compared to the RGD-motif.  
 
Figure 4.6 SNAI1 (A and B) and SMAD7 (C and D) expression level in MRC5. Red circles 
indicate MRC5 seeded on RGD-motif, whereas blue squares on collagen. Effect of 
stretch from control state (A and C) and from a treatment with TGF-ß (B and D) for 
SNAI1 and SMAD7  
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MRC5 showed an expression 10 times higher for COL1A1 compared to A549, while SNAI1 
had 10 times lower level in MRC5 compared to A549. 
Collagen as substrate induced the expression of COL1A1, SMAD7, while in SNAI1 showed a 
similar response for samples cultured on collagen, however this trend was lost once stretch was 
applied on the culture (fig. 4.6, 4.7, 4.8). COL1A1 had a significant 2-fold increase for cells cultured 
on collagen group compared to cells cultured on the RGD-motif (4.6 A). Cumulative analysis from 
all sample using paired t-test for SMAD7 highlighted a 27% increase for cells cultured on collagen 
substrate compared to RGD-motif, as also confirmed by 2-way ANOVA (fig. 4.8 and Tab 4.3). 
TGF-ß treatment accounted for a significant 78% increase level in COL1A1 mRNA in RGD-
motif from control, while collagen group did not respond to the stimulation. In CC2/CTGF TGF-ß 
treatment resulted in a 1.5-fold upregulation compared to control on both substrate from 
control. TGF-ß induced a significant 4 times increase in MRC5 cultured on RGD-motif compared 
to collagen group for SNAI1 (fig. 4.6 C). TGF-ß treatment induced a 4 time increase in SMAD7 
expression for cells cultured on the RGD-motif group, and a 9-fold increase in cells cultured on 
collagen group compared to untreated groups (Fig 4.6D). 
Mechanical stimulation through stretch assay only influenced SNAI1 and SMAD7, 
interesting CCN2/CTGF was not affect by this stimulation (fig. 4.7). SNAI1 collagen group showed 
a significant 55% reduction in SNAI1 expression compared to control (fig. 4.7A). Stretch induced 
a significant increase in SMAD7 expression from controls in both substrates, with a 2-fold 
increase in cells cultured on RGD-motif and a 3-fold increase in cells cultured on collagen (fig. 
4.7C).  
Combination of TGF-ß with stretch showed a significant increase for MRC5 cultured on 
collagen for COL1A1 and CCN2/CTGF with an increase of 91% for COL1A1 and a 63% for 
CCn2/CTGF from the RGD-motif.  
Statistical analysis using 2-way ANOVA resulted in a no significant interaction for COL1A1, 
CCN2 and SMAD7, which indicates that treatment (TGF-ß and stretch) affected SMAD7 
expression in the same direction (increase/decrease in the expression) on both substrates. By 
contrast, significative interaction for SNAI1 highlights that variables affect gene expression 





The main focus of the experiments described in this chapter was to investigate the 
effects of diverse substrates and mechanical stretch on genes and microRNAs believed to be 
involved in fibrosis, in the two main lung cell lineages: epithelial and mesenchymal.  
As mentioned in the introduction, lung compliance refers to V/P relationship, which are 
altered in many pathological conditions, reflecting alteration to lung structure. Fibrotic lungs 
need higher pressure to breathe in a same amount of volume of air in inspiration compared 
to normal lungs (Bela Suki et al., 2011). This characteristic compliance is the result of increase 
in ECM after chronic damage, which also alter lung mechanical properties (Martinez et al., 
2017). Fibrotic alteration dramatically changes lung function and physiology. Understand the 
cellular response to structural variation appears crucial to develop new antifibrotic therapy. 
Interesting, fibroblasts produce higher amount of ECM when seed on stiffer ECM (D. J. 
Tschumperlin et al., 2018). Therefore, the increase in stiffness occurring in fibrosis might have 
consequences on ECM production. Moreover, a stiffer material is always harder to stretch, 
therefore a stiffer ECM needs more work, as the product of force per distance to extend the 
surface during breathing. In addition, in later stages of lung fibrosis lungs there is a lack in 
stretch due to ECM excess. Therefore, the first hypothesis was to verify if stretch reduces 
expression of ECM gene upregulated in fibrosis. To assess this, epithelial and mesenchymal 
lung cells were seeded on an elastic material, coated with two major ECM components 
representing a healthy and profibrotic set. The system used was similar to the one invented 
by Wirtz and Dobbs in 2000, who developed a stretch assay for lung cells, using a RGD-motif 
coated elastic membrane and a sinusoidal stretch (Wirtz & Dobbs, 2000). 
Results obtained on stretch suggested a possible protective role of stretch, able to 
downregulate the expression of COL1A1 and CCN2/CTGF in A549 and upregulate SMAD7 in 
lung fibroblasts. As suggested by Wirtz and Dobbs work, stretch might regulate ECM turnover 
and epithelial/mesenchymal communication occurring in foetal alveolar development (Wirtz 
& Dobbs, 2000). Although results showed in the chapter are not focused on lung development, 
both results highlight a key role of stretch in regulation of proliferation and ECM turnover. 
Moreover, mathematical model of lung injury suggested that stretch holds a protective role 




Nevertheless, substrate showed a higher regulative power on ECM and miR gene 
regulation compared to stretch. Fibrotic substrate (collagen) upregulated COL1A1, 
CCN2/CTGF, SNAI1, PDGFRα as well as miR-21a-5p expression in A549 cells and COL1A1, 
SMAD7 in MRC5. 
As expected, TGF-ß stimulated the expression of most of the fibrotic genes in both cell 
types. A549 showed significant upregulation induced by TGF-ß in COL1A1, CCN2/CTGF, SNAI1 
and PDGFRα, while in MRC5, TGF-ß stimulated CCN2/CTGF, SNAI1 and SMAD7 expression. By 
contrast, both microRNAs did not show increased expression induced by TGF-ß treatment. 
This latest result was not in line with other publication reporting miR-21a and miR-34a 
responsiveness to TGF-ß (Cui et al., 2017). However, this might be a consequence of the 
coated membrane, strain, or diverse time points, as Cui and collaborators used a similar 
setting employing A549.  
 
Collagen type 1 is the major component of fibrillar collagen, which in lung confers organ 
structural rigidity during the “bellow-like movement” (Laurent, 1986). Moreover, it composes 
15% of the organ weight (30% of lung dry weight) and COL1A1 upregulation is a characteristic 
hallmark in all organ fibrosis (Laurent, 1986; Ricard-Blum, 2011). Thus, during fibrosis, normal 
tissue parenchyma made of collagen, laminin, elastin, fibronectin, and others protein, is 
replaced by type-I collagen. In general, COL1A1 showed a good responsiveness to TGF-ß and 
fibrotic substrate in both A549 and MRC5. Interestingly, MRC5 showed higher control levels 
of COL1A1 compared to A549, which reflect the difference between epithelial and 
mesenchymal cells. TGF-ß-induced COL1A1 with higher magnitude in A549 than in MRC5, 
although COL1A1 expression was relatively higher in MRC5 than A549. In both cell lines, TGF-
ß treatment results in relatively higher increase in COL1A1 expression in the RGD-motif group 
compared to the collagen group. In Epithelial A549 cells, collagen as substrate resulted in a 
twofold increase in COL1A1 expression under all experimental conditions, while in MRC5 cells 
cultured on collagen triggered the same effect only in the control group and for the combined 
TGF-ß and stretch group. These results indicate a possible positive feedback loop during 
fibrosis where the presence of a matrix rich in collagen type 1 further increases COL1A1 
expression. One possible mechanism is that collagen fibres act as ligand for signalling 
transduction. This possibility is supported by stereospecific bond between collagen GFOGER 
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motif and integrin α2ß1, which emerged to undergo conformational changes (Mejía et al., 
2015). Collagen-induced changes in α2ß1 structure which may activate pathways, resulting in 
increased COL1A1 expression (Jia, Li, Peng, Ding, & Alexov, 2018). In both wound healing and 
in fibrosis mechanical stretch and TGF-ß can increase COL1A1 expression (Savla, Olson, & 
Waters, 2004). My results on COL1A1 expression demonstrate that a fibrotic environment 
(TGF-ß and collagen as substrate) increases COL1A1 expression in both lung epithelial and 
mesenchymal cells. 
CCN2/CTGF is a protein belonging to CCN family and it is an ECM component. 
CCN2/CTGF has two main roles, it is an ECM protein, and it is a paracrine modulator for other 
ECM protein (Hall-Glenn & Lyons, 2011). This protein has been extensively studied in fibrosis 
and transgenic mouse models have identified it as a pro-fibrotic protein (S. Liu et al., 2011; 
Sonnylal et al., 2010). CCN2/CTGF showed similar control level between epithelial and 
fibroblast cells, however A549 were more responsive to TGF-ß, displaying also less variance 
between technical replicates. A549 showed results similar to COL1A1 with CCN2/CTGF 
expression increased by both TGF-ß and the collagen substrate. Although TGF-ß treatment 
stimulated CCN2/CTGF expression in both A549 and MRC5 cells, there were differences in the 
magnitude of the response between cell lines, with a two-fold increase in MRC5 cells and a 5-
fold increase in the A549 cells. In A549 cells the substrate significantly affected the expression 
of CCN2/CTGF, the RGD-motif group showed a higher relative increase from control state 
compared to collagen coated plate. CCN2/CTGF expression in the A549 epithelial cells was 
strongly dependent on the culture substrate, whereas in MRC5 cells this effect was not 
statistically significant. Stretch strongly affected CCN2/CTGF gene regulation in A549, and 
although a similar trend was observed in the MRC5 cells, this was not statistically significant. 
The unexpected high variability in MRC5 may have masked any stretch related effect. 
Interestingly, in A549 cells, stretch appears to have a protective antifibrotic effect as stretch 
downregulated CCN2 expression in cells cultured in fibrotic substrate condition (collagen and 
TGF-ß). 
SNAI1 is a DNA binding repressor involved in mesoderm formation during 
embryogenesis, where it represses E-cadherin expression, and stimulates N- cadherin 
expression. This is why SNAI1 was characterised as one of most important EMT regulators 
(Nieto, 2002; Thiery et al., 2009). TGF-ß induces EMT, and EMT is an important process in 
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organ fibrosis, as it augments the number of resident fibroblasts (Takano et al., 2017). 
However, the role of SNAI1 in fibroblasts is poorly understood. The results in this chapter are 
in line with a stimulatory effect of TGF-ß on SNAI1 expression in both cell lines (Hwangbo et 
al., 2016). Moreover, TGF-ß induced SNAI1 expression ten times more in epithelial A549 than 
in MRC5 fibroblasts, although a low base line expression in the epithelial A549 cells. Cells on 
a fibrosis-mimicking substrate, collagen, resulted in higher SNAI1 expression in both cell lines, 
with levels 10 times higher in A549. The effect of the fibrotic substrate was more pronounced 
in the A549 cells than in the MRC5 cells. Only in A549, SNAI1 expression was consistently 
higher when cells were cultured on collagen, which may induce EMT, contributing to fibrosis. 
Stretch only affects SNAI1 regulation in MRC5, where stretched cultures on collagen showed 
a downregulation in gene expression. This reduction in SNAI1 expression suggested that 
stretch may have a protective effect against fibrosis. 
PDGFR is a tyrosine kinase receptor with a high mitogenic activity fundamental for a 
correct wound healing repair and lung morphogenesis (Whitsett et al., 2018). Although 
PDGFR  is mesenchymal marker, we wanted to understand its role in epithelial lung cell as 
bridge between EMT and fibrosis (Wu et al., 2012). Moreover, PDGFR  is the binding receptor 
for PDGFα, a pro-inflammatory cytokine able to activate myofibroblasts and PDGFR is known 
to be activated in fibrosis (Wynn, 2011). As expected, TGF-ß stimulated PDGFR  expression 
in the A549 cells. Culture of A549 cells on collagen resulted in increased PDGFR expression 
under all experimental conditions. Stretch did not affect PDGFR expression in A549 cells. 
These results are in line with previous studies suggesting a role of PDGFR  in fibrosis and EMT 
progression (Wu et al., 2012). A fibrotic environment (TGF-ß and collagen substrate) results in 
an increase in PDGFR  expression, which may stimulate EMT in A549 epithelial cells. 
However, results obtained alone cannot be referred to increase in EMT as they lack in 
pathways analysis on PGDFRα signalling and information on cytoskeleton remodelling in EMT. 
Possibly, stimulation with PDGFRα agonist (PDGFα) might confirm a role for PDGFRα in EMT.  
SMAD7 is an inhibitory intracellular protein involved in the TGF-ß pathway, where it 
limits TGF-ß signalling cascade, which can also limit fibrosis progression (Lan, 2008; Mouratis 
& Aidinis, 2011). SMAD7 is induced by TGF-ß, and this results in a negative feedback on TGF-
ß activity. As expected, TGF-ß upregulated SMAD7 expression in the MRC5 cells. In addition, 
mechanical stretch increased SMAD7 expression, suggesting again that stretch may have an 
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antifibrotic role as it induced SMAD7 expression. This upregulation depending on stretch may 
be then lost in the course of fibrosis, as tissue become stiffer. Moreover, stretch only 
upregulated TGF-ß-induced SMAD7 expression when cells were cultured on the RGD-motif, 
while on collagen stretch no longer increased TGF-ß-induced SMAD7 expression. Therefore, 
the antifibrotic effect of stretch-induced SMAD7 expression may be lost in a fibrotic 
environment. 
miR-21a-5p is a small non-coding RNA up-regulated in lung tissue from patients affected 
by lung fibrosis. Predicted alignment algorithms indicate a 8-mer binding site at SMAD7 3’-
UTR (Li et al., 2013; G. Liu et al., 2010). In Chapter 3, miR- 21a-5p showed a pro-fibrotic 
behaviour, displaying a progressive up-regulation parallel to fibrotic progression. TGF-ß does 
not affect miR-21a-5p expression in epithelial A549 lung adenocarcinoma cells. However, 
culturing the cells on fibrotic substrate, rich in collagen, miR-21a-5p expression was resulted 
significantly increased, showing a response to fibrotic stimulation. miR-21a-5p expression was 
influenced by substrate in epithelial A549 cells, which might affect SMAD7 expression in 
fibroblasts. Although this study is limited by the use of an adenocarcinoma cell line, our results 
show an overall agreement with previous publications. Moreover, they clarify the protective 
role of stretch in lung fibrosis, and a profibrotic role of an ECM rich in collagen. 
miR-34a-5p expression has been reported to be related to EMT progression after TGF-ß 
treatment, key in IPF (Cui et al., 2017). As for miR-21a-5p, miR-34a-5p expression was 
upregulated in the experimental Bleomycin model of lung fibrosis (Chapter 3). However, in 
the experiments described in this chapter miR-34a-5p expression cells was not affected by 
TGF-ß, stretch or the culture substrate in A549. This might depend on the experimental set-
up used for this experiment, as the system used can be considered more informative than no-
coated plates. TGF-ß concentration, timing, cell variability are variables that could have 
affected miR-34a-5p levels. 
 
An important limitation which could in principle affect this set-up is undoubtedly 
substrate thickness, as it can dramatically influence ECM gene expression. In addition, 
fibronectin, laminins, elastin, and other ECM components are all upregulated during fibrosis. 
However, results obtained highlighted a stronger induction of collagen substrate compared 
to RGD-motif, demonstrating a novel role of parenchyma in the stimulation of profibrotic 
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genes. Understand this crosstalk might highlight novel roles for collagen in fibrosis.  
Another limitation of note for the study lay in the use of cell lines, as primary cells can 
better represent physiological conditions.  
In details, as A549 cells are an adenocarcinoma alveolar cell line and therefore cannot 
be considered the best model to use for a study on fibrosis. However, currently, there are no 
validated experimental procedures able to generate primary alveolar epithelial culture, 
except using stem cells or cell sorting. Generation of an alveolar epithelium from stem cells 
has several important drawbacks, as maintaining of stemness characteristics (Dye, Miller, & 
Spence, 2016). The cell sorting procedure from small rodents has a low yield. Furthermore, 
both techniques are labour intensive, take a long time and are quite expensive. On the other 
hand, the A549 cell line is widely used in lung research, as cells possess several features of 
alveolar type-I and type-II cells (Junghyun Kim et al., 2018). 
MRC5 is an immortalised cell line isolated from the lung of a 14 week-old aborted foetus. 
Although this cell line cannot represent a mature lung fibroblast, MRC5 are not a cancer cell 
type and for that can be considered a better cellular model for a study on fibrosis. However, 
they had a higher level of variability in the response compared to A549. 
Unfortunately, due to time constriction qPCRs for SMAD7 in A549 and PDGFRα in MRC5 
were not performed. 
 





Table 4.4 Sum of qPCRs from A549. In the column there are listed the 
genes and miRs of interest, whereas in the row the different 
stimulation performed. Up facing arrows (↑) indicates upregulation, 





COL1A1 ↑ ↑ - 
CCN2/CTGF ↑ ↑ ↓ 
SNAI1 ↑ ↑ - 
PDGFR ↑ ↑ - 
miR-21a-5p - ↑ - 
miR-34a-5p - - - 
 
Table 4.5 Sum of qPCRs from MRC5. In the column there are listed 
the genes and miRs of interest, whereas in the row the different 
stimulation performed. Up facing arrows (↑) indicates upregulation, 
down facing arrows (↓) downregulation in expression and ↓/↑ 
indicates a diverse result depending on experimental conditions 





COL1A1 - ↑ - 
CCN2/CTGF ↑ - - 
SNAI1 ↑ ↑ ↓/↑ 





5 Effect of ECM substrates and ageing on mRNA and miR 
expression in primary mouse lung fibroblasts in a 2D 




In chapter 4, differences in ECM highlighted a profibrotic role of collagen rich substrate 
on COL1A1, CCN2/CTGF, SNAI1 PDGFRα and miR-21a-5p expression in epithelial 
adenocarcinoma alveolar cells (A549), while it slightly increased expression of SMAD7 in 
immortalised lung fibroblasts (MRC5). As mentioned in 4.4, cells lines are immortalised and 
clonal, and do not represent a true physiological state, while primary cells are more similar to 
physiological condition. Therefore, they can represent more reliable system in term of cell 
cycle and response for in vitro studies on fibrosis. Using, then, the same in vitro culture system 
employed for cell lines experiments (chapter 4), I further studied this in vitro system in primary 
lung fibroblasts, due to their strong influence on ECM remodelling and primary role in fibrotic 
development. The fibrosis related genes analysed were fibrillar collagens (Collagen types 1 
and 3), EMT master regulators (Snai1 and Slug), Ccn2/Ctgf and inhibitory Smads (Smad6 and 
Smad7), as well as fibrosis related microRNAs (miR-21a and miR-34a). Please note that the 
rational beyond the measurement of Snai1 and Slug mRNAs in fibroblasts refer to their 
importance as regulators of genes involved in cell motility.  
Expression of Col1a1 and Col3a1 is upregulated in lung fibrosis, leading to a change in 
ECM composition (Ricard-Blum, 2011). Although fibroblasts are known to bind fibrillar 
collagen via integrin 1ß2 and discoidin receptors, it is unclear if fibrillar collagen holds a 
feedback activity in fibroblasts (Mejía et al., 2015; Ricard-Blum, 2011). In chapter 4, the results 
highlighted a possible positive feedback operated by collagenous membrane on expression of 
key genes in fibrosis in both epithelial and mesenchymal cell lines. Therefore, I studied the 
cellular responses to a fibrotic-like ECM composed of Collagen in comparison to a non-fibrotic 
matrix modelled using RGD-motif peptides. 
Lung fibrosis mostly affects the elderly, and the reasons for this are currently unclear, 
although one factor may be an increase ECM crosslinking (King et al., 2000). Moreover, during 
ageing tissue damage can increase over time which, in combination with lifestyle, genetic and 
environmental factors, might evolve into a pathological condition.  
145 
 
Obviously, immortalised cell lines do not allow the study of the effects of ageing on cell 
responses. Furthermore, as mentioned above, cell lines, although useful as model systems, 
may not completely reflect physiological condition. In contrast primary cells can be used for 
studies on age, as they can be isolated from model organisms at different ages. However, as 
mentioned in the introduction, animal ages used in an experiment must refer to the animal 
age that shows similarities with a human phenotype (also at genetic level). Therefore, in this 
chapter I performed studies similar to those in Chapter 4 but in primary lung fibroblasts 
isolated from young adult (3- months-old) and aged (14-15-month-old) mice. The rational 
beyond the use of this age was that after 12 months of age mice starts to change key 
physiological parameters, as result of ageing process (Schulte et al., 2019). Therefore, as age 
has a key role in fibrosis, I wanted to investigate in this in vitro model the differences in the 
response to profibrotic stimulation (TGF-ß and Substrate). In addition, I wanted to further 
verify stretch protective response found in A549 and MRC5 also in primary mouse lung 
fibroblasts.  
In this setup I also analysed the role of miR-21a and miR-34a, in primary lung fibroblasts 
(TGF-ß, substrate, stretch and age). The sub-aim of this procedure was to provide key insight 
for further use in the development of antifibrotic therapy for IPF. Moreover, I wanted to verify 
if miR-34a was influenced by age. This is because miR-34a has been already extensively 
documented to be fundamental in different processes correlated with ageing. As mentioned 
in the introduction, miR-34a targets to p53 and SIRT1 two key proteins involved in cancer and 
ageing, and that appeared upregulated in the Bleomycin model of lung fibrosis (chapter 3) 
(Smith-Vikos & Slack, 2012). 
 
The aged mice used in this chapter were also used by Miss Jacquelin Lin, a member of 
my group, who was studying the role of p38 (MAPK) in aged bones cells and macrophages. 
Therefore, in order to respect the principle of reduction (3Rs https://www.nc3rs.org.uk/the-







5.2 Material and Methods 
 
5.2.1 Cell culture 
 
Primary mouse lung fibroblasts were isolated from young and aged C57BL6/J mice (n=6) 
according to the method described in 2.5.2. Next, 105 cells per well at passage 2 were seeded 
on either RGD-motif- or collagen-coated 6 well plates from Flexcell as described in 2.5.4. Cells 
were stimulated with TGF-ß at 2 ng/mL for 6h while 0.1% BSA in PBS was used as vehicle. To 
mimic lung deformation during breathing, the Flexcell Tension system was set at 6% of stretch 
and 1 Hz to mimic lung parenchymal dynamics (2.4.5). 
 
5.2.2 mRNA and miR qPCR method and statistical analysis 
 
RNA isolation, reverse-transcription and qPCRs were performed as described in 
paragraph 2.5. 2-way analysis of variance was used to understand the effects of ageing and 
substrate and if there was any statically interaction between the two variables in the 
experiments. Student’s t-test was used to analyse the effects of single variables (substrate, 














5.3.1 Mechanical stretch and ageing modify primary mouse lung 
fibroblasts shape. 
 
During the 6h of mechanical loading, cells were treated with 2 ng/mL of TGF- ß or 










Figure 5.1 Phase contrast images obtained from culture of primary mouse lung fibroblast at 10X 
magnification. Cells were seeded onto either RGD-motif or collagen (type 1) 6 well plate and 
treatment with BSA (used as control for TGF-ß effect) and not stretched using the Flex system (used 
as control for the latter condition A), TGF-ß at 2ng/mL and not stretched (B), Stretched at 6% of 
Stretch and at 1 Hz and treated with BSA (C) and stretched at 6% of stretch and 1 Hz and treated 
with TGF-ß at 2 ng/mL. [scale bar 50 µm]. 
 
Figure 5.1 shows phase contrast images obtained from the application of the stretch at 
6% 1 Hz for 6 hours. At 6% of mechanical stretch cells appear to increase their confluency to 
the no-stretched cells. Moreover, mechanical stretch appears to lead to a change in cell shape. 
Application of stretch leads to differences between cultures of young and aged fibroblasts, 
where stretch seems to stimulate cell aggregation and clumping of cells in cultures from aged 
mice. 








5.3.2 Gene expression profile 
 
Quantitative polymerase chain reaction (qPCR) for genes of interest was used to 
investigate the effect of substrate, ageing and stretch on primary mouse lung fibroblasts 
(n=6). 
 
Table 5.1 2-way ANOVA results for Col1a1 calculated to identify differences induced 
by treatments (TGF-ß, Substrate and stretch) and ageing. Top of the figure gives 
numerical percentage indication on the weight of the single variable including 
interaction, while bottom figure shows statistical significance where * p-value < 0.05, 












Figure 5.2 Gene Expression analysis from primary mouse lung fibroblast for Col1a1. Scatter dot-plot 
where each dot represents an individual mouse donor (A-D). A) Control. B) Fibroblasts treated with 
2ng/mL of TGF-ß. C) Fibroblasts stretched at 6% of stretch. D)Fibroblasts receiving both 2 ng/mL of 
TGF-ß and stretch at 6% 1 Hz. E) Sum of all experimental group, where blue bar-charts indicate cell 
seeded on collagen plate and red bar-charts cells on RGD-motif plate. Patterned bar-charts indicate 
the old subgroup while the solid ones indicate the young group (panel on graph’s left). Student t-
test was used to investigate significant differences between two groups. Differences in substrate 
are indicated by “+”, differences in age-related are indicated by “*”. * and + p-value < 0.05, ** and 
++ p-value < 0.01, +++ p-value < 0.001. Differences due to the effect of stretch are indicated by the 
“#”, # p-value < 0.05. 
 
Analysis by qPCR of Col1A1 expression by 2-way ANOVA indicates a significant effect for 
the treatment applied to the culture (TGF-ß, substrate and stretch) as well as age. Moreover, 
significant interaction between age and treatment indicated that the age of the cells affected 
the response to the treatments (Table 5.1). 
In the vehicle control group, the substrate does not affect Col1a1 expression in the 
fibroblasts from young mice. However, aged fibroblasts show a 2-fold increase in Col1a1 
mRNA expression in the cells cultured on collagen compared to those cultured on the RGD-
motif. This increase indicates that in non-fibrotic environment old fibroblasts produce more 
collagen if in contact on collagenous substrate. Moreover, young fibroblasts on RGD-motif 
showed a significant 1.5-fold increase from the old group on the same substrate (fig. 5.2A).  




Treatment with TGF-ß did not significantly increase Col1a1 mRNA expression in 
fibroblasts cultured on the RGD- motif regardless of the age. Treatment with TGF-ß resulted 
in higher expression levels of Col1a1 on collagen compared to the RGD-motif for both young 
and old fibroblasts, respectively 1.7-fold in young and 2.5-fold in old (fig. 5.2B). Therefore, 
TGF-ß stimulation seems to be stronger for old fibroblast on collagen coated plates. 
Stretch alone resulted in a 2-fold increase in Col1a1 expression in the old fibroblast on 
RGD-motif but not on old cells cultured on collagen. In the young fibroblasts, mechanical 
stretch leads to a decrease in Col1a1 expression of approximately 2-fold in RGD-motif and 3 
fold in collagen (fig. 5.2C and E). 
TGF-ß alone and the combination of TGF-ß and stretch resulted in a significant 
upregulation of Col1a1 in the aged group on the collagen compared to the cells cultured on 
RGD-motif (fig. 5.2D).  
All treatments (substrates, TGF-ß and stretch) and age strongly affected Col1a1 
expression. Moreover, substrates and TGF-ß seems to be stronger independent profibrotic 
stimulation, while stretch seems to have an inhibitory role against Col1a1 increase. 
 
Table 5.2  2-way ANOVA results for Col3a1 calculated to identify differences 
induced by treatments (as row: TGF-ß, Substrate and stretch) and ageing (as 











Figure 5.3 Gene Expression analysis from primary mouse lung fibroblast for Col3a1. Scatter dot-plot 
where each dot represents an individual mouse donor (A-D). A) Controls. B) Fibroblasts treated with 
2ng/mL of TGF-ß. C) Fibroblasts stretched at 6% of stretch. D) Fibroblasts receiving both 2 ng/mL of 
TGF-ß and stretch at 6% 1 Hz. E) Sum of all experimental group, where red circle scatter-dots 
indicate cell seeded on RGD-motif plate and blue square scatter-dots cells on collagen plate 
regardless age of the cells (as 2-way ANOVA not significant for age). Student t-test was used to 
investigate significant differences. Differences in substrate are indicated by p-value < 0.05, +++ p-
value < 0.001. 
 
2-way ANOVA results showed a significance only for treatments (TGF-ß, substrate and 
stretch) in total expression variance, which accounted for 18.03% of total percentage variation 
(Tab. 5.2). 
Without stimulation, there are no differences in Col3a1 expression regardless of the age 
of the donor mice or the substrate on which the cells were cultured (Fig 5.3A).  
TGF-ß did not affect Col3a1 expression (fig. 5.3B) in any of the groups. Mechanical 
stretch resulted in a 14% significant increase in Col3a1 expression for the aged cells cultured 
on collagen compared to control conditions as well to the same cells cultured on RGD-motif 
(fig. 5.3C and E).  
Stretch alone induced a significant upregulation in Col3a1 expression from a background 
state in the old group on cultured on collagen.  
Combination of stretch and TGF-ß did not result in any significant changes in the level 
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of expression of Col3a1 compared to the control group (fig.5.3A and fig. 3D).  
Results obtained showed that without stimulation levels of Col3a1 are the highest 
obtained in this experimental setting (see below). Relative expression gives an absolute value, 
which is influenced only by the house keeping gene used. 
Table 5.3 2-way ANOVA results for Snai1 calculated to identify differences 
induced by treatments (as row: TGF-ß, Substrate and stretch) and ageing (as 










Figure 5.4 Gene Expression analysis from primary mouse lung fibroblast for Snai1. Scatter dot-plot 
where each dot represents an individual mouse donor (A-D). A) Controls. B) Fibroblasts treated with 
2ng/mL of TGF-ß. C) Fibroblasts stretched at 6% of stretch. D) Fibroblasts receiving both 2 ng/mL of 
TGF-ß and stretch at 6% 1 Hz. E) Sum of all experimental group, where red circle scatter-dots 
indicate cell seeded on RGD-motif plate and blue square scatter-dots cells on collagen plate 
regardless age of the cells (as 2-way ANOVA not significant for age). Student t-test was used to 
investigate significant differences. Differences in substrate are indicated by p-value < 0.05, +++ p-
value < 0.001. 
 
Figure 5.4 shows Snai1 expression for all experimental groups used to investigate the 
effect of ageing, ECM substrates and stretch in primary mouse lung fibroblasts. 2- way ANOVA 
results indicated a significant effect only for treatment (TGF-ß, substrate and stretch), but not 
for age (Tab 5.3). 
Controls values showed very low relative expression levels (fig. 5.4 A). 
TGF-ß treatment induced a significant 2-fold increase from control in cells cultured on 
RGD-motif (fig. 5.4 B).  
Stretch alone in young fibroblasts on collagen resulted in a 2-fold reduction of Snai1 
expression from control (fig. 5.4E). Substrate differences accounted for a 45% reduction in 
Snai1 expression for collagen plates compared to RGD-motif in young fibroblasts (fig 5.4C).  





Table 5.4  2-way ANOVA results for Slug calculated to identify differences induced by 
treatments (as row: TGF-ß, Substrate and stretch) and ageing (as column).* p-value < 











Figure 5.5 Gene Expression analysis from primary mouse lung fibroblast for Slug. A) Control. B) 
Fibroblasts treated with 2ng/mL of TGF-ß. C) Fibroblasts stretched at 6% of stretch. D) Fibroblasts 
receiving both 2 ng/mL of TGF-ß and stretch at 6% 1 Hz. E) Sum of all experimental group, where 
blue bar-charts indicate cell seeded on collagen plate and red bar-charts cells on RGD-motif plate. 
Patterned bar-charts indicate the old subgroup while the solid ones indicate the young group (panel 
on graph’s left. Student t-test was used to investigate significant differences. Differences in 
substrate are indicated by “+”, differences in age-related are indicated by “*”. * and + p-value < 
0.05, ** p-value < 0.01, *** p-value < 0.001. Differences due to the effect of stretch are indicated 
by the “#”, # p-value < 0.05 and ## p-value < 0.01. 
In the vehicle control groups there are no differences due to substrate. However, aged 
fibroblasts show consistently a lower expression with a significant decrease of 50% in Slug 
expression compared to young fibroblasts (fig. 5.5A).  
TGF-ß treatment led to a significant 65% decrease in Slug expression from control for 
the RGD-motif group for both ages (fig. 5.5E).  
Mechanical stretch resulted in a significant 1.5-fold increase in Slug expression 
compared to controls on both substrates (fig. 5.5C). Indicating that stretch induce a diverse 
response based on the substrate (fig. 5.5 E).  
The combination of TGF-ß and stretch resulted in a 45% reduction of Slug expression 
only in aged fibroblasts cultured on RGD-motif. Aged cells cultured on collagen showed a 30% 
increase in Slug expression compared to young cells on collagen, and a 3-fold increase 




Table 5.5  2-way ANOVA results for CCN2 calculated to identify differences induced by treatments 









Figure 5.6 Gene Expression analysis from primary mouse lung fibroblast for Ccn2/Ctgf. Scatter dot-
plot where each dot represents an individual mouse donor (A-D). A) Controls. B) Fibroblasts treated 
with 2ng/mL of TGF-ß. C) Fibroblasts stretched at 6% of stretch. D) Fibroblasts receiving both 2 
ng/mL of TGF-ß and stretch at 6% 1 Hz. E) Sum of all experimental group, where red circle scatter-
dots indicate cell seeded on RGD-motif plate and blue square scatter-dots cells on collagen plate 
regardless age of the cells (as 2-way ANOVA not significant for age). Student t-test was used to 
investigate significant differences. Differences in substrate are indicated by p-value < 0.05, +++ p-
value < 0.001. 
 
Figure 5.6 shows Ccn2/Ctgf expression for all experimental groups used to investigate 
the effect of ageing, ECM substrates and stretch in primary mouse lung fibroblasts. 2-way 
ANOVA results showed a significant effect due to treatment (TGF- ß, substrate and stretch), 
but not for age (Tab. 5.5). 
Control groups did not show significant difference due to substrate (fig. 5.6A). TGF-ß 
treatment induced a significant overall 20-fold increase in Ccn2/Ctgf expression level 
compared to controls regardless of age or substrate (fig. 5.6E). Stretch did not induce any 
significant changes in Ccn2/Ctgf expression (fig. 5.6C). Similar to TGF-ß alone, combination of 
TGF-ß and stretch induced increased expression of Ccn2, which was not different from the 
increase induced by TGF-ß alone (fig. 5.6E). However, in fibroblasts from young mice, the 
combined TGF-ß and stretch condition resulted in a significant 41% increase in the collagen 












Table 5.6  2-way ANOVA results for Smad6 calculated to identify differences induced 
by treatments (as row: TGF-ß, Substrate and stretch) and ageing (as column). Top of 
the figure gives numerical percentage indication on the weight of the single variable 
including interaction, while bottom figure shows statistical significance where * p-
value < 0.05, ** p- value < 0.01 and *** p-value < 0.001. 
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Figure 5.7 Gene Expression analysis from primary mouse lung fibroblast for Smad6. A) Background 
level (CTRL). B) Fibroblasts treated with 2ng/mL of TGF-ß. C) Fibroblasts stretched at 6% of stretch. 
D) Fibroblasts receiving both 2 ng/mL of TGF-ß and stretch at 6% 1 Hz. E) Sum of all experimental 
group, where blue bar-charts indicate cell seeded on collagen plate and red bar-charts cells on RGD-
motif plate. Patterned bar-charts indicate the old subgroup while the solid ones indicate the young 
group (panel on graph’s left. Student t-test was used to investigate significant differences. 
Differences in substrate are indicated by “+”, differences in age-related are indicated by “*”. * p-








Next, I analysed Smad6 expression to investigate the effect of ageing, ECM substrates 
and stretch in the primary mouse lung fibroblast culture model. 2-way ANOVA result showed 
that both treatment (TGF-ß, substrate and stretch) and age highly significantly affect SMAD6 
expression. (Tab.5.6). SMAD6 expression is decreased in aged cells compared to young cells 
under all the experimental conditions studied. 
In control cultures, aged fibroblasts showed a significant decrease of Smad6 expression 
of 49% and 61% compared to young fibroblasts on RGD-motif and collagen respectively 
(fig.5.7A).  
TGF-ß treatment induced an overall significant 2- fold increase in Smad6 expression 
from control groups (fig. 5.7E). However, Smad6 expression in aged fibroblasts was still 
decreased but around 60% compared to young fibroblasts irrespective of the substrate (fig. 
5.7B).  
Stretch did not affect Smad6 expression, and the difference between young and aged 
fibroblasts was similar to control conditions (fig. 5.7C).  
The combination of stretch and TGF-ß resulted in expression level similar to TGF-ß alone, 
with a 2-fold increase from controls (fig. 5.7E), and a similar difference between young and 
aged fibroblasts as TGF-ß alone (fig. 5.7D).  
Figure 5.8 Effect of age on Smad6 expression. Scatter-dot plot where circles indicate young 
groups and squares old groups regardless on the substrates, red dots represent no TGF-ß 
treated groups (control and stretch) while blue dots represent TGF-ß treated group (TGF-ß 
and TGF-ß with stretch). Student t-test was employed to calculate significative difference 
based on age. *** p-value < 0.001. 
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To summarise, the factors affecting Smad6 expression in this system are TGF-ß and 











                    
Table 5.7 2-way ANOVA results for Smad7 calculated to identify differences induced 
by treatments (as row: TGF-ß, Substrate and stretch) and ageing (as column). Top of 
the figure gives numerical percentage indication on the weight of the single variable 
including interaction, while bottom figure shows statistical significance where * p-








Figure 5.9 Gene Expression analysis from primary mouse lung fibroblast for Smad7. A) Background 
level (CTRL). B) Fibroblasts treated with 2ng/mL of TGF-ß. C) Fibroblasts stretched at 6% of stretch. 
D) Fibroblasts receiving both 2 ng/mL of TGF-ß and stretch at 6% 1 Hz. E) Sum of all experimental 
group, where blue bar-charts indicate cell seeded on collagen plate and red bar-charts cells on RGD-
motif plate. Patterned bar-charts indicate the old subgroup while the solid ones indicate the young 
group (panel on graph’s left. Student t-test was used to investigate significant differences. 
Figure 5.9 shows Smad7 expression for all experimental groups used to investigate the 
effect of ageing, ECM substrates and stretch in primary mouse lung fibroblasts.  
2-way ANOVA analysis showed a significant effect of both treatment (TGF-ß, substrate 
and stretch) and ageing. No significant interaction was found between treatment and age, 
indicating that treatment affects SMAD7 expression the same way for both ages (Tab. 5.7).  
Under control conditions, the only significant difference was a 60% decrease in Smad7 
expression for aged fibroblasts on collagen compared to young fibroblasts on the same 
substrate (fig. 5.9A).  
TGF-ß treatment induced a 4-fold increase in Smad7 expression for both young and old 
fibroblasts on RGD-motif, and a 2.5-fold increase for young fibroblasts and a 4-fold increase 
in old one on collagen plates compared to control conditions (fig. 5.9E).  
Although Smad7 levels after TGF-ß treatment appeared to be lower in aged fibroblasts 
than in young fibroblasts, this was not statistically significant (fig. 5.9B). Mechanical stretch 
alone showed Smad7 expression levels similar to control conditions, with a similar significant 
70% decrease in Smad7 expression in aged fibroblasts on collagen compared to the young 
171 
 
fibroblasts (fig. 5.9C).  
The combination of TGF-ß and stretch induced increases in Smad7 levels similar to those 
of TGF-ß alone (fig. 5.9E). No differences induced by substrate or ageing were found in the 
analysis (fig. 5.9D). 
 
To summarise, TGF-ß and collagen induce expression of key genes involved in fibrosis, 
while age seems to upregulate profibrotic genes as Col1a1 and downregulate antifibrotic 
genes, such as Smad6 and Smad7. Moreover, results obtained in primary lung cells highlighted 




5.3.3  microRNAs expression analysis 
 
Quantitative polymerase chain reaction (qPCR) for microRNAs was used to investigate 
the effect of substrate, ageing and stretch on primary mouse lung fibroblasts. As mentioned 
in the introduction of this chapter, the rational was to obtain more information regarding the 
magnitude of miR-21a and miR-34a response to profibrotic stimulation. Moreover, as in 
chapter 4 I was not able to complete qPCRs on miR-21a and miR-34a in MRC5, it was critical 
to obtain information on those miRs for the progression into animal model.  
 
Table 5.7 2-way ANOVA results for miR-34a-5p calculated to identify differences induced by treatments 
(as row: TGF-ß, Substrate and stretch) and ageing (as column). Top of the figure gives numerical 
percentage indication on the weight of the single variable including interaction, while bottom figure 









Figure 5.10 microRNA expression analysis from primary mouse lung fibroblast for miR-21a-5p. A) 
Background level (CTRL). B) Fibroblasts treated with 2ng/mL of TGF-ß. C) Fibroblasts stretched at 
6% of stretch. D) Fibroblasts receiving both 2 ng/mL of TGF-ß and stretch at 6% 1 Hz. E) Sum of all 
experimental group, where blue bar-charts indicate cell seeded on collagen plate and red bar-charts 
cells on RGD-motif plate. Patterned bar-charts indicate the old subgroup while the solid ones 
indicate the young group (panel on graph’s left. Student t-test was used to investigate significant 
differences. Differences in substrate are indicated by “+”, differences in age-related are indicated 
by “*”. * and + p-value < 0.05, ** and ++ p-value < 0.01, *** p-value < 0.001.  
 
Figure 5.10 shows miR-21a-5p expression for all experimental groups. 2-way ANOVA 
results showed a significant effect of both treatment (TGF-ß, substrate and stretch) and ageing 
(Tab. 5.8). Result indicated a significant interaction. 
Under control conditions, the substrate induced differences in young fibroblasts, with a 
2-fold increase in fibroblasts cultured on collagen compared to cells cultured on the RGD-
motif.  
TGF-ß induced a 67% increase of miR-21a-5p expression in young fibroblasts cultured 
on collagen only (fig. 5.10 B and E).  
Stretch did not affect miR-21a-5p expression level from control. However, as seen under 
the other experimental conditions, young fibroblasts on collagen displayed a 2.5- fold increase 
compared to both young fibroblasts on RGD-motif and old on collagen (fig. 5.10C).  
TGF-ß and stretch resulted in a significant 48% decrease in miR-21a-5p expression in 
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young cells cultured on collagen compared to the same cells stimulated with TGF-ß only (fig. 
5.10E). Moreover, young fibroblast on collagen showed a 2.5-fold increase in miR-21 
expression compared to young fibroblasts on RGD-motif. For cells cultured on collagen, 
expression in young cells was 2-fold increase compared to fibroblasts (fig. 5.10D).  
Overall, there was very little response to treatment for miR-21a-5p expression, with the 
exception of young fibroblasts cultured on collagen. The expression of miR-21a-5p was 
consistently higher in this group compared to all the other groups, and this was the only group 














Table 5.8 2-way ANOVA results for miR-34a-5p calculated to identify differences 
induced by treatments (as row: TGF-ß, Substrate and stretch) and ageing (as column). 
Top of the figure gives numerical percentage indication on the weight of the single 
variable including interaction, while bottom figure shows statistical significance where 




















Figure 5.11 microRNA expression analysis from primary mouse lung fibroblast for miR-34a- 5p. A) 
Background level (CTRL). B) Fibroblasts treated with 2ng/mL of TGF-ß. C) Fibroblasts stretched at 
6% of stretch. D) Fibroblasts receiving both 2 ng/mL of TGF-ß and stretch at 6% 1 Hz. E) Sum of all 
experimental group, where blue bar-charts indicate cell seeded on collagen plate and red bar-charts 
cells on RGD-motif plate. Patterned bar-charts indicate the old subgroup while the solid ones 
indicate the young group (panel on graph’s left. Student t-test was used to investigate significant 
differences. Differences in substrate are indicated by “+”, differences in age-related are indicated 
by “*”. + p-value < 0.05, ** p-value < 0.01, *** and +++ p-value < 0.001. Differences due to the effect 
of stretch are indicated by the “#”, # p- value < 0.05. Note that each datapoint for each experimental 
group indicates an individual mouse donor. 
 
Figure 5.11 shows miR-34a-5p expression for all experimental groups used to investigate 
the effect of ageing, ECM substrates and stretch in primary mouse lung fibroblasts. 2-way 
ANOVA indicated significant effects of both treatment (TGF-ß, substrate and stretch) and age 
(Tab. 5.9). However, the effect of ageing had a higher level of significance than treatment. 
There was no significant interaction between treatment and age, indicating that the response 
to treatment was not different between the two age groups (Tab. 5.9).  
Under control conditions there was a significant 5.5-fold increase in miR-34a-5p 
expression in the aged cells on collagen compared to the young fibroblasts. A similar increase 
was observed for cells cultured on RGD-motif, but this was not statistically significant.  
Neither TGF-ß, mechanical stretch, or the combination of both affected miR-34a-5p 
expression compared to control (fig. 5.11E).  
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However, the substrate the cells were cultured on the age of the cells did affect miR-
34a-5p expression. miR-34a-5p expression was generally higher in old fibroblasts. Young 
fibroblasts displayed 73 % decrease in miR-34a-5p expression on collagen compared to those 
cultures on RGD-motif. However, aged fibroblasts showed higher miR-34a-5p expression on 
collagen coated plates. In old fibroblasts on collagen, mechanical stretch induced a 2-fold 
decrease in TGF-ß induced miR-34a-5p expression but did not affect TGF-ß-induced miR-34a-
5p expression in young cells or aged cells cultured on RGD-motif (fig. 5.11E). 





Transforming grow factor ß (TGF-ß) is considered a key cytokine in fibrosis (Wynn, 2011). 
Transcriptional activation by Smads is limited by a negative feedback loop operated by 
inhibitory Smads (Smad6 and Smad7). 
In fibrosis, dysregulation in the TGF-ß pathway leads to a constant receptor type 1 
activation, resulting in a pathological increase in ECM. TGF-ß pathway activation also leads to 
epithelial-to-mesenchymal transition (EMT) (Z. Yan, kui, & Ping, 2014). EMT contributes to 
fibrosis by increasing the number of resident fibroblasts. Mechanical tension (stretch) has also 
been identified as EMT inductor in cardiomyocytes (Finch-Edmondson & Sudol, 2016). Stretch 
activation might result in cytoskeletal remodelling, through Slug and Snai1, inducing 
fibroblasts-dependent ECM remodelling.  
Classic in vitro molecular and cellular experiments on fibrosis employ TGF-ß treatment 
at concentrations lower than 10 ng/mL to establish a fibrotic-like phenotype. Those classic 
model present limitation due to the lack of reproducibility with organism physiology. It is now 
well accepted that the tissue environment is as important as the cells that compose it. 
Therefore, understand and then reproduce a tissue environment in terms of cytokine, ECM 
and stretch can virtually reproduce a tissue environment with maybe less cost than organoids.  
Age dramatically affects the response to the chronic damage. During ageing mammalian 
lose cell replicative power and impaired response have more probability to evolve to a 
pathological state, as in fibrosis. Clinical evidence highlights a scenario with significant 
increase in lung fibrosis in aged people, where treatments with Nintenadib and Piredenifidone 
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only slower disease progression.  
 
Hence, we developed a system able to take in account tissue environment, as cytokines 
and ECM environment, mechanical stretch, and ageing. This system was used to investigate 
the response of those stimulations to primary lung fibroblasts. The readout was again mRNA 
profiling from key genes involved in lung fibrosis pathogenesis and miR-21a and miR-34a. 
To investigate the effect of ageing, primary lung fibroblasts were isolated from young (3 
months old) and old (15 months old) wild type female C57BL/6 mice. To assess the effect of 
ECM as substrate on gene regulation, primary mouse lung fibroblasts were cultured on either 
the RGD-motif or Collagen type 1 coated tissue culture plates. RGD-motif is an Arginine-
Glycine-Aspartate repeated motif present in almost all ECM proteins such as fibronectin, 
vitronectin, fibulin, laminin, collagen, and others, and it is fundamental for cell attachment to 
matrix (Burgstaller et al., 2017). Collagen is the most abundant ECM protein, which is 
contributes more than 30% of body dry weight (Ricard-Blum, 2011). However, in pulmonary 
fibrosis, excess collagen production leads to lung failure. In order to investigate whether 
matrix composition affects gene regulation during fibrosis, I used RGD-motif as a healthy 
control and collagen as disease group. Another important feature that I wanted to include in 
the study is mechanical stretch. The increase in collagen content during fibrosis leads to an 
increase in lung stiffness, modifying lung elastic properties. Lung deformation is fundamental 
for correct air intake. Therefore, if the lung becomes stiffer, diaphragm and chest muscles 
need to operate a higher work, as force per direction, in order to compensate the increase in 
stiffness (Miller, 2010; Béla Suki et al., 2011). For this reason, stretch was included in the 
system to have information regarding the effect of stretch on gene regulation. 
Using this system, I studied the expression of 7 genes (Col1a1, Col3a1, Slug, Snai1, 
CCN2/CTGF, Smad6, Smad7) and 2 microRNAs (miR-21a-5p and miR-34a-5p) and found that 
age, substrate and stretch all affected gene expression in the cultures.  
The first observation through phase contrast microscopy regarded cell behaviour. 
Stretched cultures appear sparser in comparison with the static culture (fig 5.1). Old 
fibroblasts, regardless of substrates showed signs of cellular distress to the force applied to 
the culture, as shown in figure 5.1. Old fibroblasts were forming clumps, possibly to overcome 
the distress induced by mechanical stimulation (fig. 5.1). Percentages of stretch from 10 to 
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15% have already been reported to induce cell death, in epithelial lung systems and in Hela 
cells, therefore the percentage used was around 6% of surface elongation (Peñuelas et al., 
2013). Moreover, aged lung cells are more susceptible to mechanical force (Valentine et al., 
2017). Old primary mouse fibroblasts seem to form clumps to overcome cellular stress 
induced by the 6% stretch (fig 5.1 C and D).  
TGF-ß treatment did not induce any significant change in cell shape and cell-to-cell 
attachment. Figures were equivalent between groups; however, the use of a phase contrast 
microscopy limited the quality and quantity of information to discuss. 
Regarding gene regulation, I found that expression of Col1a1, Slug, Smad6 and 7 and 
miR-21a-5p and miR-34a-5p were all influenced by age, whereas the expression of Col3a1, 
Ccn2/Ctgf and Snai1 were not (Tab. 5.10). Col1a1 and miR- 34a-5p showed an overall increase 
in expression while Slug, Smad6 and 7 and miR- 21a-5p an overall decrease due to age. The 
increase in Col1a1 and miR-34a-5p expression is in line with the higher incidence of pulmonary 
fibrosis in the elder population (King et al., 2000; Stuart et al., 2014). Moreover, Col1a1 
showed a higher magnitude increase in the aged group when treated with TGF-ß. Col1a1 
increased level in the aged group were also found in the stretch experimental condition (fig. 
5.2). Apart from age, Col1a1 expression was also affected by a collagen as substrate and 
stretch (Tab. 5.1). 
The age-related decrease in expression of the inhibitory Smads, Smad6 and Smad7 may 
partially explain the higher incidence of fibrosis in the elderly population. The mechanism that 
I propose is that the decrease in inhibitory Smad expression (as negative feedback loop related 
to age) give rises to increased Smad2/3/4 activation in response to TGF-ß, leading to increased 
matrix production. Both epigenetic and transcriptomic mechanisms can decrease inhibitory 
Smad expression (X. Yan et al., 2009). Moreover, Smad7 increased expression have been 
found in age-related skin cancer, which results in a ubiquitin-ligase dependent TGF-ß 
degradation (through Smurfs) (Han et al., 2006). Then, considering that fibrosis has an 
opposite response to cancer in chronic damage, the decrease found with age for Smad6 and 
7 is in line with differences in TGF-ß between cancer and fibrosis. In physiological condition a 
decrease in Smad6 and 7 increases activatory Smads, powering then the fibrosis in ageing. 
Smad7 overexpression with transgene was demonstrated to revert fibrotic phenotype in the 
Bleomycin model of lung fibrosis (Nakao et al., 1999). This means that Smad7 holds antifibrotic 
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properties, however most of those studies does not employ old mice for the Bleomycin model 
of fibrosis. Therefore, results obtained arise a question on the role of Smad7 in aged fibrotic 
lung, which might highlight a connection between ageing and fibrosis.  
From prediction analysis miR-21a-5p/Smad7 interacts in mammals and while Smad7 
holds antifibrotic role, miR-21a-5p showed profibrotic characteristic (see chapter 3 and 4). 
The possibility of miR-21a-dependant Smad7 inhibition represents one of rational of this PhD 
project, as if this hypothesis is true miR-21a inhibition should result in a Smad7 increase and 
vice versa (see chapter 6). 
Age clearly influenced Slug expression in untreated conditions, where I found an overall 
downregulation in expression in relation with age. This decrease is in line with Slug 
intervention in development. TGF-ß condition (fig. 5.5B) showed a decreased expression in 
old fibroblasts on RGD-motif, whereas a dynamic fibrotic environment triggers an opposite 
behaviour (fig. 5.5D). Slug is widely study in embryology, and it is a transcriptional repressor 
involved in neural crest formation, it is a source of smooth muscle vascular cells in lung 
(Whitsett et al., 2018). Results suggested a role in response to fibrotic stimulation for Slug in 
fibroblasts for the first time. 
Overall miR-34a-5p expression was higher in the aged compared to the young 
fibroblasts. The increase in miR-34a-5p expression was most pronounced in cells cultured on 
collagen. Increased expression of this microRNA has previously been shown in aged lung 
epithelial cells, and to promote organ disfunction related to fibrosis. (Cui et al., 2017a; Smith-
Vikos & Slack, 2012). 
Main limitation of the study was that expression levels were only assessed at a single 
time point. The decrease in expression of Smad6 and -7 expression with age strongly suggest 
increased TGF-ß induced signalling. However, additional experiments, such as Smad 
phosphorylation studies, need to be performed to confirm this mechanism. In summary, 
results obtained, identified ageing as profibrotic stimuli through inhibition of Smad6 and 
Smad7 and increase in Col1a1. Collagen as substrate confirmed also in primary cells to be a 







Table 5.9 Sum of qPCRs from primary mouse lung fibroblasts results. In the column there are 
listed the genes and miRs of interest, whereas in the row the different stimulation performed. 
Up facing arrows (↑) indicates upregulation, while down facing arrows (↓) downregulation 








Col1a1 ↑ ↑↑ ↓ ↑ 
Col3a1 ↓ - ↑ - 
Ccn2/Ctgf ↑↑ - - - 
Snai1 ↑ ↑ ↓ - 
Slug ↓ - ↑ ↑ 
Smad6 ↑ ↑ - ↓↓ 
Smad7 ↑↑ - - ↓ 
miR-21a-5p ↑ ↑ ↓ - 











6 miR-29a mirmimic and miR-21a antagomiR as 




Pulmonary fibrosis belongs to Interstitial lung disease family. The disease is 
characterised by a low survival rate and resistance to drug treatment. Current 
treatments only treat disease symptoms but so not slow of reverse disease 
progression (Fischer & Brown, 2015). IPF is the form of fibrosis with the highest 
mortality, and rational drug design for treatment is difficult as its aetiology is 
currently unknown (Meltzer & Noble, 2008). Current disease models for IPF do not 
fully recapitulate the full disease phenotype, and show phenotype overlap with other 
forms of lung fibrosis. In addition, most models for lung fibrosis although 
representing major disease features, such as increased lung volume, increased ECM 
production and collagen crosslinking, are more similar to an acute response than a 
chronic disease (see introduction). Despite disease phenotypes showing high 
variability, features such as mesenchymal activation and increased ECM production 
are considered hallmarks of fibrosis (Kendall & Feghali-Bostwick, 2014). Those 
hallmarks are mostly the result of the activity of mesenchymal cells, which have been 
a focus of this experimental thesis. The main strategy for the work presented in this 
thesis was to first identify microRNAs that are differentially expressed in fibrotic 
lungs, followed by in vitro experiments to study the effect of these microRNAs on 
fibrotic lung fibroblasts, and finally to test the effect of the most promising 
microRNAs in a mouse model of IPF. 
Currently only Pirfenidone and Nintedanib are accepted for the treatment of 
PF, which although a low efficacy they reduce PF symptomatology and slow disease 
progression (Fujimoto et al., 2015). Currently, several strategies are being used to 
develop better treatments for IPF, such as monoclonal antibodies and microRNAs, 
targeting ECM protein (as for CCN2/CTGF, SMAD cascade, etc.). 
Evidence from in vitro and in vivo, and clinical data suggest that microRNAs 
change their expression in response to fibrotic development. As an example miR-21a 
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and miR-155 were found to be upregulated in patients affected by IPF compared to 
healthy control subjects (Li et al., 2013). Fine tuning the expression of microRNA, 
then, might be a potential strategy against lung disease as IPF (Rajasekaran, Rajaguru, 
& Sudhakar Gandhi, 2015). The basic principle of microRNA therapies is to either 
mimic the repression activity of the microRNA itself (mirmimic); or repressing the 
repressor activity of a microRNA (antagomir) (see introduction). For some of those 
therapies, lead development has now reached phase three clinical trials (miR-34a, 
miR-92, miR-16 and miR-122). However, it should be noted that only few leads reach 
this stage, as they have limited applicability (Hanna et al., 2019). microRNAs have a 
unique mechanism of action, where the 3’-UTR repression can bind to multiple target 
mRNAs, as it is based on energy favourable events. This unspecific target affinity 
creates off-target effects that might be lethal or result in an unexpected response. 
However, experimental evidence based non-ambiguous annotation of microRNA 
targets could possible predict these off-target effects, and lead to more specifically 
targeted modified microRNA and prevent or minimise adverse effects. Another 
limitation of microRNA therapies lies in the vehicle used (PEG, Lipofectamine, etc.), 
as it affects lead molecular structure, or increases the toxicity or being not adequate 
for that type of delivery. An example of clever drug administration is represented by 
the work of Patel and collaborators, who successfully “transfected” a mRNA-PEG-
conjugate into mouse lung, which resulted in the expression of the mRNA (Patel et 
al., 2019). This elegant strategy resulted in a lower toxicity in the experimental model 
and in low systemic effect, as delivery was localized to animal lung. 
 
microRNA arrays showed that several microRNAs are differentially expressed in 
the Bleomycin model of fibrosis, several of which target intracellular proteins 
involved in the TGF-ß signalling pathway, an important target pathway in IPF (Xie et 
al., 2011). microRNAs can regulate transcripts involved IPF pathogenesis, where 
increase in a specific ECM protein were correlated with decrease in microRNA 
expression and vice versa. This miRs:mRNA relationship needs to be further validated, 
as the change in expression might be random. The strategy used in this chapter 
involved application of both mirmimics and antagomirs, as miR reduction should lead 
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to an increase of mRNA target, and microRNA overexpression should lead to a 
decrease in the target gene. Validations of this interactions are needed to 
understand if variation in a chosen microRNA correlates to amelioration in the fibrotic 
phenotype. In chapter 3, I showed a progressive increase in 4 microRNAs (miR-21a, 
miR-34, miR-29a and miR-378) followed by Bleomycin treatment in C57BL/6J. Studies 
regarding the Bleomycin model of lung fibrosis and clinical target discovery found 
quite often a miR-29a-3p expression suppression (Montgomery et al., 2014; Slusarz 
& Pulakat, 2015; Ting Xie et al., 2011). miR-29a-3p has been associated with the 
regulation of more than 4000 transcripts and shows conservation among vertebrates 
and connection with diabetes, cancer, and organ fibrosis (Slusarz & Pulakat, 2015b). 
miR-29a-3p is an evolutionary conserved microRNA and therefore, represents a good 
candidate for antifibrotic therapy. Thus, using a gain and loss of function approach, I 
studied the effect of miR-29a-3p in primary mouse lung fibroblasts to clarify its role 
as ECM regulator. In chapter 5, miR-34a and miR-21a were investigated in primary 
mouse lung fibroblast in response to different fibrotic stimuli, such as TGF-ß, collagen 
as substrate and aging. miR-21a-5p was significantly influenced by TGF-ß and collagen 
in mouse lung primary fibroblasts. miR-21a-5p showed an upregulation in epithelial 
A549 cells induced by collagen type-I substrate (Chapter 4). Results obtained on miR-
21a-5p suggested an involvement of this microRNA in fibrosis. Therefore, I focussed 




6.2 Material and Methods 
 
Predicted alignment were conducted using TargetScan7.2 
(http://www.targetscan.org/vert_72/). (Agarwal et al., 2015). Primary mouse lung 
fibroblasts were isolated as described in 2.4 and were cultured in DMEM standard 
media and treated with a scramble sequence, used as control; a mirmimic and 
antagomir sequence, to boost and inhibit miR-21a-5p and miR-29a-3p expression 
(ref. 2.4.6). miR-29a-3p and miR-21a-5p were first evaluated in terms of gain and loss 
of expression through qPCR. Then, Col1a1 and Col3a1 (miR-29a-3p predicted targets, 
see below) and Col1a1, Col3a1, Ccn2/Ctgf and Smad7 were evaluated in their 
expression (miR-21a predicted target, see below). Expression level were evaluated 
using qPCRs as described in 2.5. 
Four five month old male C57BL/6J mice for each experimental group received 
tail vein intravenous injection (iv.) once a week of 2 µg/g of cholesterol modified 
mirmimic and antagomir for miR-21a-5p and scrambled sequence as control, as 
described in 2.2.5. Fibrosis was induced through intratracheal administration of 
Bleomycin, as described in chapter 2.2.5. Progression of fibrosis was monitored 
through in vivo µCT Scans (Quantum GX-2) at the start of the experiment and at 7, 11 
and 17 days after Bleomycin administration as described in 
On day 18 day, mice were sacrificed, lungs were dissected out inflated filled 
with O.C.T. (ref.2.2.2). Lungs were analysed first for miR-21a-5p, then for Col1a1 and 
Smad7 with qPCRs (ref. 2.5). Slides of 5-7 µm were cut using cryotome and then 








6.3.1 miR-29a-3p in primary mouse lung fibroblasts 
 
6.3.1.1 miR-29a-3p predicted target on Col1a1 and 
Col3a1 
 
TargetScan 7.2 is one of the most used bioinformatic tool for microRNAs target 
identification (ref. 2.9). A list of predicted mRNA targets generated by TargeetScan7.2 
algorithm through sequence complementary between mRNA transcript and the miR 
sequence are shown in Table 6.1. TargetScan7.2 lists all microRNA predicted target 
based on the number base pair complementarity between microRNA core sequence 























Table 6.1 TargetScan7.2 results for miR-29, in the table are shown only the first 12 entries 
generated by the system. The table shows the name of miR-29a targets, the number and 
type of binding site as conserved or not among species shows as “conserved site” and 
“poorly conserved site” and the miRs isoform. In red are highlighted predicted interaction 











































4 0 3 1 0 0 0 0 1 
COL1A1 
collagen, type I, 
alpha 1 
3 1 0 2 0 0 0 0 0 
ELN elastin 3 2 1 0 0 0 0 0 0 
COL4A5 
collagen, type IV, 
alpha 5 
2 2 0 0 1 1 0 0 0 
ATAD2B 
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III, alpha 1 
2 1 0 1 0 0 0 0 1 
 
Table 6.1 shows mRNAs targets for miR-29a-3p alignment. Among top 12 
predicted target, I focused my attention on mRNAs relevant in terms of ECM, such as 
collagen type-I, III (highlighted by red boxes). Top entries targets are more favourable 
events as presented higher number of sequence complementarity and species 
conservation. However, as in lung Col4a5 is little expressed it was excluded by any 
further analysis, while Col1a1 and Col3a1 were took in consideration as main 
constituent of collagen fibres. Please note that collagen 4a5 was not taken in 
consideration as non-fibrillar. 
From the list in Table 6.1, each entry is linked to hyperlinked files, containing 
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information regarding the conservation miR:mRNA interaction between main species 
used in experimental biology (fig. 6.1, 6.2 and 6.8), and the base pair interaction 
between a microRNA of interest and the predicted target (6.2, 6.3 and 6.8).  
Predictions on Col1a1 showed one 8-mer and two 7-mer A1 binding sites, while 
Col3a1 showed one 8-mer and one 7-mer A1 site. 8-mer indicated an exact match to 
position 2-8 of the mature microRNA followed by an A, and a 7-mer-A1 an exact 






Figure 6.3 Col3a1 3’-UTR and miR-29a-3p interactions 
 
Figure 6.1 miR-29a-3p binding site on Col3a1 3'- UTR and 
conservation of the binding among the species  




Figure 6.1 to 6.3 shows sequence complementarity between miR-29a-3p and 
Col1a1 (fig. 1 and 3) and miR-29a-3p and Col3a1 (fig. 6.2 and 6.3) 3’-UTR and their 
conservation among species. Interestingly, Col1a1 interactions with miR-29a were 
not conserved in macaw, chicken, lizard and in Xenopus tropicalis (fig. 6.1), while 
Col3a1 interaction showed to be conserved among all analysed species (fig. 6.2). 
Figure 6.2 and 6.3 shows details of miR-29a-3p and target genes interaction, which 




6.3.1.2 qPCRs results 
 
Primary mouse lung fibroblasts were transfected with 50 nM of scramble 
sequence (control), 50 nM of mirmimic sequence (stimulator of miR expression) or 
50 nM of antagomir sequence (inhibitor of miR expression) for miR-29a-5p. 
 
 
Figure 5 shows expression level for miR-29a-3p. miRmimic group showed a 100-fold 
time increased from scramble (control) for miR-29a-3p, while antagomir group 
showed a 99.4% decrease from scramble (control). Expression trend demonstrated 
that the transfection conditions were partially achieved.  
This meant that the transfection of miR-29a-3p was effective in modifying microRNA 
expression, resulting in the induction of miR expression for mimic group and 
inhibition for antagomir group (fig. 6.4). 
Next, Col1a1 and Col3a1 expression level were evaluated through qPCRs, the 
rational was to evaluate if the treatment with mirmic and antagogomir were able to 
modify target expression. 
 
 
Figure 6.4 qPCRs from primary mouse lung fibroblasts transfected with 50 
M of Scramble (red circles), miRmimic (blue squares) and antagomiR 
(green triangles) for the miR-29a-3p. Results shown in the figure were 
significant for 1-way-ANOVA with an overall p-value < 0.001. Turkey post-




Figure 6.5 shows the effect of treatments with miR-29a-3p on Col1a1 and 
Col3a1 mRNAs. Treatment with the mirmimic resulted in a significant 2-fold decrease 
in Col1a1 expression, while there was no significant upregulation in the antagomir 
group from scrambled (control). However, antagomir group showed a 50% significant 
upregulation from miRmimic group (fig.6.5A). Therefore, treatment aiming at 
modifying miR-29a-3p expression are efficient in fine tuning Col1a1 expression. 
Treatments modifying miR-29a-3p expression did not resulted in changes in 
Col3a1 expression (fig. 6.5B). Therefore, treatments miR-29a-3p analogue did not 





Figure 6.5  qPCRs results from mLFs transfected with 50 M of Scramble (red circles), 
miRmimic (blue squares) and antagomiR (green triangles) for col1a1 (A) and col3a1 
(B). Col1a1 expression level were significant for 1-way-ANOVA with an overall p-value 
< 0.01. Turkey post-hoc test was used for single column comparison *: p-value < 0.05, 
**: p- value < 0.01. 
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6.3.2 miR-21a-5p role in models of lung fibrosis 
 
6.3.2.1 miR-21a-5p target Smad7 3’-UTR 
 
TargetScan7.2 results from predicted alignment between miR-21a-5p 
sequence and genome wise 3’-UTRs, generated a table containing 274 conserved 
sites and 67 poorly conserved. As mentioned above, TargetScan7.2 output (tab 6.2) 
contains a hyperlink information regarding miR:mRNA binding and conservation of 
this predicted interaction between species (fig. 6.6 and 6.7).  
Although microRNAs do not need a complete match between sequences, 7 
and 8- mer interaction are generally assumed to be more energetic favourable 
events. Among top list genes, Smad7 (tab. 6.2 highlighted by red box) belonging to 
TGF-ß canonical pathway, was in the top 15 entries in the list produced by 
TargetScan7.2. Smad7 showed the presence of an 8-mer conserved site for miR-21a-
5p. Figure 6.7 shows the high conservation among species for the predicted 
alignment, in white in the figure. Smad7 3’-UTR displays conserved sites for miR-21a-
5p binding, which is not present only in Macaw, animal that has a different Smad7 3’-
UTR. Figure 6.8 shows sequence complementarity and sequence location of predicted 
alignment, which identified in miR-21a-5p and miR-21c possible target of mRNA-
microRNA interaction with Smad7. 
This means that miR-21a-5p has affinity to bind Smad7 3’-UTR, which was 
further evaluated experimentally to identify the role of miR-21a-5p in fibrosis. 
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Table 6.2 TargetScan7.2 results for miR-21a, in the table are shown only the first 20 
entries generated by the system. The table shows the name of miR-21a targets the 
number of sites of binding and the type of binding, diving them in “conserved site” and 
“poorly conserved site” and in the last type of miRs isoform. In red is highlighted 
predicted interaction between miR-21a and Smad7. Please note that the column named 
















































1 1 0 0 0 0 0 0 0 
FASLG 
Fas ligand (TNF 
superfamily, member 
6) 
2 1 1 0 0 0 0 0 0 
CCL1 
chemokine (C-C motif) 
ligand 1 
1 1 0 0 0 0 0 0 0 
SCML2 
sex comb on midleg- 
like 2 (Drosophila) 
2 1 1 0 0 0 0 0 1 
AIM1L 
absent in melanoma 1- 
like 
1 1 0 0 0 0 0 0 0 
IL12A interleukin 12A 1 1 0 0 0 0 0 0 0 
ZNF367 
zinc finger protein 
367 
2 2 0 0 0 0 0 0 0 
SPRY1 sprouty homolog 1 1 1 0 0 0 0 0 0 2 
RNFT1 
ring finger protein, 
transmembrane 1 
1 1 0 0 0 0 0 0 0 
PELI1 
pellino E3 ubiquitin 
protein ligase 1 
1 1 0 0 0 0 0 0 0 
YOD1 YOD1 deubiquitinase 2 2 0 0 0 0 0 0 1 
SMAD7 SMAD family member 7 1 1 0 0 0 0 0 0 0 
SRL sarcalumenin 1 1 0 0 1 0 1 0 1 




1 1 0 0 1 0 0 1 0 
ARHGAP2 
4 
Rho GTPase activating 
protein 24 
1 1 0 0 0 0 0 0 1 
ELF2 E74-like factor 2 1 1 0 0 0 0 0 0 1 
ZNF704 
zinc finger protein 
704 








Figure 6.6 Screenshot obtained from TargetScan7.2 showing predicted binding location of miR-21a-





6.3.2.2 miR-21a-5p mirmimic and antagomir in primary 
mouse lung fibroblast 
 
Primary mouse lung fibroblasts were isolated from C57BL/6 and cultured as 
described in 2.2.2. Cells were transfected with 50 nM of scramble sequence (control), 
100 nM of mirmimic sequence (stimulator of miR expression) or 150 nM of antagomir 
sequence (inhibitor of miR expression) for miR-21a-5p. To assess the effect of TGF-ß, 
cells were stimulated for 1 hour before lysis with TGF-ß at 2 ng/mL. Cells were 
incubated for a total of 48 hours in the above mentioned condition, according to 
2.2.5. microRNA gain and loss of function was evaluated through qPCR for miR-21a-
5p normalised SNORD68 (ref. 2.6) to further assess the effect of a miR- 21a-5p gain 
and loss of function on Smad7 mRNA (fig. 6.8). 





Figure 6.8 miR-21a-5p gain and loss of function in primary mouse lung fibroblasts. qPCRs 
result from primary mouse lung fibroblasts treated with a scramble (control), mirmimic 
(upregulation) and antagomiR (downregulation) for miR-21a-5p. Results are significant 
for 1-way ANOVA with an overall p-value < 0.001. Student T-test was conducted to 
evaluate single significance of treated group compared to control and it is indicated by the 
symbol “*”. *** p-value < 0.001. 
Transfection with mirmimic resulted in a significant 8-fold increase in miR-21a-
5p expression, while transfection with antagomir resulted in a 44% decrease in miR-
21a-5p expression from control (fig. 6.8). Therefore, treatments with miR-21a-5p 
analogue were able to fine tuning microRNA expression, with induction of miR-21a-
5p for mirmimic group and inhibition in antagomir group (fig. 6.8). 
Next, I assessed whether treatment miR-21a-5p mirmimics and antagomirs 
resulted in significant changes in Smad7 mRNA expression (fig. 6.9). Primary lung 






Figure 6.9  Smad7 expression level from gain and loss of function experiments for miR-21a-
5p in primary mouse lung fibroblasts. qPCR for Smad7 were conducted to asses if changes 
in miR-21a-5p expression would affect Smad7 expression. Cells were treated with or 
without TGF-ß at concentration of 2 ng/mL to reproduce a fibrotic phenotype. Results are 
significant for 1-way ANOVA with an overall p-value < 0.001. Student T-test was conducted 
to evaluate significance differences between pairs of columns and are indicated by “*”. *< 
p-value 0.05, ** p-value < 0.01 and *** p-value < 0.001. 
 
In the absence of TGF-ß, there was a significant 56% decrease in Smad7 
expression in cells transfected with the mirmimic, and 84% increase in cells treated 
with the antagomir group. In cells stimulated with TGF-ß, SMAD7 expression 
increased approximately 10-fold. Although transfection with mirmimic resulted in a 
36% reduction in Smad7 expression, this was not statistically significant. Transfection 
with antagomir resulted in a significant 35% increase in Smad7 expression. SMAD7 
expression after TGF-ß stimulation was twice as high in the antagomir treated cells 
as in the mirmimic treated cells. 
Treatments miR-21a-5p analogues were able to fine tuning Smad7 expression, 
with induction of Smad7 for antagomir group and repression for mirmimic group, 
regardless of TGF-ß treatment. This meant that increase in miR-21a-5p resulted in 
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repression in Smad7 and miR-21a-5p repression in Smad7 increase. This suggested 
that miR-21a-5p can regulate Smad7 expression. Interesting, TGF-ß treatment did not 
modify the trend induced by treatments with miR-21a-5p analogues. 
Next, I wanted to evaluate if modifications in miR-21a-5p would affect the 
expression of key ECM genes. Therefore, Col1a1, Col3a1 and Ccn2/Ctgf expression 

































































































































































































































Treatment with miR-21a-5p mirmimics and antagoMirs did not significantly 
affect Col1a1 expression (fig. 6.10A). Col3a1 showed reduction in expression in the 
mirmimic group of 1.5 for the TGF-ß and 5-fold time in the untreated group compared 
to each control. Without TGF-ß, Col3a1 antagomir group showed a significant 
increase of 7.5-fold time from the mirmimic group. In untreated condition, 
transfection with mirmimic resulted in a significant 74% decrease of Ccn2/Ctgf 
expression, while the antagomir had no effect on Ccn2/Ctgf expression. TGF-ß 
stimulation resulted in an overall 11.5-fold time increase in Ccn2/Ctgf expression, 
however, neither the mirmimic nor the antagomir had any effect on this expression. 
Interesting, regardless of TGF-ß stimulation mirmimic group showed a general 
decrease in the expression of the three main genes involved in fibrosis, despite 




6.3.2.3 miR-21a-5p mirmimic and antagomir in the 
Bleomycin model of lung fibrosis (1) 
 
miR-21a-5p expression was assessed through qPCRs in liver and lung to 
measurement the efficacy of the experimental treatment following the method 
illustrated in 2.2 (fig. 6.11). qPCR for miR-21a-5p from liver samples was performed 
to assess systemic adsorption for treatments with mirmic and antagomir. 
 
 
Figure 6.11 miR-21a-5p gain and loss of function in the Bleomycin model of lung fibrosis 
(n=4). qPCRs result from mice liver (A) and lung (B) treated with a scramble (control red), 
mirmimic (upregulation blue) and antagomir (downregulation green) sequences for miR- 
21a-5p. Results are significant for 1-way ANOVA with an overall p-value < 0.05. Student T- 
test was conducted to evaluate significant differences between pairs of columns, indicated 
by “*” symbol. * p-value < 0.05. 
 
miR-21a-5p expression in the Liver showed a non-significant 4-fold increase for 
the mirmimic group and a 68% decrease for antagomir group, resulting in a significant 
12-fold increase in the mirmimic group compared to the antagomir group (fig. 6.11A). 
Lungs showed a significant 3-fold time increase in the mirmimic and a non-significant 
25% reduction in the antagomir group from scramble. miR-21a-5p expression 
increased 4-fold in the mirmimic group compared to the antagomir group (fig. 6.11B). 
The results demonstrated that treatments with mirmic and antagomir were efficient 
in fine tune miR-21a-5p expression in circulation, as expected. 
Next, Smad7 (predicted target), Col1a1 and Ccn2/Ctgf were evaluated in the 




Figure 6.12 qPCRs from miR-21a-5p gain and loss of function experiments for Smad7 (A), 
Col1a1 (B) and Ccn2/Ctgf (C)in lungs from mice treated with Bleomycin (n=4). Bleomycin 
was used to recapitulate fibrotic phenotype. Ccn2/Ctgf comparison for samples treated 
with Bleomycin (in red) and untreated (CTRL in blue) (D). Results in Smad7 and Col1a1 are 
significant for 1-way ANOVA with an overall p-value < 0.05 for Smad7 and an overall p-
value < 0.01 for Col1a1. Student T-test was conducted to evaluate significance differences 
between pairs of columns and are indicated by “*”. *< p-value 0.05. 
 
Smad7 expression levels were decreased by 37% in the miR-21a-5p mirmimic 
group, however, this was not statistically significant. In the antagomir group SMAD7 
expression was increase by 58%. SMAD7 expression was 2.5- time higher in the 
antagomir group compared to the mirmimic group (fig. 6.12A). This meant that 
antagomir treatment for miR-21a-5p results in increase in Smad7 expression. 
Collagen α1-chain mRNA showed a significant 65% decrease in the antagomir, 
while there was no significant effect on Col1A1 expression in the mirmimic group (fig. 
12B). Interesting, the antagomir group showed for the four mice treated a consistent 
decrease in Col1a1 expression, which suggest an amelioration in the fibrotic 
phenotype induce by the treatment.  
Ccn2/Ctgf did not showed significant changes induced by the experimental 
condition (fig. 6.12C), however Bleomycin increase Ccn2/Ctgf expression level from 
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not Bleomycin treated mice (fig. 6.12D).  This meant that treatment with Bleomycin 
were efficient in reproduce the fibrotic phenotype experimentally. 
 
6.3.2.4 miR-21a-5p mirmimic and antagomir in the 
Bleomycin model of lung fibrosis (2) 
 
In vivo µCT scans imaged lung at different stages during the follow-up study on 
the role of miR-21a-5p in the Bleomycin model of lung fibrosis. Resulting images at 
endpoint were further used for qualitative analysis regarding fibrotic development in 
mice lungs. 
 
Figure 6.13 Orthogonal mice cross section from lung scanned with µCT from 
Control (without Bleomycin treatment, top left), scramble (Bleomycin 
treated, top right), mirmimic (Bleomycin treated, bottom left) and 
antagomir (Bleomycin treated, bottom left) groups. Grey levels (0-251) 
were set with 0 (black) indicating air while 251 (white) set as bones. 
Therefore, soft tissue referred to middle value using this scale setting. White 
arrow indicated an area that shows a localised attenuation of X-ray that 




Lungs treated with Bleomycin showed qualitative increase in ECM contents, 
represented in lung cross-section as patch of light grey (fig. 6.13) Control group lungs 
showed areas with light grey, indicating major blood vessel. Both scramble and 
antagomir groups showed similar light grey patterns, while the mirmimic group 
shows a quite significant dark area reduction in lung cross-section (fig. 6.13). The 
increase in grey colour over black, indicated an increase in lung volume with 
reduction of air capability. This suggested that alveoli are replaced by a thin net of 




6.3.2.5 miR-21a-5p mirmimic and antagomir in the 
Bleomycin model of lung fibrosis (3) 
 
Sections were visualised and imaged through both Brightfield and Polarized light 





Figure 6.14 Representative images from lung sections from untreated lung (A) and lungs 
treated with Bleomycin (B-D), stained with Sirius Red and imaged through Brightfield (left) 
and Polarised light microscopy (right). Lung treated with Bleomycin also received a scramble 
sequence (B) mirmic (C) and antagomir. From images obtained through polarised light 
microscopy it is possible to notice an increase in dichroism for Bleomycin treated lungs(B-D). 
Treatments with miR-21a-5p analogue resulted in worsening of fibrotic phenotype for mirmic 


























Control lung section shows a normal lung architecture with Picrosirius stain 
limited to the blood vessels, without positive stain in the alveoli. Polarized light 
microscopy shows few events of dichroism, most of that with low intensity. (fig. 
6.14A). 
Lungs from the Bleomycin/scrambled group show tissue aggregates with 
parenchymal disruption. Polarised light microscopy highlighted event of dichroism 
around alveoli with bright colour intensification. (fig. 6.14B). 
Lung section from Bleomycin/mirmimic group shows tissue degeneration and 
intensification of red stain around alveoli. Polarized light microscopy showed 
increased in red colour formation (fig. 6.14C). 
Lung section from Bleomycin/antagomir group shows normal appearance of 
the alveoli. However, polarized light microscopy displayed events of dichroism in the 
alveolar space (fig. 6.14D). 
Section comparison of above showed sections allows to obtain qualitative 
information regarded treatment combination. Scramble and mirmimic group treated 
with Bleomycin displayed a higher tissue disruption with clearer level of dichroism 
highlighted by polarised light microscopy. Antagomir group treated with Bleomycin 
showed a higher level of tissue integrity and less level of dichroism compared with 
the other Bleomycin treated groups. Antagomir group showed similarity with control 





Figure 6.15 Quantification of collagen fibres content from control not treated with 
Bleomycin (clear circle), scramble treated with Bleomycin (red circle), mirmimic group 
treated with Bleomycin (blue squares) and antagomir group treated with Bleomycin 
(green triangles). Results showed are significant for 1-way ANOVA with an overall p-value 
< 0.01. Student T-test was conducted to evaluate significant differences between pairs of 
columns, indicated by “*” symbol. ** p-value < 0.01. 
 
Quantification of the polarised light images using image analysis (see Chapter2) 
showed that Bleomycin treatment resulted in a significant 3.2-fold compared to the 
no-Bleomycin control group. This was even further increased to a 5-fold increase in 
polarised light signal in the mirmimic group, however, this was not significantly 
different from the scramble group. In contrast, treatment with the antagomir did not 
result in a significant increase in polarised light signal. Moreover, scramble and 
mirmimic group showed a non-significant 2-fold and 3-fold increased level of collagen 
fibres formation compared to the antagomir group (fig. 6.15). 
Bleomycin treatments were able to induce a fibrotic phenotype, which seem to 
be rescued by a treatment with antagomir for miR-21a-5p. On the other hand, a 
treatment that increases miR-21a-5p seem to lead to a worser phenotype when 






PF is a debilitating progressive disease where lung parenchyma is replaced by a 
collagenous scar tissue, which led to a breathing imbalance and death, and currently there 
are no treatments able to reverse the disease (Wynn, 2011). Reducing collagen fibres 
deposition by blocking the TGF-ß pathway is a promising strategy for the treatment of IPF 
(Fujimoto et al., 2015). microRNAs are a promising class of compounds able to block TGF-ß 
and collagen formation (Rajasekaran et al., 2015). In the present chapter, I focused on the role 
of miR29a-3p and miR-21a-5p. 
miR-29a-3p appears from a comprehensive microRNAs analysis as one of the most 
encourageing target for antifibrotic therapy (Xie et al., 2011). Thus, to evaluate the benefits 
in a treatment with miR-29a-3p, a gain and loss of function experiments was performed. The 
main focus of the procedure was to discover from silico to in vitro the role of miR-29a-3p in 
primary fibroblast, cells considered at basis of fibrosis pathogenesis. To reduce genetic intra-
organ variability primary lung fibroblast were employed for the purpose. Although lung is 
composed by a wide range of mesenchymal cells with different role and characteristic, 
fibroblasts used for the experiments expressed characteristic proteins common to matrix and 
myo- fibroblasts, such as, α-smooth actin, vimentin and HSP47 (Whitsett, Kalin, Xu, & 
Kalinichenko, 2018). Likewise, miR-29a, did not showed pronounced sequences differences 
between human and mice. TargetScan 7.2 analysis showed for miR-29a-3p microRNA-mRNA 
interactions, a high level of conservation between mammalian species. Targetscan prediction 
suggested inhibitory interaction miR-29a-Col1a1 and miR-29a-Col3a1, lung major ECM 
component, which were conserved in mammalian species. Moreover, 8 and 7-A1 mer 
complementarity are more probable events as enough stable to maintain a miR- mRNA 
interaction (Agarwal et al., 2015). 1-way ANOVA showed that treatments were significantly 
efficient in reproducing a gain and loss of function for miR-29a in primary mouse lung 
fibroblasts. Although, antagomir group did not showed significant decrease from control 
(scramble), its expression was 99.4% decreased from miRmimic. qPCRs on Collagen type-I 
resulted in mirmimic significant downregulation in Col1a1 from both experimental groups, 
correlated to the increase in the same group in miR-29a-3p expression. By contrast, no 
changes were detected in Col3a1. Thus, miR-29a-3p mirmic can downregulated Col1a1 
expression, but not Col3a1 in primary mouse lung fibroblasts. Interestingly, miR-29a-Col1a1 
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inhibitory interaction is conserved only in mammalian species, which highlights difference in 
fibrillar collagen between diverse species (Agarwal et al., 2015). Therefore, this repression 
might represent a mechanism to reduce fibres formation probably acquired in mammalian 
evolution. Moreover, miR-29a-3p protective role in fibrosis in response to collagen 
overexpression is a topic supported by evidence in human fibroblasts, where IPF patients 
showed miR-29a suppression (Parker et al., 2014). Consistently, miR-29a mirmic leads to 
decrease in collagen biosynthesis induced by Bleomycin in a mouse model of pulmonary 
fibrosis. Mice treated with Bleomycin, receiving a therapeutic dose of mirmimic showed a 
return to a normal lung parenchyma architecture (Montgomery et al., 2014). Results obtained 
are in line with previous publications and support an antifibrotic role for miR-29a-3p mirmic. 
In addition, they provide information regarding a selective regulative role for miR-29a on 
Col1a1, but not on Col3a1 for mouse lung fibroblasts. This fact is important considering that 
it was postulated that Col1a1 and Col3a1 have a diverse role in fibrillar formation and 
therefore in fibrosis. Recently, a clinical trial from miRagen is developing a miR-29 mirmic 
therapy against different forms of organ fibrosis (Gallant-Behm et al., 2019). Therefore, my 
evidence together with previous work confirmed that miR-29a-3p can be a potential target 
for disease affecting Collagen turnover. This because it is important to understand that 
microRNA analogue can be used to fine tune mRNA expression. Evidence showed in chapter 
are limited by the lack of result on collagen at protein level, however it should be noticed that 
if Col1a1 is not translated, protein will decrease. 
 
miR-21a has been identified as a profibrotic microRNA in other tissues (Li et al., 2013; 
G. Liu et al., 2010). As mentioned in the introduction, miR-21a-5p is a potential drug for the 
treatment of nephropathy (Ivan G. Gomez et al., 2015).  
Bioinformatic analysis using TargetScan7.2 identified Smad7 as miR-21a target, 
presenting an 8-mer binding site from the predicted alignment. 
Smad7 is a negative regulator of the TGF-ß pathway, by inhibiting TGF-ß signal 
transduction and positive feedback on TGF-ß1 receptor. As a result, Smad7 limits TGF-ß-
stimulated matrix production. In chapter 4 and 5, I showed that Smad7 expression is induced 
by TGF-ß and a collagen-based cell culture substrate in both primary mouse lung fibroblasts 
and in the human MRC5 lung fibroblast cell line (Chapter 4 fig. 6 and 7, chapter 5 fig.10). My 
findings are in line with previous work identifying Smad7 as a potential inhibitor of organ 
210 
 
fibrosis (Lan, 2008; Troncone et al., 2018; Zhang et al., 2007). 
To evaluate if Smad7 is indeed regulated by miR-21a I performed experiments using 
miR-21a antagomirs (a specific hairpin inhibitor for miR-21a) and mirmimics, both in vitro and 
in vivo. 
Treatment of lung fibroblasts with miR-21a mirmimics resulted in a reduction of Smad7 
expression levels, while inhibition of miR-21a using antagomirs resulted in an increase of 
Smad7 expression. These results indicate that Smad7 is indeed a target for miR-21a. 
Quantitative PCRs for Col1a1, Col3a1 and Ctgf/Ccn2 were conducted in the three 
experimental systems with or without TGF-ß (fig 6.10). ECM expression level showed in all 
analysed genes a dependency to TGF-ß. Regarding the effect of transfected sequences, Col1a1 
and Ccn2/Ctgf did not show significant changes in the TGF-ß treated groups (fig 6.10A and C), 
while Col3a1 resulted in a significant decrease in mirmimic group compared to control (fig. 
6.10B). Col3a1 downregulation triggered by TGF-ß and miR-21a elevated levels, drawing again 
a possible Col3a1 protective role against fibrosis (chapter 3 and 5). 
Next, I investigated the role of miR-21a in the development of pulmonary fibrosis using 
the in vivo mouse model of Bleomycin induced lung fibrosis. Mice were assigned to three 
experimental groups, receiving either a scramble (control), mirmimic (to increase miR-21a 
expression) or an antagomir (to inhibit miR-21a expression). Treatment with miR-21a 
mirmimic resulted in a significant increase in miR-21a in both lung and liver tissue. However, 
in both livers and lungs the downregulation by the miR-21a antagomir was not significant 
compared to the scramble control (fig. 6.11). This may be due to intra-individual variation or 
accelerated clearance of the molecular treatments. Moreover, mice were sacrificed 7 days 
after the last injection, and therefore the treatment’s limited one week half- life, levels in the 
tissue may have decreased below detection levels. 
Smad7 expression was significantly higher in the antagomir treated group compared to 
the mirmimic group. Although Smad7 levels were higher than scramble control, this difference 
was not statistically significant, and similarly, the increased levels of Smad7 in the antagomir 
group was not statistically significant from the scramble control group (fig. 6.12). Statistical 
limitations between treatment groups may be due to the relatively small group size. 
Next, I evaluated the effect of the antagoMir and mirmimicic on expression of fibrosis 
related genes Ccn2/Ctgf and Col1a1 (fig. 6.12). 
Ccn2/Ctgf is a member of CCN family strongly related with fibrosis development. 
211 
 
Through transgenic strategies Leask et al. demonstrated the profibrotic role of CCN2/CTGF 
gene (S. Liu et al., 2011; Sonnylal et al., 2010). Moreover, a monoclonal antibody for 
CCN2/CTGF is currently in a phase II clinical trial for the treatment of IPF (Fujimoto et al., 2015; 
Raghu et al., 2016). Neither the antagomir nor the mirmimic microRNA treatment had any 
effect on Ccn2/Ctgf expression in the Bleomycin mouse model (fig. 6.12C). Moreover, µCT 
endpoint scans showed an overall worsening for the mirmimic group indicating that an 
increase in miR-21a-5p might correlate with increase in ECM (fig. 6.12). 
Col1a1 encodes for the α1-chain of type I collagen, which is a major component of 
mammalian ECM (Vuorio, 1990). Col1a1 changes are strongly related with tissue repair 
imbalance and organ fibrosis, which is one of the main hallmarks of IPF. Different strategies 
have been developed during time, targeting collagen biosynthesis and transportation for the 
cure of fibrosis, however none of them is currently in use for disease treatment (Staab-
Weijnitz et al., 2015). The miR-21a-5p mirmimic did not affect Col1a1 expression, although 
increased level of ECM was found in µCT scans (fig. 6.13). However, treatment with the 
antagomir lead to a 65% reduction in Col1a1 RNA expression compared to scramble. Hence, 
inhibition of miR-21a expression might reduce fibrosis through Col1a1 inhibition (fig. 6.15B). 
Histology of the lungs confirmed the antagoMir not only inhibition of Col1A1 expression, 
but also Collagen fibre formation in the Bleomycin model (fig. 6.14). Collagen fibre area was 
reduced to levels comparable to those in animals that did not receive Bleomycin. In contrast, 
the mirmimic group displayed an impaired tissue parenchyma with a significant increase in 
collagen fibre formation (fig. 6.14C). 
 
Interesting miR-21a-5p has affinity for TGF-ß 3’-UTR with an 8-mer site of binding (Tab. 
6.1), which theoretically should reduce the autocrine effect of TGF-ß. Results from primary 
fibroblasts treated with miR-21a-5p mirmic and antagomir, and TGF-ß suggested a possible 
inhibitory role for miR-21a-5p on TGF-ß. Mirmimic group treated with TGF-ß showed 
significant decrease from scramble and antagomir group for Ctgf/Ccn2 and Col3a1 expression. 
However, without TGF-ß stimulation, the mirmic group showed a lower expression for the 
analysed genes. In addition, in vivo results highlighted a phenotypical worsening for mice 
treated with Bleomycin and mirmic compared to antagomir or scramble.  
 
These results show that miR-21a-5p is a promising candidate for the treatment of PF. In 
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vitro and in vivo models of fibrosis resulted in a miR-21a-5p upregulation, leading to a 
decrease in Smad7 expression. In particular, miR-21a inhibition showed to be a possible 
strategy for the cure of IPF, as decreased level in miR-21a reflected in Smad7 upregulation. 
Smad7 upregulation, achieved through miR-21a inhibition, resulted in reduced Col1a1 
expression and collagen fibres deposition in the Bleomycin model of lung fibrosis. This latter 
is in line with previous reports which identified Smad7 upregulation as a promising strategy 
for the cure of IPF and other types of organ fibrosis (Lan, 2008; Nakao et al., 1999). Moreover, 
the strategy used to induce Smad7 with antagomir treatment can be considered less toxic and 
does not modify DNA, which represent benefits for a future therapy. miR-21a gain of function 
resulted in a worsening of the fibrosis in the animal model, in particular in tissue parenchyma 
architecture and ECM deposition (fig. 6.11 and 6.13).  
To conclude, figure 6.16 proposes the mechanism to explain experimental results 
obtained on the role of miR-21a inhibition in the in vitro and in vivo model of fibrosis. In 
pathological conditions, TGF-ß activates the expression of several ECM gene through a Smad-
dependent mechanism. In lung fibroblasts TGF-ß increases also miR-21a expression, leading 
to Smad7 repression, which augments activatory Smad power and ECM expression. Then if 
miR-21a is inhibited by a specific miR-21a target, it might be possible to restore Smad7 




Figure 6.16 Schematic view of the molecular mechanism at the basis of pulmonary fibrosis 









Pulmonary fibrosis is a debilitating progressive disease mostly affecting the elderly. The 
name “Idiopathic” implies that the underlying cause of IPF is currently unknown. However, 
IPF is due to dysregulated wound healing repair, characterised by increased matrix production 
as well as changes in ECM composition, leading to increased tissue rigidity (Vancheri, 2015; 
Wynn, 2011). The main ECM component overexpressed in fibrosis is collagen (Meltzer & 
Noble, 2008). So far there has been very limited success in the development of antifibrotic 
therapies, and the disease usually leads to death within 2-5 years (Wynn, 2011). 
The first aim of this PhD project was to identify microRNAs that are differentially 
expressed in lung fibrosis, and to test whether these miRs or corresponding antagomiRs can 
suppress lung fibrosis in a mouse model. Using the Bleomycin model, I identified 4 microRNAs 
(miR-21a-5p, miR-34a-5p, miR-29a-3p and miR-378-5p) as potential pro-fibrotic microRNAs 
due to progressively increased expression correlated with progression of fibrotic features. 
However, Montgomery and collaborators found reduced miR-29a-3p expression in the same 
Bleomycin model of fibrosis (Montgomery et al., 2014). 
In vitro experiments using primary mouse fibroblasts demonstrated then that miR-29a-
3p overexpression results in a reduction of Col1a1 expression, whereas it has no effect on 
Col3a1, the other predicted target. Primary mouse lung fibroblasts were used as more 
relevant cell type in a context of wound healing alteration triggering fibrosis. In conclusion the 
in vitro results obtained confirmed a possible antifibrotic effect previously proposed by 
Montgomery et al. 
miR-21a-5p and miR-34a-5p have previously been identified upregulated in 
experimental and clinical data on IPF (Cui et al., 2017; Li et al., 2013). Cui and collaborators in 
2017 already demonstrated the potential benefit in miR-34a suppression in the mouse model 
of fibrosis, which was the reason why I focused more on miR-21a, which was not yet studied 
in this model (Cui et al., 2017). 
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Of the miRs I identified in the bleomycin model, miR-21a showed the highest expression 
level, miR-21 expression was significantly increased in the early stages of fibrosis (3 days after 
Bleomycin treatment), whereas mir-34a and miR-29a were increased only at the late stages, 
when fibrosis is already apparent (10-21 days after Bleomycin). Therefore, miR-21a 
suppression might be able to reverse lung fibrosis in early stages of the disease. miR-21a-5p 
expression also showed an in vitro increase dependant on TGF-ß and an ECM rich in collagen 
type 1, conditions which mimic a pro-fibrotic environment. 
Predicted target analyses identified Smad7 as potential target for miR-21a- 5p. Smad7 
is a negative regulator of TGF-ß induced signalling and is a potential therapeutic target for 
treatment of fibrosis (Zhang et al., 2007). Next, I validated the interaction between miR-21a-
5p and Smad7 in primary mouse lung fibroblast using mirmimic and antagomir treatments. 
My results showed mirmimic decreased Smad7 expression, while the antagomir increased 
Smad7 expression. As increased Smad7 is expected to decrease TGF-ß signalling, I next studied 
whether miR-21a mirmimics and antagomirs affect development of fibrosis in vivo using the 
Bleomycin model of lung fibrosis. I found that the miR-21a-5p mirmimic increased fibrosis in 
this model, while the antagomir ameliorated lung fibrosis. miR-21a-5p antagomir increased 
Smad7 expression in the lungs of the mice, while the mirmimic had no significant effect. The 
trend in the mirmimic group showed decreased expression of Smad7, however this was not 
significance due to limitations in statistical power, as only 3-4 animal replicates were used for 
each experimental group. 
This part of the present study provides rational insight regarding a possible 
pharmacological strategy to prevent the development of lung fibrosis through miR- 21a 
inhibition. The uses of mirmimic or antagomir treatments as more similar to treatments 
against IPF and were preferred to a tamoxifen-induced knockout strategy. Moreover, 
knockout systems would impair epigenetic regulation in response to profibrotic stimulation 
induced by Bleomycin. This because microRNAs repression has been seen to tune the 
expression of entire signalling networks (Avraham & Yarden, 2012). However, to demonstrate 
a reduction in TGF-ß network 
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activation, the balance between activatory and inhibitory Smads should have been 
investigated in the antagomir group, for instance by performing western blots for phosphor-
SMADS after TGF-ß stimulation. 
Tail vein injection (iv.) of miR-21a represented a major pharmacokinetic limitation of 
this experiment, as the intravenous administration can lead to systemic side effects. However, 
an aerosol administration may be a safer route to take in consideration for the future 
experiments. Recently, Patel and collaborators have been able to deliver and express PEG-
coated polyplexes mRNA only in mouse lungs, which is a suitable strategy also for miRNAs 
(Patel et al., 2019). 
Future possible combinatory strategy employing a pool of microRNAs, like for example 
combined inhibition of miR-21a and miR-34a, and overexpression of miR-29 might result in a 
stronger amelioration of lung fibrosis. However, possible off-target effects need to be 
considered in experimental planning. 
Another interesting feature to explore is miR-21a inhibition at early stages of fibrosis, 
which may ameliorate lung fibrosis through a IL-12 overexpression dependant mechanism in 
T helper cells (Murugaiyan, Garo, & Weiner, n.d.). IL-12 is a predicted target for miR-21a and 
its overexpression results in an amelioration in the Bleomycin model of lung fibrosis (Keane 
et al., 2001). Therefore, miR-21a- repression may increase IL-12 expression triggering 
amelioration in the Bleomycin model. A possible strategy to investigate this mechanism is 
evaluating the reduction in immune T-cell infiltration for antagomir group after a Bleomycin 
treatment. 
 
My next aim was to study the effect of changes in ECM composition analysing the 
expression of ECM genes and miRs associated with organ fibrosis in vitro, using lung epithelial 
and fibroblast cells. In general, it is reductive to assume that a treatment with TGF-ß is the 
only driving force in lung fibrosis. Changes occurring in fibrosis regarding matrix composition 
demonstrated to equally influence the expression of key genes involved in lung fibrosis for 
both epithelial and fibroblasts cells. The increase in fibrillogenesis during lung fibrosis triggers 
changes in ECM composition, which holds profibrotic characteristic. However, the 
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model used was not able to mimic 3D lung septa structure and cannot account 
that RGD-motif is present also in collagen fibres (Burgstaller et al., 2017). Results 
showed that a number of genes and both miR-21a-5p and miR-34a-5p were 
influenced by collagen as substrate. 
miR-21a showed a profibrotic-like synergistic effect from TGF-ß treatment and 
collagen as coated substrate, which was found only in the young fibroblast 
population. However, as TGF-ß treatment used for the study (2 ng/mL) does not 
represent a physiological condition, there is the needs to test miR-21a-age- 
dependency in vivo, may be using the Bleomycin model of fibrosis in old mice. 
Results identified that Col1a1 expression was influenced by collagen as 
substrate in a positive feedback manner. Collagen substrate gave rise to increase in 
Col1a1 expression which powered-up the profibrotic induction by TGF-ß. Moreover, 
matrix composition, consistently affected the expression of CCN2/CTGF and PDGFRα 
in epithelial cells and Slug, Smad6, miR-21a and miR-34a in fibroblast cells. This 
positive feedback effect is in line with the idea that not only RGD-motif, but also 
collagen, in ECM can transduce signals impacting gene regulation. The interaction 
between Collagen type-I GFOGER motif and integrin α2ß1 have been experimentally 
demonstrated and it suggest that α2ß1-GFOGER activate intracellular signalling 
pathways (Mejía et al., 2015). However, there are no current cellular evidence 
suggesting this mechanism, which can be key in this field of study. Positive feedback 
loop effect of collagen substrate on Col1a1 needs also to be further investigated at 
protein level. 
In mammalian lungs, mechanical stretch is generated by diaphragm and chest 
muscle and transferred first to lung septa and then at cellular level (Bela Suki et al., 
2011). Evidence in biomechanics shown that mechanical stretch can exert effects on 
gene regulation (Junghyun Kim et al., 2018). In lung fibrosis the increase in ECM 
causes mechanical stretch impairment due to the increase in tissue stiffness (Scotton 
et al., 2013). Applying mechanical stretch in the culture, I found in both primary and 
immortalised cells a stretch-dependant protective effect. Stretch decreased 
expression of CCN2/CTGF, SNAI1 and upregulated SMAD7 in immortalised cell line, 
and Col1a1, Snai1, miR-21a-5p and miR-34a-5p in primary cells. Interestingly, Col1a1 
showed age dependant differential response to mechanical stretch, which raises a 
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number of questions related to wound healing repair response in ageing. 
IPF affects most of the elder population with highest incidence in the 40-70 
years old population (Raghu et al., 2011). In my in vitro system aged fibroblasts 
showed increase in Col1a1, Slug and in miR-34a-5p and decrease in Smad6 and 
Smad7, confirming a stronger profibrotic response in age cells. Hence, ageing 
decreased TGF-ß repressor and increased expression of profibrotic effectors. Results 
obtained suggests that increase incidence of lung fibrosis in aged population depends 
on stronger susceptibility to chronic damage for aged fibroblasts. Future 
experimental insights are necessary to confirm this effect also on human primary 
fibroblasts, as interspecies difference may correlate to different mechanism. 
In conclusion, the in vitro system was able to produce significant results on the 
effect of cytokines, substrates, and ageing, also taking in consideration cell stretch. 
However, this model could be improved through the use of 3D lung mimic bioprinting 
or lung decellurization. This is because those methods can be more representative of 
lung parenchyma than a coated surface. Moreover, those methods can be taken in 
account also the direction of stretch, key feature not analysable with Flexcells. 
Moreover, a 3D system represents more physiological condition and therefore 
represent a more reliable system to use. Lung decellurization or 3D bioprinting might 
provide better system to use regarding the effect of fibrotic feature on gene 
regulation (Parker et al., 2014). However, 3D lung bioprinting is a very recent reality, 
which have been only able to reproduce lung endothelia but not the epithelia 
(Albritton & Miller, 2017). 
My experiments have shown that miR-21 could be a good target for the 
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